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Abstract 
This thesis addresses the role of microglia and the 
concept of ^neuroinflammation' in Parkinson's disease (PD) using 
clinically well-characterised post-mortem human brain tissue. 
The first part of the project employs established 
immunohistochemical markers for defining microglial activation 
and PD-related protein aggregation and attempts to define the 
disease-specificity of the microglial response in PD. The 
results presented reconcile earlier conflicting reports using 
these markers and highlight the inadequacy of common microglial 
markers to fully characterise these cells in disease. These 
findings are significant to the interpretation of human imaging 
and animal models of PD, as well as future work on post-mortem 
tissue. Drawing from the conclusions of this work, the second 
part of the project involves the cell-type-specific analysis of 
a microarray profile of the PD brain and a protein-level back-
mapping of specific gene transcripts that are hypothesised to 
have a functional significance to immune-associated changes 
therein. Our findings support the hypothesis that 
neuroimmunological changes may play a significant role in PD 
progression, expand upon the traditional view of microglia as 
the primary effector cell of the brain's immune defence and 
raise more questions into how the brain's intrinsic immune 
response pathways can be adapted to slow or even prevent PD 
progression. 
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Chapter 1: Introduction 
1.1 Microglia 
1.1.1 Microglial origins and developmental overview 
Unlike astrocytes, oligodendrocytes and neurons, microglia 
and perivascular macrophages are derived from hematopoietic 
precursors, which are still able to enter the CNS and transform 
into microglia in low numbers even in mature animals (Flugel et 
al. 2001; Wehner et al. 2003; Hess et al. 2004). The 
mesenchymal rather than ectodermal origin of microglia was 
postulated as early as 1932 (del Rio-Hortega 1932). 
Microglia migrate to the brain during early development. 
In transgenic mice in which enhanced green fluorescent protein 
(EGFP) is under the control of the promoter for the ionised 
calcium-binding adaptor molecule 1 (Ibal), a microglia-specific 
protein in the CNS, EGFP-expressing cells are detected primarily 
around the pial surface and vessel walls, as early as embryonic 
day 10.5 (Hirasawa et al. 2005). In human foetal brain, 
microglia have been detected immunohistochemically after 13 
weeks of gestation (Hutchins et al. 1990). 
Upon entering the CNS, microglial cells closely resemble 
other macrophages and have been described as amoeboid, with 
short, thick processes (Cuadros et al. 1994) . The adhesion 
molecules lymphocyte function-associated antigen 1-alpha (LFA-
la) and intracellular adhesion molecule-1 (ICAMl) may be 
involved in the migration of microglia during development 
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(Dalmau et al. 1997) . In rats, microglia proliferate 
considerably during the embryonic period (as indicated by 
immunohistochemical detection of proliferating cell nuclear 
antigen (PCNA)), while apoptosis detected by in situ detection 
of nuclear DNA fragmentation (TUNEL) was very infrequent and 
occurred primarily after birth (Dalmau et al. 2003). 
1.1.1.1 The function of microglia during development 
During development, amoeboid microglia are actively 
involved in shaping the connections of the CNS. They remove 
cellular debris and temporary or inappropriately connected axons 
(Ashwell 1990; Ashwell 1991). They promote neuronal 
differentiation through the release of trophic factors (Nagata 
et al. 1993; Jonakait et al. 1996; Mazzoni and Kenigsberg 1997). 
1.1.1.2 Maturation 
Microglial processes become longer, thinner and more 
ramified from the late embryonic period through postnatal 
maturation (Cuadros et al. 1994). This morphological change is 
accompanied by a downregulation of many of the molecules 
expressed by amoeboid microglia and peripheral macrophages. 
Mature microglia are described as resting, although in vivo two-
photon imaging of resting microglia has indicated that they are 
active monitors of their environment with highly motile 
processes (Nimmerjahn et al. 2005; Davalos et al. 2005) . Upon 
the detection of a CNS injury, microglia rapidly transform into 
an activated state reminiscent of their early amoeboid period. 
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1.1.2 Overview of microglial activation 
The speed with which microglia are able to respond to 
changes in their microenvironment is known to be very rapid, on 
the order of milliseconds (Nimmerjahn et al. 2005; Davalos et 
al. 2005) . Upon the detection of a disturbance, microglial 
processes shorten and thicken, and they may eventually adopt a 
full macrophage morphology, at which time they are 
phenotypically indistinguishable from blood-borne phagocytes and 
able to phagocytose neuronal debris (Figure 1.1) . This change 
in morphology is accompanied by a change in protein and gene 
expression. Within hours after neuronal injury the complement 
type 3 receptor (CR3) has been observed to be significantly 
increased in microglia (Graeber et al. 1988b). After 
stimulation with the pro-inflammatory cytokine interferon-gamma 
(IFNG) in vitro, the most notably upregulated genes are 
associated with antigen presentation, cytoskeletal binding, and 
cell adhesion and signalling (Moran et al. 2004). 
The upregulation of immune-associated molecules including 
major histocompatibility complex class II (MHCII), cytokines and 
inducible nitric oxide synthase (iNOS) may encourage the further 
proliferation, migration and altered gene expression of 
neighbouring microglia, as well as astrocytes, and trophic 
factors may induce axonal sprouting (Streit et al. 1999; Akiyama 
et al. 2000) . 
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Resting Activated Phagocytic 
Figure 1.1 Schematic illustration of microglial activation 
Upon detecting an injury in the CNS, microglial processes 
shorten and thicken. Activated microglia can ultimately adopt a 
phagocytic morphology. This schematic in reverse roughly 
corresponds to the maturation of microglia during development, 
from early migration into the CNS to a resting, adult state. 
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1.1.2.1 The effect of experimental conditions on observations 
of microglial activation 
Much of the information available on the expression 
changes of microglia are based on in vitro studies of microglia 
in culture. Culture conditions cannot adequately reproduce the 
environment of the CNS, and the variability of culture 
conditions across studies limits the extent to which a systemic 
difference between microglia in vivo and in vitro can be 
established. 
The absence of additional cell types in culture, 
particularly neurons and astrocytes, fundamentally alters the 
relationship between microglia and their surroundings. As 
evidenced by observations of microglia during development, a 
microglial cell without the unique environmental cues of the CNS 
is simply a macrophage. Co-cultures of astrocytes and blood- or 
spleen-derived macrophages lead to those macrophages adopting 
the morphology of microglia, suggesting that neurons are crucial 
to microglial maturation (Sievers et al. 1994). Microglia adopt 
a more ramified morphology when they are co-cultured with 
astrocytes (Tanaka and Maeda 1996). Astrocytes are able to 
release ATP and synthesise and activate cytokines, which may 
mediate the extent of the neuroinflammatory response of 
microglia (Vincent et al. 1997; Bianco et al. 2005). 
Neurons also release factors that can regulate the 
microglial phenotype. Neuron-conditioned culture media has a 
profound, differential effect on the survival of activated and 
ramified microglia (Polazzi and Contestabile 2003). Deletion of 
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the gene encoding CD200, expressed in neurons, leads to a 
persistent activated phenotype in microglia, which express the 
CD200 receptor (Hoek at al. 2000). 
1.1.2.2 Animal models of microglial activation: the facial 
nucleus axotomy model of microglial activation in 
neuronal injury 
Microglial activation has been assessed in a vast number 
of animal models of different CNS diseases and injuries. 
Axotomy of the facial nucleus is one animal model that has 
permitted the extensive analysis of microglial activation 
following nerve injury in a system in which either regeneration 
or degeneration can be induced. 
The severity and methodology of a facial nerve lesion can 
be varied to affect the survival rate of the motor neurons 
involved. Crushing of the nerve often results in a nearly full 
functional recovery, while avulsion or retrograde axonal 
transport of toxins such as ricin result in neuronal death. The 
proximity of a lesion to the facial nucleus is inversely related 
to neuronal survival, and young animals show less neuronal 
survival than adults (Soreide 1981; Dai at al. 2000). Species 
differences are also a confounding factor; most notably, rats 
tend to have more robust recovery from lesion than mice (Moran 
and Graeber 2004). 
The facial nucleus axotomy model highlights the diversity 
and complexity of the microglial response to different types of 
injury. Microglia proliferate, upregulate CR3, the cell 
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adhesion molecule LFA-1, macrophage colony stimulating factor 
(M-CSF) and granulocyte-macrophage stimulating factor (GM-CSF), 
express (de novo) MHCII and activate cytoskeletal proteins 
(Graeber et al. 1988a; Graeber et al. 1988b; Graeber et al. 
1988c; Streit et al. 1989; Moneta et al. 1993). Microglia do not 
become phagocytic, however, unless the nerve injury is designed 
to result in neuronal death rather than regeneration (Streit and 
Kreutzberg 1988). A second increase in intercellular adhesion 
molecule-1 (ICAMl), which would otherwise increase at the time 
of lesion and then gradually taper off, is also associated with 
this phagocytic change (Werner et al. 1998). 
1.1.2.3 Activation and inflammation 
Classical inflammation involves the recruitment of 
monocytes and lymphocytes, as well as neutrophils and other 
circulating cells, to an affected area. Molecules that 
facilitate the initiation and progression of the inflammatory 
response are involved in cellular processes including antigen 
presentation, adhesion and transmigration, chemotaxis and 
phagocytosis. The effects of molecular signals can vary 
depending on cell type and the time-line of the inflammatory 
process (Cotran et al. 1999). 
The upregulation of inflammation-associated molecules by 
activated microglia and their adoption of a more macrophage-like 
state has led to microglial activation being described as 
inflammatory. However, in the absence of infiltrating T-cells, 
such as is observed in classical neuroinflammatory conditions 
such as multiple sclerosis (MS) , true inflammation can not be 
considered to occur. Purely glial inflammation as observed in 
neurodegenerative disease conditions is a distinct process. 
When T-cell infiltration does occur, as in the facial 
nucleus axotomy model of neurodegeneration in mice, the 
inflammatory response is highly specialised and aimed to limit 
the extent of neuronal death (Raivich et al. 1998; Serpe et al. 
1999). 
1.1.2.4 Antigen presentation 
The MHCII molecule is used to present extracellular, 
generally bacterially derived, antigen to cluster of 
differentiation (CD) 4-expressing T-cells. MHCII is a 
heterodimer of two homologous peptide chains, with a peptide-
binding domain between the two (Figure 1.2 A). Antigen 
presentation is illustrated schematically in Figure 1.2 B. In 
the brain, MHC expression is one of the earliest microglial 
responses to neuronal injury. 
In MHCII chimeric mice in which either microglia or 
peripheral immune cells were unable to present antigen, the 
protection of motor neurons after facial nucleus axotomy was 
found to be wholly dependent on antigen presentation by 
microglia (Byram et al. 2004). 
MHCII alone is not sufficient to recruit T-cells, and 
MHCII expression may also serve to prevent T-cell activation in 
some instances. Co-stimulatory molecules B7.1 and B7.2 are also 
required in conjunction with MHCII for T-cell recruitment (Perry 
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1998) . After experimental spinal cord lesion, microglia caudal 
to the injury express MHCII and CD68 but not B7.1 or B7.2. The 
absence of T-cell infiltration may prevent secondary damage 
(Schmitt et al. 2000). 
In those instances in which T-cell recruitment does not 
occur subsequent to microglial activation, MHCII expression is 
still evident. MHCII expression may function as a form of 
communication between microglia alone, or may represent a 
component of microglial activation that is always evoked upon 
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Figure 1.2 MHCII-mediated antigen presentation 
(Preceding page) MHCII is composed of two homologous peptides 
and contains an extracellular peptide-binding domain (A). 
Extracellular proteins are endocytosed by antigen-presenting 
cells (Bl) and broken down in an endosomal compartment (B2) . 
The MHCII molecule is produced in the endoplasmic reticulum with 
the addition of an invariant chain bound in the peptide-binding 
domain to prevent the binding of self antigens (B3) . MHCII is 
transported to the endosomal compartment via the Golgi apparatus 
and the invariant chain removed (B4) . An antigenic protein 
fragment is bound to MHCII, and the molecule is transported to 
the cell surface for presentation to CD4+ T-cells (B5). 
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1.1.2.5 Regulation of the microglial inflammatory process: 
interleukins, cytokines, chemokines and complement 
Cytokines, chemokines and some growth factors are involved 
in stimulating the response of immune cells and used by 
microglia to modulate their response to injury. Those molecules 
involved in microglial activation include a number of 
interleukins (IL) including IL-IB, IL-2, IL-4, IL-6, IL-10, IL-
12, IL-15 and IL-18, IFNG, colony stimulating factors M-CSF and 
GM-CSF, transforming growth factor beta (TGF-B) and tumour 
necrosis factor alpha (TNF-A) (van Rossum and Hanisch 2004) . 
IL-IB and TNF-A have been shown to exacerbate lesion size and 
cell loss in models of acute brain injury (Allan and Rothwell 
2001) . Conversely, TNF-A and IL-IB, as well as IL-6, have also 
been demonstrated to have neurotrophic effects (Hama at al. 
1991; Cheng et al. 1994; Barger et al. 1995; Ho and Blum 1997). 
Chemokines are a subset of cytokines that induce 
chemotaxis and may be pro-inflammatory by increasing the 
migration of additional cells to the site of an injury. 
Microglia have been demonstrated to express chemotactic cytokine 
receptor (CCR) 3, CCR5, CXCR, CXCR2, CXCR4, CX3CR1 and IL-8R. 
The complement system and immunoglobulins (Ig) work in 
concert to target foreign substances for phagocytosis. While 
Igs target specific antigens and bind to pathogens, complement 
molecules work in concert to actively destroy the target cell by 
rupturing the cell membrane. IgA, M and G, and complement 
factors Clq and C5a have been shown to affect microglial 
activation. 
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Additional molecular modulators of microglial activation 
include beta-amyloid (A(3) and prion protein (PrP) , prostaglandin 
E2, steroids and adenosine triphosphate (ATP). 
One of the difficulties in understanding the effect of any 
one of the abovementioned molecules is the manner in which they 
work together. Microglia have an ^analog' rather than ^binary' 
relationship with any particular cytokine, and some cytokines in 
combination can have very different effects than the same 
molecules alone or paired with a new partner. For example, IFNG 
is widely considered to have pro-inflammatory effects (Meda et 
al. 1995; Panek and Benveniste 1995). In hippocampal slice 
cultures, IFNG has also been demonstrated to lead to an anti-
inflammatory response in microglia (Butovsky et al. 2005). 
Finally, microglia may be ^primed' by earlier events, 
confounding the predictability of their response to a new change 
in the microenvironment. Microglia from different regions or 
different individuals, even those with the same expression 
profile of cytokines, can respond differently to the same 
stimuli (Meeuwsen et al. 2005). 
1.1.2.6 Markers of microglial activation 
Many different histochemical and immunohistochemical 
markers have been used to visualise microglia in brain tissue. 
There is no single, specific marker with which microglia can be 
differentiated from all other cell types. While this situation 
can lead to difficulties in distinguishing amoeboid microglia 
from peripheral macrophages, many markers suitable for light 
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microscopy can distinguish microglia from other glia and 
neurons. 
A number of lectins have been used successfully to label 
microglia. Generally, expression is observed in resting 
microglial populations and increased upon microglial activation. 
Ricinus communis agglutin (in several forms), B4 isolectin from 
Griffonia simplicifolia seeds, mistletoe lectin-1, B4 isolectin 
of Bandieraea simplifolia-1 lectin, soybean agglutinin, and 
tomato lectin have all been used to identify microglia (Mannoji 
et ai. 1986; Streit and Kreutzberg 1987; Suzuki et al. 1988; 
Tillotson and Wood 1989; Streit 1990; Nagao et al. 1992; Acarin 
et al. 1994). 
Immunohistochemically, MHCII, CR3, CD68, CD45, Ibal and 
OX-42 have all been used widely to identify microglia. Ibal has 
been reported to label both resting and activated microglia (Ito 
et al. 1998). 
CD68 is a lysosomal marker. Many monoclonal antibodies 
directed against CD68, including KPl and EBMll, label both 
macrophages and myeloid cells (Micklem et al. 1989). These 
clones have been reported to label resting microglia (Hulette et 
al. 1992). Clone PGMl identifies CD6B in a form that occurs in 
actively phagocytic cells (Falini et al. 1993). PGMl is not a 
marker of microglia per se, but of phagocytosis. Conversely, 
MHCII (clone CR3/43 is used most commonly) is upregulated early 
in the activation process and persists throughout (Graeber et 
al. 1994a). 
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1.1.3 Variations in microglial response 
1.1.3.1 Regional differences 
Macrophages have been demonstrated to be a highly-
heterogeneous and dynamic cell population in peripheral tissue. 
It is not known to what extent microglia are a homogeneous 
subtype of monocyte, or if they can reflect the diversity 
observed in peripheral monocyte populations. 
Developmental evidence suggests that microglia emigrate to 
the CNS in distinct populations (Hutchins et al. 1990). The 
localisation of vault molecules, large particles that contain 
both proteins and RNA, in the brain, supports this assertion in 
identifying two distinct cell populations of monocytic lineage 
that migrate into the brain at different locations over 
different time courses (Chugani et al. 1991; van Rossum and 
Hanisch 2004). 
The distribution of microglia in normal adult mouse brain 
is also heterogeneous, with the hippocampus, basal ganglia 
including the substantia nigra (SN), and olfactory bulb 
containing a much higher density of microglia than other brain 
areas (Lawson et al. 1990; Mittelbronn et al. 2001). 
Furthermore, studies of the microglial response to injury 
suggest that different microglial populations express different 
immunologically relevant proteins such as MHCII and CD4 (Streit 
and Graeber 1993). 
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1.1.3.2 Microglia and aging 
Aging may have an underlying effect on observations of 
microglia in diseases such as PD which primarily affect the 
elderly. In humans, non-human primates and rodents, MHCII 
expression has been reported to increase steadily with age, 
independent of disease or trauma and particularly in the white 
matter (Perry at al. 1993; Ogura at al. 1994; Sheffield and 
Berman 1998; Streit et al. 2004a). It is unclear whether this 
change in phenotype is a result of changes in the CNS, immune 
system or a combination of the two. 
Microglia and astrocytes in culture harvested from older 
rats are more inclined to proliferate and express MHCII, and 
they are less sensitive to TGF-B that glia from younger donor 
animals (Rozovsky et al. 1998). Mixed microglia-astrocyte 
cultures harvested from the hippocampus and cortex of older 
animals express increased levels of IL-1 and IL-6 upon exposure 
to lipopolysaccharide (LPS) , a component of the cell membrane of 
some bacteria that triggers inflammation, compared to younger 
animals (Xie et al. 2003). 
1.1.3.3 Microglia and cardiovascular change 
Cardiovascular health may also affect microglia and their 
propensity to activation. Increased microglial MHCII expression 
has been reported in humans with heart disease and 
hypercholesterolemic rabbits (Streit and Sparks 1997). Statins, 
used to treat high cholesterol, have also been shown to reduce 
microglial expression of IL-6 (Lindberg et al. 2005). 
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1.1.3.4 Microglia and agonal state 
The primary cause of death may be the most important 
factor in differences in microglia in studies of age-matched 
tissue. The cause of death has been shown to affect microglial 
protein expression in post-mortem tissue (Mattiace et al. 1990). 
Additionally, microglia remain viable for a short time after 
death, as evidenced by their successful extraction from post-
mortem tissue and subsequent study in vitro (De Groot et al. 
2000; de Groot et al. 2001). Hence, delays in brain processing 
after death may also factor in tissue comparisons of microglia. 
1.1.3.5 Is activation reversible? 
The facial nucleus model provides evidence that microglia 
do not sustain an activated state when it is no longer needed, 
as their numbers decrease at the site of injury and the 
expression of inflammation-associated molecules decreases. 
TUNEL-labelled microglia have been observed in the 
recovery phase of injury models, but considering the 
proliferative potential of microglia, the frequency with which 
they are observed to undergo apoptosis after recovery from 
injury seems rather low (Gehrmann and Banati 1995; Jones et al. 
1997). 
Activated microglia have also been demonstrated to return 
to a ramified state. Labelled axonal debris taken up by 
phagocytic microglia was initially observed only on cells with 
an amoeboid morphology. Eight days after the lesion, highly 
ramified cells were observed to contain the same labelling 
(Bechmann and Nitsch 1997). Pre-labelled amoeboid microglia 
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placed in hippocampal cultures have also been observed to ramify 
with sufficient time (Mailer et al. 1997). 
1.1.4 Perivascular cells and microglia 
Perivascular macrophages are more similar than microglia 
to macrophages found in blood. They are localised between 
pericytes and the feet of astrocytes at the glia limitans 
surrounding blood vessels in the CNS. They represent a distinct 
immunohistochemically definable cell population (Kida et al. 
1993). More recent work using GFP-transfected bone marrow cells 
has suggested that perivascular macrophages are in fact a 
transient population regularly replaced by blood-borne 
peripheral macrophages (Bechmann et al. 2001b). 
Interestingly, perivascular macrophages located 
contralateral to the site of a lesion have been observed to 
upregulate MHCII, suggesting that they may be part of an immune 
regulatory network able to recognise distal changes in the glial 
inflammatory status of the brain (Streit and Graeber 1993). 
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1.2 Parkinson's disease 
1.2.1 Clinical overview 
The movement disorder now known as Parkinson's disease 
(PD) was first described by Dr. James Parkinson in his 1817 
"Essay on the Shaking Palsy," in which he described patients 
which shared the clinical features including rigidity, a resting 
tremor and stooped posture. 
Dr. Parkinson's initial analysis of the clinical signs of 
PD remains accurate to this day, with the exception of his 
statement that "the senses and intellect" are spared in the 
disease. Resting tremor and rigidity are the most common 
presenting signs of PD, but many new clinical features of PD 
have become more prominent as treatment options to address motor 
symptoms have improved. Most notably, the co-occurrence of 
neuropsychological impairment such as dementia, psychosis, 
anxiety and depression in PD has become a major issue in 
contemporary treatment (Lemke et al. 2004; Weintraub and Stern 
2005; Papapetropoulos and Mash 2005; Richard 2005). The 
prevalence of dementia in PD is approximately 30% and has been 
reported to be as high as 78% after 8 year follow-up (Emre 2003; 
Richard 2005). Autonomic and sleep disturbances are also 
prominent clinical features of PD (Jost 2003; Adler and Thorpy 
2005; Chaudhuri et al. 2006). In a cohort of 141 PD patients, 
48% reported orthostatic dizziness, 45% bladder dysfunction, 64% 
erectile dysfunction, and 39% bowel dysfunction, with 56% of 
patients reporting two or more symptoms (Magerkurth et al. 
2005). 
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1.2.1.1 Pharmacological treatment of PD 
In 2000, Dr. Arvid Carlsson was awarded a Nobel Prize in 
Medicine for his research in which he demonstrated the 
neurotransmitter properties of dopamine (DA) and subsequently 
used 3,4-dihydroxy-L-phenylalanine (L-DOPA), a precursor to DA, 
to elicit a functional recovery in mice treated with the DA-
depleting drug reserpine (Carlsson 1954; ANDEN et al. 1964; 
Utley and Carlsson 1965). L-DOPA was approved for general use 
by physicians to treat PD by the 1970s. 
Newer drugs have been developed in an attempt to replace 
DA while minimising dyskinesias, the primary side effect of L-
DOPA and DA replacement therapies in general. Direct DA 
agonists including bromocriptine, pergolide, ropinirole and 
pramipexole act by stimulating primarily the DA D2 receptor. 
The monoamine oxidase B (MAOB) inhibitor selegiline is involved 
in preventing the breakdown of DA, and reduces symptoms to the 
extent that patients can delay L-DOPA treatment for some months 
(Palhagen et al. 1998). 
1.2.1.2 Incidence and prevalence of PD 
PD is the second most common neurodegenerative disease 
after AD. European studies have reported a disease prevalence 
of 1 - 2.5% of the general population (von Campenhausen et al. 
2005). 
90% of PD cases are sporadic, and age is the primary risk 
factor for the development of PD. Exposure to environmental 
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toxins and genetic factors can impact disease susceptibility, 
but unless a specific environmental trigger, such as ingestion 
of the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine 
(MPTP) or a Mendelian inheritance pattern within a family has 
been established, PD cases are considered idiopathic. 
1.2.1.3 Familial parkinsonism 
Eleven gene loci that confer forms of genetic PD are now 
known (Table 1.1). The corresponding gene has been identified 
for six of these loci. Parkin (PARK2) mutations in particular 
are associated with juvenile-onset PD. PARKS, PARK7 and PARK9 
are also associated with early-onset forms of PD. The other 
loci are associated with a disease course more typical of 
idiopathic PD. The clinical and neuropathological features of 
the different mutations vary, but individuals with genetic PD 
consistently respond well to L-DOPA (Mizuno at al. 2006). 
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Table 1.1 PARK loci 
SNCA, alpha-synuclein; 3xSNCA, alpha-synuclein triplication; 
UCHLl, ubiquitin carboxy-terminal hydrolase LI; PINKl, PTEN-
induced kinase 1; PTEN, phosphatase and tensin homolog; DJl, 
oncogene DJl; LRRK2, leukocine-rich repeat kinase 2. All gene 
inheritance is autosomal. 
Gene Inheritance Locus References 
(Polymeropoulos et al. 
1997; Kruger et al. 
1998; Zarranz et al. 
PARKl SNCA Dominant 4q21.3-23 2004) 
(Kitada et al. 1998; 
PARK2 Parkin Recessive 6q25.2-27 Abbas et al. 1999) 
PARKS - Dominant 2pl3 (Gasser et al. 1998) 
PARK4 3xSNCA Dominant 4p21.3-23 (Singleton et al. 2003) 
PARKS UCHLl Recessive 4pl6.3 (Leroy et al. 1998) 
(Valente et al. 2001; 
PARK 6 PINKl Recessive lp36 Valente et al. 2004) 
(van Duijn et al. 2001; 
PARK? DJl Recessive lp36 Bonifati et al. 2003) 
(Funayama et al. 2002; 
12pll.2- Paisan-Ruiz et al. 
PARKS LRRK2 Dominant ql3.1 2004) 
PARK 9 - Recessive lp36 (Ramirez et al. 2006) 
PARK10 - - lp32 (Hicks et al. 2002) 
PARKl1 IGYF2 Dominant 2q36-37 (Pankratz et al. 2003) 
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1.2.2 Neuropathological overview 
The substantia nigra (SN) is widely regarded as the 
primary locus of neurodegeneration in PD. The SN can be roughly 
divided into two regions, the SN pars compacta (SNpc) and pars 
reticulata (SNpr), although numerous subnuclei have been 
described (Hassler 1937; Braak and Braak 1986) . The SN, 
particularly the SNpc, is populated by large cells containing 
neuromelanin, a by-product of the production of DA. The SN is a 
major site of DA production in the brain and entirely 
responsible for the dopaminergic input to the striatum (Figure 
1.3) . The death of DA neurons in the SN and subsequent lack of 
DA in the striatum is considered the primary cause of motor 
symptoms in PD. Microscopically, the SN of PD cases shows a 
marked reduction of DA neurons. The ventrolateral SNpc appears 
to be selectively vulnerable, demonstrating nearly 70% neuronal 
loss at the time of symptom onset (Hassler 1938; Fearnley and 
Lees 1991) . The resulting loss of DA input, which can be 
visualised with immunohistochemical labelling of tyrosine 
hydroxylase (TH), a catalytic enzyme involved in DA synthesis, 
primarily affects the putamen, in the caudal portion of which 
just 1% of normal DA levels were measured in post-mortem PD 
cases (Kish et al. 1988). This DA deficit causes a 
dysregulation of the basal ganglia with repercussions on 










Figure 1.3 Connectivity of the basal ganglia 
Excitatory pathways are indicated in red and are primarily 
glutamatergic. Inhibitory, GABA-ergic pathways are indicated in 
blue. Dopamine signalling is indicated in black. STN, 
subthalamic nucleus; GPint, internal globus pallidus; GPext, 
external globus pallidus; T_VLN, ventrolateral nucleus of the 
thalamus. 
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1.2.2.1 Protein aggregation in PD 
The Lewy body (LB) is a protein aggregate representing the 
pathological hallmark of PD. F. Lewy first described the LB in 
the brain stem as a component of paralysis agitans in 1912. In 
1923 he described the more diffuse, cortical variant (Holdorff 
2002) . The classical, brainstem LB is a dense, eosinophilic 
sphere surrounded by a halo. 
1.2.2.2 Additional neuroanatomical features of PD 
The dopaminergic system is not the only one impaired in 
PD. Other neurotransmitter signalling pathways including 
serotonin, norepinephrine and acetylcholine are also affected. 
The raphe nuclei, locus coeruleus and Nucleus Basalis of Meynert 
accordingly demonstrate neuronal death and LB-type pathology in 
surviving cells. The hippocampus and amygdala, involved in 
.memory and emotion, and the hypothalamus and mamillary bodies 
which maintain control over the autonomic system, are also 
profoundly affected in PD in some cases. 
1.2.2.3 Possible causative factors in PD 
Many biochemical pathways have been suggested to play a 
role in the induction of PD. The role of oxidative stress in PD 
has been studied extensively (Sofic et al. 1992). Increased 
levels of iron are found in the PD brain and may promote 
damaging oxidation (Kienzl et al. 1995). The production of DA 
is metabolically demanding and generates pro-oxidative by-
products, particularly neuromelanin, that may trigger or 
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exacerbate metabolic problems in DA neurons (Faucheux et al. 
2003). Mitochondrial dysfunction, specifically of complex I, 
has also been implicated in PD (Schapira et al. 1989; Schapira 
et al. 1990). A disruption of the ubiquitin-proteasome 
mechanism of protein degradation has also been implicated in PD 
through the localisation of proteasomal structures in LBs (li et 
al. 1997) and reports of impaired proteasomal function in PD 
(McNaught and Jenner 2001; McNaught et al. 2002; McNaught et al. 
2003). 
These mechanisms leading to cell injury or death are 
inter-related. Iron plays a key role in mitochondrial electron 
transport, as well as inhibiting proteasomal function after 
release from neuromelanin (Shamoto-Nagai et al. 2006). 
Impairment of the proteasome has also been linked to 
mitochondrial dysfunction (Sullivan et al. 2004; Duke et al. 
2006). 
1.2.3 Alpha-synuclein: Parkinson's disease is a synucleinopathy 
Alpha-synuclein (SNCA) is a highly conserved, natively 
unfolded 18 kDa protein (Uversky and Fink 2002). 
SNCA is a major component of LBs (Spillantini et al. 1998) 
and the glial cytoplasmic inclusions (GCIs) associated with 
Multiple system atrophy (MSA) (Wakabayashi et al. 1998), as well 
as being a target of mutations which result in familial PD 
(Polymeropoulos et al. 1997; Kruger et al. 1998; Singleton et 
al. 2003; Zarranz et al. 2004). The increased sensitivity of 
SNCA immunohistochemistry over conventional histological stains 
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has established the technique as a standard tool in the 
diagnosis of PD, Dementia with Lewy bodies (DLB) and MSA (Munoz 
1999; Dickson 2001) , and led to new insights regarding the 
extent and variation of SNCA-containing structures and their 
formation. 
PD, DLB and MSA are now commonly designated as 
synucleinopathies, in recognition of SNCA-immunoreactive protein 
aggregates being of great neuropathological significance to all 
three (Goedert and Spillantini 1998) . Other brain disorders in 
which SNCA may feature pathologically are familial and sporadic 
Alzheimer's disease (AD) (Lippa et al. 1998; Hamilton 2000), 
neurodegeneration with brain iron accumulation type I (Galvin et 
al. 2000), parkinsonism-dementia complex of Guam (Yamazaki et 
al. 2000), diffuse neurofibrillary tangles with calcification 
(Hishikawa et al. 2003), and Creutzfeldt-Jakob disease (Haik et 
al. 2002), as well as incidentally in normal aging (Forno 1969; 
Perry et al. 1990; Parkkinen et al. 2001; Saito et al. 2003). 
PD, DLB and MSA are all marked clinically by varying 
degrees of progressive motor, cognitive and autonomic decline, 
and there is substantial overlap in their patho-anatomical 
characteristics. Prior to the identification of SNCA as a 
common underlying pathological theme in all three diseases, MSA 
in particular was identified as an unrelated disorder and the 
high level of pathological overlap between PD and DLB 
manifesting itself in "shared" SNCA deposition was not fully 
recognised. 
It is unclear to what extent SNCA aggregation reflects 
neurodegeneration and clinical features of disease. Attempts to 
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correlate neuronal death and/or protein aggregation with 
clinical symptoms are plentiful, but many studies report 
contradicting or inconclusive results. 
1.2.3.1 Glial degeneration 
Glial degeneration has not been widely reported in PD. 
However, some studies have indicated that it may be a common and 
pathologically meaningful occurrence in PD. SNCA-positive 
protein aggregates localised to astrocytes and oligodendrocytes 
have been reported in post-mortem PD tissue but not control 
tissue or cases of so-called Incidental Lewy body disease 
(ILBD) , in which LBs are located in the SN and/or LC but there 
is no clinical history of parkinsonism or dementia. 
Importantly, the presence of these glial SNCA aggregates was 
significantly positively correlated with the severity of 
clinical symptoms of PD, suggesting that glial SNCA aggregation 
may reflect disease progression (Wakabayashi et al. 2000). 
Another study reports argyrophilic glial inclusions in all ten 
PD cases and none of five control cases examined, distributed 
throughout the brain and, in cortex, roughly correlated with the 
number of LBs in the tissue (Hishikawa et al. 2001). SNCA 
aggregates have also been described in Bergmann glia in PD (Piao 
et al. 2003), as have tau-immunoreactive astrocytic protein 
aggregates (Hishikawa et al. 2005). 
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1.2.4 Current problems in the study and treatment of 
Parkinson's disease 
1.2.4.1 The pharmacological ^glass ceiling' of dopamine 
replacement therapy 
PD is not simply a disease of DA deficiency, as 
demonstrated by the extent of SNCA aggregation and neuronal loss 
throughout the PD brain. The good response of PD patients to 
anticholinergic drugs highlights the complexity of the disease. 
DA replacement therapy has improved dramatically, and new 
neurosurgical techniques have been developed to stimulate basal 
ganglia signalling. Improvements in disease management are not 
necessarily positive steps toward the development of a 
breakthrough in ^curing' PD. 
1.2.4.2 Animal models 
The existence of a good animal model is an important step 
in the development of novel treatments to a disease. Animal 
models of dopaminergic death are numerous, but it is unclear to 
what extent they replicate the pathological processes involved 
in PD. 
Many rodent and primate models of PD are generated through 
the stereotactic injection of MPTP, a mitochondrial complex I 
inhibitor, either acutely or chronically. Primates are far more 
sensitive to MPTP than rodents. MPTP chronically administered 
to monkeys results in dopaminergic cell death and LB formation 
in the SN and the development of many of the clinical signs of 
PD, which respond positively to L-DOPA. Another commonly used 
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neurotoxin, 6-hydroxydopamine (6-OHDA), enters neurons via DA 
reuptake transporters and kills them by inducing oxidative 
stress on the cellular environment. 
Genetic knock-out mice have been developed which express 
human wild-type or mutated SNCA. The expression of SNCA alone 
does not result in impairment, but when these animals are 
subjected to neurotoxins they also develop motor deficits and 
LBs. 
An intriguing animal model involves the injection of 
immunoglobulins or serum extracted from humans with PD into the 
brain of rodents. These animals also undergo specific neuronal 
death of DA neurons in the SN (Chen et al. 1998). 
1.2.4.3 Disease variability 
PD is not a homogeneous disease. The clinical and 
pathological variability of individuals makes them a challenge 
to group, compare or model. As discussed in Section 1.2.1, the 
high prevalence of dementia and autonomic disorders in PD lends 
complexity to any cohort. 
Confounding issues of sex and age are also problematic. 
As in animals, females tend to have more innate defence from 
dopaminergic degeneration than males (Tamas et al. 2005). Drug-
naive women diagnosed with PD were older and had a lower PD 
severity score than their male counterparts (Haaxma et al. 
2006). As the population ages, PD becomes a more common 
phenomenon. Individuals diagnosed with PD in their ninth decade 
are grouped with those who developed PD thirty years younger 
51 
under the umbrella of idiopathic PD, although the etiology of 
the clinical signs of PD may be quite different. 
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1.3 Microglial involvement in Parkinson's disease 
An increased number of MHCII-expressing, putatively 
activated microglia have been described in PD, Alzheimer's 
disease (AD) and other neurodegenerative diseases (McGeer et ai. 
1988b; McGeer et al. 1988c; Graeber et al. 1994a). Observations 
of activated microglia in neurodegeneration have led to the 
hypothesis that chronic inflammation in the brain may lead to or 
exacerbate neuronal injury in PD {McGeer and McGeer 2004) . 
1.3.1 Microglia associated with alpha-synuclein 
It is possible that SNCA acts as a pathological substrate 
which initiates microglial activation in PD, as A(5 has been 
suggested to do in AD (Bodies and Barger 2005) . Using MHCII as 
a marker of microglial activation, some microglia have been 
identified in close proximity to LBs and others appeared 
completely independent of them, in the amygdala and cerebral 
cortex of DLB patients, in the hippocampus of DLB and PD brains 
and in the SN, putamen and cerebral cortex of PD cases (McGeer 
et al. 1988b; Togo et al. 2001; Imamura et al. 2003a; Imamura et 
al. 2005). MHCII expression has also been reported to parallel 
system degeneration, as demarcated by SNCA-immunoreactive GCIs, 
in some neuroanatomical systems in MSA but not in others 
(Ishizawa et al. 2004). 
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1.3.2 Alpha-synuclein and glial inflammation 
SNCA and cytokines can have a synergistic effect on glia. 
Astrocytes upregulate SNCA in response to stimulation with IL-IB 
(Tanji et al. 2001). Like astrocytes, macrophages in culture 
increase SNCA expression in response to IL-IB and LPS (Tanji et 
al. 2002). These findings are in line with reports of neuronal 
upregulation of SNCA in response to oxidative stress and 
administration of neurotoxins that increase expression of pro-
inflammatory molecules, suggesting that SNCA may play a role in 
glial inflammation-related pathways (Shavali et al. 2004; 
Matsuzaki et al. 2004; Quilty et al. 2005; Purisai et al. 2005). 
1.3.3 Cytokines and PD 
TNF-A, IL-IB, IL-2, IL-4, IL-6, TGF-A, TGF-Bl and TGF-B2 
have all been reported to be increased in the nigrostriatal 
region and cerebrospinal fluid (CSF) of PD patients compared to 
controls (Boka et al. 1994; Mogi et al. 1994a; Mogi et al. 
1994b; Blum-Degen et al. 1995; Imamura et al. 2003a). IL-6, IL-
IB and TNF-A mRNA are significantly upregulated in the cingulate 
cortex (CING) in PD and DLB brain compared to controls. IL-6 is 
also upregulated in the putamen and hippocampus while IL-IB is 
downregulated in the hippocampus (Imamura et al. 2005). 
Cytokines are able to induce the expression of iNOS, which 
is expressed by microglia, upregulated in PD and suggested to 
increase neuronal death through oxidative stress mechanisms 
(Moncada et al. 1991; Chao et al. 1992; Simmons and Murphy 1992; 
Hunot et al. 1996). 
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1.3.4 Glial inflammation and susceptibility to PD 
Single nucleotide polymorphisms (SNPs) in some genes that 
encode cytokines have been suggested to increase susceptibility 
to PD or influence disease course. SNPs in IL-IB, IL-6, IL-8 
and TNF-A have been associated with increased risk of developing 
PD (Mattila et al. 2002; Schulte et al. 2002; Ross et al. 2004; 
Hakansson et al. 2005a). Within PD cohorts, IL-IB, IL-10 and 
TNF-A SNPs have been associated with earlier disease onset 
(Nishimura et al. 2000; Nishimura et al. 2001; Nishimura et al. 
2005; Hakansson et al. 2005b). 
1.3.5 PK11195 PET imaging of microglia in vivo 
The peripheral benzodiazepine receptor (PER) is considered 
a marker of early microglial activation (Kassiou et al. 2005). 
The radioligand [^^C](R)-PK11195 binds PER and allows microglial 
activation to be observed in vivo with positron emission 
tomography (PET) imaging (Banati et al. 1997). [^^C](R)-PK11195 
binding has been observed in anatomical regions that undergo 
pathological change in MSA and PD (Gerhard et al, 2003; Gerhard 
et al. 2005; Ouchi et al. 2005a). While [^^C](R)-PK11195 binding 
appears to correlate with disease severity in early PD, a long-
term study of PD patients found that after early activation 
[^C](R)-PK11195 binding remains stable (Gerhard et al. 2005; 
Ouchi et al. 2005a). These results suggest that a population of 
PBR-expressing microglia persists in affected brain areas in PD 
and raise the question of whether these microglia can fuel the 
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disease progression by maintaining a persistent state of 
activation. 
1.3.6 Microglia in animal models of Parkinson's disease 
Subtle changes in the complex expression profile of 
activated microglia can have marked effects on the 
microenvironment, and studies of animal models of PD highlight 
the impact that microglia can have on neuronal survival. In 6-
OHDA and MPTP animal models of nigrostriatal degeneration 
(discussed in Section 1.2.4.2), chemical inhibition of 
microglial activation with minocycline has been demonstrated to 
reduce neuronal death in the SN, but the same pharmacological 
treatment over a different time course has also been shown to be 
neurotoxic (He et al. 2001; Wu et al. 2002; Yang et al. 2003). 
Genetic and pharmacological inhibition of cytokines can also 
affect neurodegeneration, both positively and negatively, by 
altering the microglial response to MPTP (Cardenas and Bolin 
2003; Sugama et al. 2004; Ferger et al. 2004). A study on MPTP-
treated mice demonstrated that the toxin acts in an age-
dependent manner, with protracted microglial activation in older 
animals (Sugama et al. 2003). 
Interestingly, selective dopaminergic neuronal 
degeneration in the SN can be induced through the activation of 
microglia by stereotactic injection of LPS (Liu et al. 2000a). 
Neuronal loss in this model, which highlights the selective 
sensitivity of DA neurons to microglial activation, is prevented 
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by the inhibition of microglial activation (Herrera et al, 
2 0 0 0 ) . 
1.3.7 Other relevant animal models 
Of possible importance to the study of PD are studies of 
microglia in a knock-out model of amyotrophic lateral sclerosis 
(ALS) in which mice carry the same mutation in superoxide 
dismutase (SOD-1) that causes genetic ALS in humans. A 
reduction in mutant SOD-1 in microglia does not significantly 
affect disease onset, but it substantially reduces disease 
progression (Boillee et al. 2006). SOD-1 mutated microglia in 
mice without any myeloid cells cannot induce ALS-type symptoms. 
However, wild-type microglia introduced to SOD-1 mice also 
lacking myeloid cells are able to delay disease progression as 
well (Beers et al. 2006). These studies suggest that the gene 
expression of microglia can profoundly affect neuronal survival, 
and provide evidence for a primary glial component to 
neurodegenerative disease progression. 
1.3.8 Parkinson's disease and autoimmunity 
Abs directed against DA neurons have been identified in 
the CSF of some PD patients (McRae-Degueurce et al. 1988; 
Dahlstrom et al. 1990). A similar finding has been reported in 
AD, with Abs able to recognise cholinergic neurons when injected 
in rat (McRae-Degueurce et al. 1987; Dahlstrom et al. 1990). PD 
CSF can induce specific DA neuronal cell injury (Le et al. 
2001). 
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Two epidemiological studies have demonstrated that NSAIDS 
and specifically ibuprofen may be protective against PD, 
suggesting that inflammatory mechanisms may be involved in the 
disease (Chen et al. 2003; Chen et al. 2005). A diagnosis of PD 
has been found to be significantly associated with an earlier 
history of asthma, allergic rhinitis and hay fever, diseases 
which affect individuals whose humoral immune systems are 
hypersensitive (Bower et al. 2006). 
1.3.9 SNCA and microglia 
An understanding of the relationship between SNCA 
aggregation and microglial activation could improve our 
understanding of synucleinopathies as a whole. The similarities 
and differences in microglial response could refine current 
diagnostic criteria and possibly play a predictive role in the 
development of new drug treatments and preventative measures. 
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1.4 Aims 
The aim of the work presented in this thesis is to 
investigate the relationship between microglial activation and 
pathological protein deposition in PD and to attempt to identify 
novel protein markers of microglial and immune response to 
neuronal death in PD. 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Human brain samples 
A summary of the human tissue used in this study is 
contained in Table 2.1. Unless otherwise stated, all brain 
tissue used in this research was provided by the UK Parkinson's 
Disease Society Tissue Bank (PDSTB). Tissue was fixed in 3.7% 
formalin buffered in phosphate-buffered saline (PBS) (recipe in 
Appendix I) unless otherwise noted. Formalin-fixed, paraffin-
embedded tissue was provided either in blocks from which 
sections were subsequently cut (as described in 2.2.1) or in 8 
pm sections on SuperFrost Plus slides. Snap-frozen unfixed 
tissue was provided in 10 pm sections mounted on SuperFrost Plus 
slides or in blocks which were sectioned in the Department of 
Neuropathology. 
Formalin-fixed, paraffin-embedded tissue blocks from 3 
brains with no clinical or neuropathological signs of 
neurological disease were provided by Dr. Manuel Deprez at the 
University of Liege, Liege, Belgium. Archival sections from the 
SN of 17 PD cases, originally collected at the Institute of 
Neuropathology, University of Munich, Germany, and used in a 
previous study were provided by Professor Graeber (Kosel et al. 
1997c). These cases were fixed using the same methodology 
described above. Sections from a case of MS with incidental LB 
discovered during the neuropathological diagnostic screening of 
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the SN, as well as sections from MS-affected spinal cord were 
provided by the UK Multiple Sclerosis Tissue Bank (MSTB). These 
tissues undergo a slightly different fixation procedure; they 
are fixed in 4% paraformaldehyde rather than formalin. 
A block of snap-frozen unfixed human colon and sections of 
formalin-fixed, paraffin-embedded tonsil used as positive 
controls in antibody optimisation and comparison were provided 
by the Department of Histopathology, Imperial College London. 
Table 2.1 Summary of human tissue used throughout this thesis 
(The following two pages) Cases in black were obtained from the 
PDSTB, also designated with a ^PD' ^MSA' or ^PDC (control 
cases). Cases in blue are from the MSTB, also designated by ^MS' 
or ^MSC (controls) . Cases in bold are from the University of 
Liege, Belgium, and cases in green from the Department of 
Histopathology, Imperial college. Italicised cases were 
included in a microarray comparison of PD tissue with control 
(Moran et al. 2006). Case numbers (i.e. PD29, MS155) are those 
assigned by the tissue bank from which the case originated. 
ATYP indicates a case with no clear neuropathological diagnosis 
but a Parkinsonism-type clinical history. CON in front of any 
case indicates that it was used as a control in comparison to a 
PD cohort. The cause of death reported is the clinical cause of 
death listed on the death certificate. AAO, age at disease 
onset; DD, disease duration in years; AAD, age at death; IHD, 
ischaemic heart disease; MRSA, methicillin resistant 
Staphylococcus aureus; CA, carcinoma; GI, gastrointestinal; PM, 
post-mortem delay in hours; Ch, chapters. 
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CASE sex AAO DD AAD Cause of death PM Ch 
PDOl F 76 12 87 Unknown 29 6 
PD02 M 75 9 83 Bronchopneumonia 3 6 
PD04 M 65 3 68 Unknown 16 3,5, 6 
PDOl M 65 10 78 Bronchopneumonia 21.75 6 
PD08 M 63 9 72 Unknown n/a 4,5 
PD09 F 72 15 86 sudden collapse 5.5 6 
PDIO F 67 14 81 analgesia, pain 17.5 4,5,6 
PD15 M 57 14 70 Unknown 32.5 4,5 
PD16 F 67 18 85 Bronchopneumonia 13.5 3-7 
PD17 M 57 18 75 Chest infection 22 4,5 
PD18 M 78 5 82 Unknown 35 4,5,7 
PD19 F 55 18 72 aspiration pneumonia 36 4,5 
PD20 M 42 34 75 Unknown 1.3 5,6 
PD21 M 49 28 76 Unknown 17 4-7 
PD22 F 65 10 76 IHD 13.5 4,5,6 
PD23 M 75 1 82 IHD 28 4,5 
PD24 M 72 9 81 Unknown 17 4,5 
PD26 M 69 6 74 Unknown 74 4,5,7 
PD28 M 65 18 82 Bronchopneumonia 13.5 4-7 
PD29 M 70 7 76 Unknown 15 4-7 
PD32 M 86 3 89 Bronchopneumonia 16 4-7 
PD34 F 72 11 84 Unknown 15 4-7 
PD36 M 66 10 76 Unknown 9.75 4,5,6 
PD39 F 69 13 82 Bronchopneumonia 12 5,7 
PD45 M 60 19 80 Unknown 16 5,6 
PD55 F 58 18 76 Unknown 6.5 5,6 
PD67 M 73 9 83 Unknown 10 5,6 
PD74 M 76 9 85 Bronchopneumonia 17 5,6 
PD81 M 65 8 73 "MSA" 19 5,6 
PD8 6 F 77 9 87 GI haemorrhage 22 5,6,7 
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CASE sex AAO DD AAD Cause of death PM Ch 
ATYPPD4 6 F 62 6 68 
Brain metastasis of 
CA 21.7 6 
MSAPD12 M 32 10 42 Unknown 24 3,5 
MSAPD25 F 57 6 63 Unknown 80 5 
MSAPD43 M 78 8 86 Unknown 11 5,6 
CONPDCOi M - - 76 MI n/a 5 
CONPDC02 M - - 88 Biliary sepsis 21 5,7 
CONPDC03 M - - 84 Unknown 49 5,7 
CONPDC04 M - - 84 Organ failure,MRSA 47 7 
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C0NMSC32 M - - 75 Metastatic prostate cancer 22 6 
C0NMSC34 F - - 88 Bronchopneumonia 20 6 


















MS90 M 23 39 62 Multiple sclerosis 17 7 
MS126 M n/a n/a 75 Pneumonia 22 7 
MS133 M n/a n/a 63 Metastatic lung CA 20 7 
tonsil n/a - - n/a n/a n/a 7 
colon n/a - - n/a n/a n/a 6 
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2.1.2 Antibodies 
The antibodies (Abs) used in this project, their supplier, 
dilution and pre-treatment, are summarised in Table 2.2. 
Antibodies are discussed in further detail in the experimental 
chapters in which they are used. 
The two most frequently utilised Abs identified MHCII and 
CD68. To detect MHCII, monoclonal anti-HLA-DP, DQ, DR clone 
CR3/43 (Dako) (Graeber et al. 1994b) was used. To detect CD68, 
monoclonal antibody (mAb) clone PGMl (Dako) was used. Clone 
PGMl is specific to macrophages and does not label resting 
microglia (Falini et al. 1993). 
2.1.3 Chemicals 
All chemicals used in this project were provided by VWR 
(www.VWR.com) unless otherwise specified. 
64 
Table 2.2 Antibodies used throughout this research 
Cit, citrate; EDTA, ethylenediaminetetraacetic acid; FA, formic 
acid; Ht, high temperature; MBP, myelin basic protein. 
Anti- Manufacturer Clone Dilution Pre-Treatment 
SNCA Abeam Syn204 1/50 5 min. 100% FA 
SNCA Alexis 15G7 1/10 5 min. 100% FA 
SNCA Becton-Dickinson 42 1/300 5 min. 100% FA 
SNCA Chemicon 7B12.2 1/400 5 min. 100% FA 
SNCA NovoCastra KM51 1/40 Ht EDTA 
SNCA SantaCruz Syn211 1/100 5 min. 100% FA 
SNCA Zymed LB509 1/200 Ht Cit + FA 
MBP Dako - 1/200 -
CD68 Dako PGMl 1/200 -
MHCII* Dako CR3/43 1/100 Ht EDTA 
Fc-gamma Chemicon ClKmS 1/50 -
Fc-gamma LabVision 7 .30 1/25 -
Fc-gamma Serotec ATIO 1/1000 -
CD163 NovoCastra 10D6 1/200 Ht EDTA 
Ap * * 1E8 1/1000 8 min. 80% FA 
Tau AutogenBioclear AT 8 1/800 -
*anti-HLA-DP,DQ,DR 
** gift of Dr. SM Gentleman, Imperial College London 
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2.2 Methods 
2.2.1 Clinical and pathological assessment of cases 
For cases provided by the PDSTB, clinical histories are 
evaluated in detail by an experienced neurologist (Dr. R.K.B. 
Pearce) who prepared clinical summaries for each case. Relevant 
clinical data such as predominant motor symptoms (hemi-tremulous 
(H-T) or akinetic-rigid (A-R) ) and age at disease onset (AAO) 
and death (AAD) as well as drug treatment are found in these 
summaries and used for subsequent analyses. Neuropathological 
assessment and diagnosis by two clinical neuropathologists 
(Professor M.B. Graeber and Dr. F. Roncaroli) and one research 
neuropathologist (Dr. S.M. Gentleman), all from the Department 
of Neuropathology, Imperial College London, are based on slides 
provided by the PDSTB for SNCA, tau and A(3 immunohistochemistry 
of the SFG, hippocampal formation and midbrain as minimum data 
sets. Screening of the cases for confounding pathology is based 
on H&E examination of a standard series of 18 tissue blocks 
following a standardised dissection procedure (Vonsattel et al. 
1995) . Ratings of AD-associated pathology are assigned using 
International Classification of Diseases of the Nervous System 
(ICONS) criteria (http://www.ICDNS.org) on a scale of 1 (mild) 
to 4 (severe) in both entorhinal (ER) and isocortical (IC) 
tissue. 
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2.2.2 Sectioning of formalin-fixed, paraffin-embedded tissue 
Paraffin blocks were stored at 4°C prior to sectioning. 
Sections were cut at a thickness of 8 pm on a microtome using 
disposable blades (Accu-Edge). Sections were floated in a water 
bath at 50 °C until smooth and then dried onto Superfrost Plus 
slides at room temperature for approximately 30 min. Sections 
were incubated at 37°C overnight and subsequently stored at room 
temperature until used. 
2.2.3 Cryostat sectioning 
Fresh brains are cut into 1 cm-thick coronal slices, and 
those slices are cut into 2 cm square blocks on transparency 
paper with gridlines and photographed. The blocks are snap-
frozen in isopentane cooled in dry ice and stored at -80°C. 
Prior to sectioning, a block is left to equilibrate in a 
cryostat chamber cooled to approximately -18°C for a minimum of 
30 min. When the block is ready, a chuck is covered in O.C.T. 
embedding matrix, and the tissue placed on to it before the 
O.C.T. freezes. Once the tissue has frozen into place, the 
chuck is mounted into the cryostat, and 10 pm sections are cut 
and mounted onto Superfrost Plus slides. The sections are left 
to dry at room temperature for approximately 30 min. and then 
stored at -80°C until use. 
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2.2.4 Immunohistochemistry 
2.2.4.1 History of the ABC method 
Immunohistochemistry (IHC) is the primary methodology used 
in the research described in this document. IHC allows for the 
visualisation of specific tissue components by attaching a 
visible molecule to an antibody/antigen reaction. 
Polyclonal antibodies (pAb) are generated by injecting a 
mammal with an antigen that is specific to an amino acid 
sequence of interest found in another species, inducing the 
production of antigen-specific immunoglobulins which are then 
purified. Different B cells each produce different antibodies 
to the same antigen, so Abs derived from this methodology may 
bind to a spectrum of epitopes within the antigen of interest. 
Monoclonal antibodies (mAb) are generally produced in hybridoma 
cells, a fusion of mouse-derived B cells and an immortalised 
myeloma tumour cell line. A single hybridoma cell can be cloned 
to produce large amounts of a specific antibody, and clones can 
be selected based on the affinity to antigen of the Ab they 
produce (Kohler and Milstein 1975). Often, mAb can subsequently 
be mapped to a specific amino acid sequence on the antigen. 
Abs were first conjugated to a fluorescent label to 
observe their localisation in tissue (COONS and KAPLAN 1950). 
Enzyme-conjugated Abs allow for the visualisation of the 
antigen-Ab complex by a reaction between the enzyme and a 
substrate compound (Nakane and Pierce, Jr. 1967; Moriarty at al. 
1973) . This method is permanent and visible with a standard 
light microscope. The specificity and intensity of the 
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immunohistochemical reaction can be increased through layering, 
using the primary Ab as an antigen for a subsequent, secondary 
Ab. 
The avidin-biotinylated enzyme complex (ABC) was developed 
by Hsu et al. and relies on the very high affinity between 
avidin, a molecule found in egg white, for the vitamin biotin, 
which can also be conjugated to peroxidase or alkaline-
phosphatase enzymes as well as Abs (Hsu et al. 1981a; Hsu et al. 
1981b). Avidin, with four binding sites to biotin, forms a very 
high-affinity bridge between a biotinylated Ab and biotinylated 
enzyme, which can be visualised in the presence of the enzyme 

















Figure 2.1 An illustration of the avidin-biotinylated enzyme 
complex method of immunohistochemistry 
(Preceding page) Primary Ab binds to the antigen against which 
it was raised (1) . Species-specific secondary Ab conjugated to 
one biotin molecule binds to the primary Ab (2) . Avidin, with 
four biotin-binding sites and bound to three biotin molecules, 
binds the biotin-conjugated secondary Ab (3). Peroxidase 
enzymes conjugated to avidin-bound biotin bind and react with 
DAB in the presence of hydrogen peroxide resulting in a brown 
colour associated with the site of primary Ab binding (4). 
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2.2.4.2 Immunohistochemistry with formalin-fixed, paraffin-
embedded tissue 
A detailed protocol can be found in Appendix I. Sections 
are first dewaxed in xylene. They then pass through a series of 
four 5 min. alcohol washes (100%, 100%, 90% and 70%) in 
industrial methylated spirits (IMS) and are finally placed in 
distilled water. Sections are then incubated in methanol 
containing 0.3% hydrogen peroxide for 30 min. to quench any 
endogenous peroxidases, returned to distilled water. If a pre-
treatment for antigen unmasking is required (see Section 
2.2.2.1), it is carried out at this point. Sections are then 
rinsed in PBS with pH 7.4. Each slide is then taken from PBS, 
dried with paper towel around the area of the section, and the 
section is encircled with a delimiting wax pen. Primary Ab 
diluted in PBS containing 0.3% Triton-XlOO and 2% normal serum 
from the animal in which the secondary Ab was raised is applied 
to each slide, which is then placed in a humidified chamber and 
incubated overnight at 4°C. The following day, after rinsing in 
PBS, slides are incubated in biotinylated horse anti-mouse or 
goat anti-rabbit secondary antibody (Vector) diluted 1/100 in 
PBS for 60 min. at room temperature in the same humidified 
chamber. Slides are rinsed again in PBS and finally incubated 
in ABC complex (Vector) diluted 1/200 in PBS with respect to 
reagent A and B, giving a 1/100 dilution overall, again for 60 
min. at room temperature in a humidified chamber. After a final 
rinse in PBS, immunoreactivity is visualised with 3, 3'-
diaminobenzidine (DAB) in PBS (recipe in Appendix I) for 2 min. 
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Instead of DAB, the Vector VIP kit was also occasionally used to 
visualise immunoreactivity with a purple chromogen. Sections 
are transferred to distilled water, counterstained with a brief 
dip in Mayer's haemalum, and rinsed in running tap water until 
clear. Finally, sections are dehydrated by serial passage 
through 5 min. IMS washes (70%, 90%, 100%, and 100%) and then 
placed in xylene for complete dehydration. Slides are 
coverslipped with DPX mounting medium. 
To ascertain the specificity of the primary Ab a negative 
control slide was included in most instances, which was treated 
identically to the other slides with the exception that no 
primary Ab was applied to it. These slides were expected not to 
demonstrate any immunopositivity provided that no non-specific 
binding to tissue occurred in the rest of the reaction. 
2.2.4.3 Antigen unmasking 
Formalin fixation and wax embedding alters the structure 
of some proteins in such a manner as to prevent binding by an 
Ab. Antigen unmasking is a process which makes tissue more 
permissive to Ab labelling (Maclntyre 2001) . The structural 
biochemistry of antigen masking and unmasking is unclear. It 
has been reported that a need for antigen unmasking after 
formalin fixation is associated with the presence of a tyrosine 
residue in or near the Ab binding site and an arginine elsewhere 
on the antigen, suggesting that the Mannich reaction, in which 
formaldehyde and arginine can form a reactive intermediate that 
binds to tyrosine, may be involved (Sompuram et al. 2004). 
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Two antigen unmasking techniques were used in this series 
of experiments. For some antibodies (described in Table 2.2), 
sections are incubated in 100% formic acid (FA) for 5 min. For 
one Ab, anti-Ap clone 1E8, a similar antigen unmasking pre-
treatment consisting of an 8 min. incubation in 80% FA was used. 
This Ab was optimised elsewhere and, because it was non-
commercial and only a limited supply was available, the 
established protocol was used (Table 2.2). 
The other primary method of antigen unmasking, high-
temperature antigen unmasking (Ht) , involves microwaving 
sections in a solution of O.OOIM EDTA in distilled water, pH 8. 
Sections are placed in approximately 400 mL of EDTA and 
microwaved at 350W for 20 min. 
For one antibody, Zymed anti-SNCA, the best antigen 
unmasking protocol was determined to consist of 5 min. 100% FA 
followed by Ht treatment of 20 min. in the microwave (350W) in 
O.OIM citrate buffer (Cit) (Table 2.2). 
2.2.4.4 Immunohistochemistry with unfixed, snap-frozen tissue 
A detailed protocol can be found in Appendix II. Sections 
are removed from a -80 °C freezer and left to thaw at room 
temperature for 5-10 minutes. Sections are fixed in 3.7% 
formaldehyde buffered in PBS pH 7.3, the standard formalin used 
by the PDSTB, for 5 min. Sections are transferred to 50% 
acetone for 2 min, 100% acetone for 3 min, back to 50% acetone 
for 2 min and then rinsed in distilled water. Endogenous 
peroxidases are blocked in methanol containing 0.3% hydrogen 
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peroxide for 30 min. Sections are then rinsed in distilled 
water and then in Tris (2-Amino-2-(hydroxymethyl)-1,3-
propanediol)-buffered saline (TBS) pH 7.4. Sections are washed 
in TBS containing 1% bovine serum albumin (BSA), then each slide 
is dried around the area of the section and the section 
encircled with a delimiting wax pen. Primary antibody diluted 
in TBS containing 2% normal serum from the animal in which the 
secondary antibody was raised is applied to each slide, which is 
placed in a humidified chamber and incubated overnight at 4°C. 
The following day, slides are dipped briefly in TBS, rinsed in 
TBS with 1% BSA, and incubated for 60 min. at room temperature 
in the same humidified chamber with either horse anti-mouse or 
goat anti-rabbit secondary Ab (Vector) diluted 1/100 in TBS. 
Slides are again dipped in TBS and rinsed in TBS with 1% BSA, 
and then incubated for 60 min. at room temperature with ABC 
complex diluted 1/100 in TBS. After another dip in TBS and 
rinse in TBS with 1% BSA, slides are rinsed once more in TBS and 
incubated in DAB in Tris pH 7.6 for 2 min. Instead of DAB, the 
Vector VIP kit was also occasionally used to visualise 
immunoreactivity with a purple chromogen. Sections are 
transferred to distilled water, counterstained with a 2 second 
dip in Mayer's haemalum, and rinsed in running tap water until 
clear. Finally, sections are dehydrated by serial passage 
through 5 min. washes in IMS (70%, 90%, 100%, and 100%) and then 
placed in xylene. Slides are coverslipped with DPX mounting 
medium. 
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2.2.5 Histological staining 
Detailed protocols and recipes are included in Appendix III 
2.2.5.1 Haematoxylln & Eosin (H&E) 
Haematoxylin is derived from the Haematoxylon campechianum 
tree and, when oxidised, stains cell nuclei a dark blue/purple. 
Mayer's haematoxylin, used here, is chemically oxidised with 
sodium iodate. Eosin is a xanthene dye that differentially 
stains cell bodies, connective tissue and protein aggregates in 
varying shades of pink/red (Wilson and Gamble 2002). 
Formalin-fixed, paraffin embedded sections are dewaxed and 
hydrated to water as described in Section 2.2.3.2. Sections are 
transferred to tap water and immersed in Mayer's haematoxylin 
for 5 min. Sections are washed in tap water until clear, then 
differentiated with a brief dip in 1% acid alcohol and rinsed 
again for approximately 20 sec. in tap water. Sections are then 
immersed in 1% eosin Y (recipe in Appendix I) for 5 min. and 
rinsed in tap water. • Sections are dipped in 70% IMS, then 
placed in 2 washes of 100% IMS for 1 min. each. Sections are 
dehydrated in xylene and then coverslipped with DPX mounting 
medium. 
2.2.5.2 Luxol Fast Blue 
Luxol fast blue (LFB) is a copper phthalocyanine dye which 
labels myelin in paraffin-embedded tissue (KLUVER and BARRERA 
1953). 
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Formalin fixed, paraffin-embedded sections are dewaxed in 
2 X 10 min, washes of xylene and 5 mins. in 100% IMS. Sections 
are incubated in LFB solution overnight at 60°C. Upon removal 
from LFB, they are dipped in 100% IMS and rinsed in tap water. 
Sections are then dipped very briefly in saturated lithium 
carbonate (LiCOs) solution, after which the grey and white 
matter can be clearly distinguished as only white matter is 
stained. Sections are rinsed in tap water, counterstained in 
Mayer's haematoxylin for 45 sec, and rinsed again in running tap 
water. Sections are dipped in 70% IMS, then placed in 2 washes 
of 100% IMS for 1 min. each. Sections are dehydrated in xylene 
and then coverslipped with DPX mounting medium. 
2.2.6 Analysis of immunohistochemical tissue labelling 
Immunoreactivity was compared using semi-quantitative 
severity ratings. Slides were assessed using an Olympus BX50 
light microscope at 4x to 40x primary magnification. The 
specific criteria and methodology applied to each immunostain is 
described thoroughly in the chapter in which it is assessed 
(Sections 3.3.5, 4.3.3, 5.3.3, 6.3.5, 7.3.5) 
Slides were randomised, their case and block number 
obscured with tape, and marked with a number or letter prior to 
assignment of semi-quantitative ratings in order to minimise any 
bias held by the assessors. The reliability of semi-
quantitative ratings was ensured in two ways. Either ratings 
were assigned by two independent observers and averaged, or a 
percentage of slides (>10%) was rated by a second observer to 
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ensure consistency. In either case, the two sets of ratings 
were compared with General Linear Model and Student's T-tests to 
test their similarity. 
The use of semi-quantitative severity ratings is 
problematic in that it is not necessarily possible to replicate 
the methodology of a study without also replicating to some 
degree the training of the author. However, semi-quantitative 
methods allow for the assessment of large numbers of cases and 
are more robust to flaws in data acquisition. 
Computerised image analysis of immunoreactivity is 
vulnerable to numerous variables. Limiting a count to a 
particular area of the section, delineated anatomically or by 
the presence of another protein, precludes any differences in 
other areas from being detected. Automated cell counts do not 
distinguish cell types, and measurements of the density of 
immunoreactivity across an area are prone to inaccuracies, as 
software tends to pick up haemalum-counterstained nuclei and, 
depending on the antibody used, cross-reactive blood vessels or 
lipofuscins. Manual cell counting is also particularly 
problematic in the case of cells like microglia, in that it 
excludes the many microglial processes without associated nuclei 
in the tissue and cannot account for clusters of microglial 
cells in which individual nuclei are not quantifiable. 
Chapter 3: Comparative Study of 
Commercially Available anti- Alpha-
Synuclein Antibodies 
3.1 Introduction 
SNCA immunohistochemistry (IHC) is currently the best 
available method for identifying LBs (Munoz 1999; Dickson 2001). 
As such, an accurate picture of the SNCA status of a particular 
brain region is crucial to the subsequent description of how 
markers of microglial activation relate to PD-type 
neurodegeneration in that area. Despite the growing frequency 
with which SNCA IHC is used in the neuropathological diagnosis 
and study of PD, DLB and MSA, a standard protocol for its use 
had not been established. 
3.1.1 Variability of alpha-synuclein iirmunopositive structures 
SNCA deposits vary throughout the brain, with brainstem 
pathology characterised by compact LBs and neuropil threads also 
referred to as Lewy neurites (LN) . Pigmented neurons of the SN 
may also contain diffuse fine or coarse granules, which likely 
represent the state of aggregation preceding LBs (Kuusisto et 
al. 2001; Saito et al. 2003). Cortical pathology consists of 
more diffuse LBs and peripheral punctate granular positivity 
that corresponds to pre-synaptic terminals (Maroteaux et al. 
1988) . While GCIs are associated primarily with MSA, SNCA-
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immunopositive protein aggregates have also been identified in 
astrocytes and oligodendrocytes in PD. While the role of these 
glial inclusions in the pathogenesis of PD is not yet 
understood, their frequency both within the SN and in the 
cerebrum was found to correlate with the severity of 
dopaminergic neuronal loss in the SN (Wakabayashi et al. 2000). 
3.1.2 The importance of recognised epitope and pre-treatment 
Previous analyses of glial fibrillary acidic protein 
(Halliday et al. 1996) and prion protein (Kovacs et al. 2002) 
have demonstrated that variability across Abs could account for 
discrepancies between research studies and affect diagnostic 
accuracy. Pre-treatment with FA or proteinase K has been 
reported to increase the number and type of structures 
immunoreactive for SNCA, but the only studies to investigate 
this finding systematically were conducted with non-commercial 
Abs (Takeda et al. 2000) or brain tissue unaffected by 
neurodegenerative disease and devoid of any pathologically-
associated protein aggregations (Mori et al. 2002). FA pre-
treatment has also been reported to increase the 
immunoreactivity of some non-commercial mAbs for GCIs (Duda et 
al. 2000) . 
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3.2 Aims 
Due to the variability of current practices and the 
importance of establishing a reliable protocol in which all 
possible forms of SNCA-positive protein aggregates could be 
identified, a review of the literature in which SNCA IHC was 
carried out on human tissue was undertaken. Based on this 
analysis of the literature, it was deemed necessary to complete 
a comparative study of commercially available SNCA Abs prior to 
attempting to compare SNCA with microglial markers in order to 
establish a reliable, reproducible protocol which maximises both 
the sensitivity and specificity of the reaction. 
3. 3 Materials and Methods 
3.3.1 Literature review 
To assess the use of commercial versus non-commercial 
anti-SNCA Abs and different antigen unmasking pre-treatments in 
research, a review of the available literature was carried out. 
A search of the PubMed database updated to 30 June, 2005 for 
^alpha-synuclein' resulted in 1567 citations. Their abstracts 
were all reviewed to identify those papers that used SNCA IHC on 
human tissue (n = 270) . The methodology of the 242 articles 
available online or in the Charing Cross branch of the Imperial 
College London library was screened for the antibody used, its 
dilution and pre-treatment for antigen unmasking. 
3.3.2 Human tissue 
Five representative cases (also outlined in Table 3.1) 
were selected on the basis of neuropathological features: 1. 
C0N3, a case with no history of neurological problems and devoid 
of pathological protein inclusions (provided by Dr. Manuel 
Deprez, University of Liege, Belgium), 2. PD16, a case of 
typical idiopathic PD, 3. PD04, a case of PD with extensive 
concurrent AD-type pathology, 4. MSA12, a typical case of MSA 
(all provided by the PDSTB) and 5. MS69, a case of MS with 
striking incidental LB pathology in the SN but no clinical 
history of parkinsonism (provided by the MSTB). 
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3.3.3 Panel of commercially available anti-SNCA antibodies 
We compared the seven monoclonal anti-SNCA Abs (mAbs) 
available in 2004. Since that time, additional manufacturers 
have produced anti-SNCA mAbs; however these seven remain 
representative of the clones and immunogens currently available. 
Details of the mAbs' manufacturer, clone and the epitope 
recognised or immunogen against which they were raised are 
outlined in Table 3.2. The Abs' recognised epitopes with 
respect to the full-length SNCA protein are illustrated in 
Figure 3.1. 
3.3.4 SNCA immunohistochemistry 
Sections from case 1 (C0N3) were cut as described in 
Section 2.2.1. For all other cases, sections were provided by 
the PDSTB and MSTB. Formalin-fixed, paraffin-embedded sections 
(8 pm thick) from the SFG and SN of each case were immunostained 
with each Ab. Immunohistochemistry was carried out as described 
in Section 2.2.3.2, with specific pre-treatments and antibody 
dilutions outlined in Table 3.2. As all antibodies were mouse 
monoclonals, a biotinylated horse-anti-mouse secondary antibody 
was used in all instances. All reactions were visualised with 
DAB and included controls with omission of the primary mAb. All 
mAbs were first optimised, using the guidelines provided by the 
manufacturer as a starting point, for the combination of 
dilution and pre-treatment that resulted in the immunostain with 
the best ratio of staining intensity to non-specific background. 
We tested incubation in 100% formic acid (FA) for 5 min and 
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heating in a microwave oven at 350W for 20 min. using lOmM Cit 
pH 6 and 1 mM EDTA pH 8 as described in 2.2.3.3. 
LFB counterstaining was also carried out on tissue from 
cases 2 and 5 (PD16 and MS69) following the protocol described 
in Section 2.3.2. 
3.3.5 Semi-quantitative ratings 
All immunoreactions were independently assessed by two 
investigators. Each mAb was assessed on the intensity of its 
immunolabelling of LBs (intracellular and extracellular LBs were 
considered together), cytoplasmic granular positivity, large and 
small neuropil threads, pre-synaptic terminals, periaxonal 
deposition and GCIs using a four-point rating system from - (no 
reaction) to +++ (intense staining) . A rating of +/- was also 
included in our assessment of GCIs to indicate that the Ab did 
not stain GCIs readily distinguishable from background with the 
same frequency as observed on adjacent sections stained with 
different Abs. We also assessed non-specific background 
staining of the neuropil, rating it either none, low (light, 
non-specific staining, generally confined to white matter (WM) 
tracts) or high (non-specific staining throughout the neuropil, 
dark enough to compete with specific labelling). 
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Table 3.1 Summary of cases 




1 C0N3 features 
2 PD16 PD 
3 PD04 PD/AD 
4 MSA12 MSA 
5 MS69 MS/ILB 
Table 3.2 Source and usage parameters of mAbs 
If no reference is provided, the epitope is described as 
reported on manufacturers' data sheet. Ht, high-temperature 
unmasking (20 min. microwave at 340 W) ; FA, formic acid; EDTA, 
ethylenediaminetetraacetic acid. 
Manufacturer 
[clone] Immunogen [epitope] Dilution 
Pre-
treatment 
A Abeam [Syn204] 
Human SNCA aa 87-




B Alexis [15G7] Synthetic peptide 




C Becton-Dickinson [42] 
Rat synuclein aa 





Chemicon Human recombinant 1 . 400 100% FA 5 [7B12.2] SNCA i. • min. 
E NovoCastra [KM51] 
Human recombinant 
SNCA 1 40 Ht EDTA 
Human recombinant 
SantaCruz SNCA [aa 121-125] 1 100 100% FA 5 [Syn211] (Giasson et al. 
2000) 
min. 
Purified LBs [aa Ht citrate 
G Zymed [LB509] 115-122] (Jakes et 
al. 1999) 
1: 200 + IOC 
min. 
% FA 5 
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1 amphipathic repeat region 61 NAC 95 acidic region 140 
mdvfmkglsk akegwaaae ktkqgvaeaa gktkegvlyv gsktkegwh gyatyaektilj eqvtnygggyvtgytavaqktvegagsiaaatgfv| kkdql gkneegapqe giledmpvdp dneayempse egyqdyepea 




Figure 3.1 Cartoon representation of rtiAb epitope localisation on 
SNCA full-length protein 
Abs D and E are not shown, as they were raised against full-
length recombinant human SNCA and the specific epitope they 
recognise has not been described in the literature. The epitope 
recognised by mAb C is also not known. The SNCA protein is 
colour-coded to indicate regions with different biochemical 
properties, and known mutation sites which lead to familial 
parkinsonism are indicated with arrows. 
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3.4 Results 
3.4.1 Literature meta-analysis 
Seventy-five (31%) of the 242 studies reviewed used 
commercial anti-SNCA Abs. Thirty-seven studies (15%) reported 
using a pre-treatment for antigen unmasking and 17 (7%) included 
no details at all regarding the Abs used. Many studies 
performing IHC with the same commercial Abs used different 
dilutions and protocols. 
3.4.2 SNCA immunostaining 
The mAbs A, B, C, D and F were not significantly affected 
by pre-treatments for antigen unmasking. In contrast, mAbs E 
and G showed far more intense immunostaining after microwaving 
in EDTA and citrate buffer, respectively. All mAbs detected 
.both cortical and brainstem LBs, large neuropil threads and 
cytoplasmic granular deposition characteristic of cortical grey 
matter. However a broad range of staining intensity was 
observed across the panel. The intensity of Immunolabelling of 
large neuropil threads paralleled that of LBs. Smaller threads 
were only clearly highlighted by three mAbs (A, B and C) (Figure 
3.2). In the SFG, diffuse labelling of terminals, particularly 
in Case 3, allowed grey matter (GM) to be clearly distinguished 
from WM. Cortical LBs were observed frequently in Case 3 and 
occasionally in Case 2 (Figure 3.3). Four mAbs showed 
periaxonal positivity in the WM of the PD and PD/AD cases, which 
appeared denser and more evenly distributed that that observed 
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in the cortical grey matter and appeared to correspond to the 
myelin sheath (Figure 3.4). Immunostaining of GCIs showed 
marked differences across mAbs. With three mAbs (A, D and E) 
these structures were only faintly distinguishable, while the 
rest stained them clearly (Figure 3.5). 
Table 3.3 Semi-quantitative ratings of staining intensity 
Rating assigned as described in Section 2.3.2. LN, Lewy 
neurites (neuropil threads); Terms, pre-synaptic terminals; 
Gran, cytoplasmic granular immunostaining; GCIs, glial 
cytoplasmic inclusions. 
mAb LBs Large 
LN 
Small 





A + + + + + + + + + + + - + / - High 
B + + + + + + + + + + + + + + + + + None 
C + + + + + + + + + + + + + + + + None 
D + + - + + + - + / - High 
E + + + + - + + + + + + + + None 
F + + + + + + + + + + + + + + + + + High 
G + + + + + + + + + + + None 
Lewy body 
Small neuropil thread 
Large neuropil thread 
Neur omelanin 
# 
Fine granulation \ Coarse granulation 
Extracellular Lewy body 
Figure 3.2 Immunostaining of brain stem SNCA pathology in PD 
IHC with mAb C demonstrates LBs, large and small neuropil 
threads, and fine and coarse cytoplasmic granular deposition. 
Neuromelanin found in dopaminergic neurons can be clearly 
differentiated (Case 5 (MS69), 20x magnification). 
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Figure 3.3 Diffuse Cortical SNCA immunolabelling 
Demonstrated in Case 3 (PD/AD) with mAb B in the SFG (A, whole 
mount) . Many neurones are seen to contain cortical LBs at 
higher magnification, and the diffuse staining appears finely 
punctate (B, lOx) 
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Figure 3.4 Immunostaining in white matter tracts and neuronal 
processes 
Peri-axonal SNCA deposition, delineated with arrows, is 
visualised with mAb G in the SFG (case 2 (PD16) , 20x 
magnification) (A). Luxol Fast Blue (LFB)-counterstaining of 
mAb C in the SN (case 5 (MS69) , 40x magnification) highlights 
the axonal origin of large neuropil threads (arrows, B) . This 
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Figure 3.5 Contrast between immunostaining of GCIs with 
different anti-SNCA antibodies 
(Preceding page) MAbs C (A) and A (B) illustrate the degree of 
variation in immunostaining GCIs observed in the panel tested 
(Case 4, SN, lOx) . GCIs are strongly immunoreactive for SNCA, 
appearing as dense, tangle-like structures that appear to be 
wrapped around an oligodendrocyte nucleus (A, inset). In the SN 
of MSA cases that are often found in close proximity to DA 
neurons (indicated by a in A and A inset) . Both the 
intensity with which GCIs are labelled and the ability to 
distinguish immunolabelling from non-specific background 
staining vary considerably. 
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3.5 Discussion 
As a result of this comparative study, mAb C, recognising 
amino acids 15-123 of rat synuclein, was selected for use in 
subsequent portions of this study based on its consistency and 
strong immunoreactivity for a variety of SNCA-containing 
structures. Depending on experimental design, however, other 
mAbs may be preferable. For example, although it is not of 
primary concern in studies of post-mortem human tissue, cross-
reactivity with mouse synuclein would be a major concern for 
investigators studying human SNCA expression in transgenic 
animals. 
Antigen unmasking was observed to have a pronounced effect 
on the observed staining pattern and intensity of Abs E and G. 
The lack of a clear description of antigen unmasking technique 
in the majority of studies reviewed strongly suggests that much 
Q.f the variability across studies could be attributable to 
methodological differences. The effect of antigen unmasking on 
an Ab may be a reflection of the structure of the epitope it 
recognises (Sompuram et al. 2006) . As SNCA is a natively 
unfolded protein, and the structure it adopts in the process of 
pathological aggregation is not well understood, the findings 
outlined here could aid in elucidating structural differences in 
SNCA aggregates of different morphologies. 
The marked difference in immunostaining of GCIs is the 
most diagnostically relevant difference observed across mAbs 
assessed in this study. Chemical differences have been reported 
between SNCA aggregates in MSA and PD (Campbell et al. 2001), 
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which may explain these differences. An earlier 
immunohistochemical study of MSA tissue suggests that 
immunoreactivity for GCIs is maximised by Abs directed to the 
carboxyl-terminal of SNCA, but immunoreactivity can be improved 
for other Abs after FA pre-treatment (Duda et al. 2000). Three 
of the mAbs in the present study (A, F and G) are identical to 
non-commercial clones used in that previous study (Jakes et al. 
1999; Giasson et al. 2000), and, with respect to these three 
mAbs and mAb B, our findings support the observations of Duda et 
al. (Duda et al. 2000) in that the immunostaining we observed 
appeared progressively more intense as epitopes moved 
progressively closer to the carboxyl-terminus. However, the 
other clones raised against full-length recombinant ASYN (D and 
E) showed only weak immunoreactivity while mAb C, raised against 
amino acids 15-123 of rat synuclein, demonstrated intense 
immunostaining of GCIs with minimal background. Because the 
specific epitope recognised by these mAbs has not been reported, 
it is not yet possible to make the generalisation that staining 
intensity is affected by proximity to the carboxyl terminus. 
The differential immunolabelling of large and small 
neuropil threads suggests that they may correspond to different 
anatomical structures (i.e. axons and dendrites). After 
immunostaining with mAb G, tissue from the SN of cases 2 and 5 
(PD16 and MS69) was counter stained with LFB. We observed some 
large neuropil threads surrounded by or associated with LFB-
labelled myelin (Figure 3.4). No small neuropil threads 
appeared to be myelinated, suggesting that there are anatomical 
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differences between the location of large and small neuropil 
threads. 
The frequency of periaxonal, extracellular, axonal and 
dendritic SNCA aggregates in the PD cases examined highlight the 
importance of SNCA pathology other than that of a LB-type 
morphology. Further analysis of how different varieties of SNCA 




Methodological differences in SNCA IHC could have a 
significant effect on measurements of other factors in PD 
including microglial activation. Subsequent studies of 
microglia carried out in this project are dependent upon the 
careful characterisation of other disease characteristics. 
Because SNCA aggregation is the primary pathological hallmark of 
PD and the related diseases of DLB and MSA, this preliminary 
study is crucial to the interpretation of further studies in 
which SNCA is considered a standard to which the variable of 
microglial activation can be compared. This analysis of SNCA 
Abs allows the selection of an Ab which maximises the number and 
variety of SNCA aggregates observed in brain tissue and allows 
for a more sophisticated analysis of earlier studies that use 
SNCA IHC. 
97 
Chapter 4: Microglial Activation and 
Alpha-synuclein Deposition in the 
Parkinson's disease-affected Substantia 
Nigra 
4.1 Introduction 
The SN has been the focus of extensive research into the 
onset of and susceptibility to PD. Dopaminergic cell loss in 
the SN as discussed in Section 1.1.2 is considered the cause of 
the onset of the classical motor deficits observed in early PD, 
and SNCA aggregation in the region is regarded as an indication 
of underlying neurodegenerative processes, the quantity of which 
has been reasoned to reflect the extent of neurodegeneration 
(Braak et al. 2002) . On the basis of its importance in the 
disease, the SN is also the primary anatomical region in which 
microglial involvement in PD has been assessed, particularly in 
animal models of PD which are designed specifically to reproduce 
this aspect of disease neuropathology. In spite of the numerous 
post-mortem immunohistochemical studies of either SNCA or 
activated microglia in the SN, the relationship between these 
two markers has not been thoroughly evaluated. 
4.1.1 SNCA in the substantia nigra in PD 
No causal relationship has been established between SNCA 
aggregation and the selective neuronal death characteristic of 
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PD, although they are found in conjunction in post-mortem PD 
tissue and in animal models of the disease. An anatomical 
staging model of PD based on SNCA aggregation has been proposed 
(Braak at al. 2003). However, this model has been called into 
question by subsequent studies in which clinical data were also 
considered (Parkkinen at al. 2005). LBs are also found 
incidentally in the aged brain in the absence of other 
pathological features or a clinical history suggestive of 
parkinsonism or dementia (Parkkinen at al. 2001; Saito at al. 
2003). Additionally, in vitro studies of protein aggregation in 
which pathological proteins are expressed, or over-expressed, in 
cultured cells suggest that aggresome formation may be a 
protective and proactive mechanism that increases cell survival 
(Taylor et al. 2003; Tanaka at al. 2004) . A better 
understanding of how SNCA aggregation ties into the bigger 
neurodegenerative picture of PD, which includes microglial 
activation, could aid in directing future research to maximally 
reduce the rate of neurodegeneration that occurs in PD. 
4.1.2 Microglia in the substantia nigra in PD 
The removal of cellular debris is a primary function of 
fully activated phagocytic microglia, thus their reported 
presence in a region of active cell death is unsurprising 
(McGeer et al. 1988a) . Neuromelanin pigment and aggregated SNCA 
taken up from degenerated dopaminergic neurons is 
characteristically observed in the SN in post-mortem PD tissue 
(Figure 4.1). It remains to be seen whether the presence of 
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activated microglia and/or their activity as phagocytes leads to 
cytotoxicity in PD. 
An increase in MHCII-expressing microglia in the SN of 
post-mortem PD cases has been well-documented (McGeer et al. 
1988b; Banati et al. 1998; Mirza et al. 2000). MHCII-expressing 
microglia were also upregulated in the SN of individuals 
poisoned with MPTP (Langston et al. 1999). 
Some evidence suggests that microglia may be instrumental 
in the progression of PD as a result of the microglial response 
to injury in the SN. Microglia are more numerous in the SN than 
in other brain areas, which may affect the region's 
susceptibility to cell death (Kim et al. 2000). They have also 
been demonstrated to have the capacity to dictate the extent to 
which neurodegeneration occurs in the rat SN after a neurotoxin 
is introduced to the area. Degeneration of the SNpc following 
stereotactic injection of lipopolysaccharide can be prevented by 
pharmacologically inhibiting microglial activation (Liu et al. 
2000a; Liu et al. 2000b). 
In spite of the potential that microglia have been 
demonstrated to have in determining the extent of cell death in 
animal models, MHCII expression in the SN has not been reported 
to reflect a specific disease process in PD. In a cohort of ten 
post-mortem PD cases, MHCII expression was observed to be 
independent of disease duration or the severity of neuronal loss 
(Banati et al. 1998) . Activated microglia are less frequent in 
the striatum than the SNpc in post-mortem PD tissue although the 
dopaminergic deficit and extent of degeneration in the two areas 
is comparable (McGeer et al. 1988b). Supporting this finding, a 
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study of chronic MPTP administration in monkeys reports that, 
although MHCII-expressing microglia are present in the SN and 
globus pallidus, they are conspicuously absent from the 
striatum, in which active neurodegeneration is detectable. As 
in Banati et al. 1998, the extent of MHCII expression in the SN 
appeared to be independent of the severity of neurodegeneration 
(Hurley et al. 2003). 
While an increase in MHCII in the PD SN is well-
documented, the functional significance of this upregulation 
remains unclear. MHCII is putatively a marker of activated 
microglia, which can be distinguished from their resting 
counterparts on the basis of both a change in morphology and 
protein expression as discussed in Section 1.1.2. However, 
reports of MHCII in microglia from aged brain and in resting 
microglia in white matter (WM) raise questions regarding the 
functional relevance of MHCII expression by microglia (Gehrmann 
et al. 1993; Streit et al. 2004b). 
4.1.3 Linking pathological events in PD 
Previous studies of MSA, progressive supranuclear palsy 
(PSP), and corticobasal degeneration (CBD), have detected a 
stochastic link between the presence of activated microglia and 
disease-associated protein deposition in some of the 
neuroanatomic systems involved in the progression of these 
diseases and hypothesise that microglial activation may in part 
be induced by the accumulation of pathological protein (SNCA in 
MSA and tau in PSP and CBD) in tissue (Ishizawa and Dickson 
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2001; Ishizawa et al. 2004). If this relationship exists 
between MHCII-expressing microglia and aggregated SNCA in PD, 
the SN is likely to be a brain area in which it could be 
detected. 
LBs may promote microglial activation. In addition to 
SNCA, LBs have been reported to contain chromagranin A and 
complement, which have been shown to activate microglia in vitro 
and may trigger microglial activation in an SNCA-independent 
manner (Yamada et al. 1992; Togo et al. 2001). 
MHCII-expressing microglia are not necessarily observed in 
close association with LBs or neurons in the SN (McGeer et al. 
1988b; Imamura et al. 2003a). However, MHCII expression is 
affected by a number of confounding factors unavoidable in a 
post-mortem cohort of long-standing PD cases and may not be the 
best indication of a functionally significant glial inflammatory 
response. 
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Figure 4.1 Phagocytes in the Substantia Nigra 
Small cells phagocytosing neuromelanin-containing debris in the 
SN of a PD case (lOOx) . 
103 
4.2 Aims 
The aim of this study is to evaluate microglial activation 
in the SN of PD cases with respect to SNCA aggregation and 
clinical course. If microglia play a primary role in PD, the 
activated microglial phenotype should correspond to other 
histopathological and/or clinical features of the disease. Two 
microglial markers, MHCII and CD68, which identify the early and 
late stages of activation respectively (as described in Section 
1.1.2.6), were assessed independently in order to better 
understand how different phases of activation are involved in 
the disease process. By comparing MHCII with CD68, a marker of 
phagocytosis representative of late microglial activation or the 
invasion of peripheral lymphocytes into the CNS, it may be 
possible to identify the functional significance of MHCII as an 
indication of microglial activation or a marker of diseased 
tissue. Furthermore, the pathological link between microglial 
activation and SNCA is explored. 
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4 .3 Materials and Methods 
4.3.1 Human tissue 
Thirty-seven PD nigrae were evaluated 
immunohistochemically. Tissue sections from twenty cases were 
provided by the PDSTB (outlined in Tables 2.1 and 4.1). Three 
cases from the PDSTB were excluded from this study based on 
final pathological diagnoses of AD, progressive supranuclear 
palsy (PSP) and young-onset familial PD, leaving a cohort of 17 
cases in each the Munich and PDSTB groups. Nine of the 
remaining cases showed varying degrees of concurrent ER AD-type 
Ap and tau pathology; six of these also contained IC plaques and 
tangles (Table 4.1). 
Additional tissue sections from 17 other PD cases were 
used as a disease control group to ensure that variation within 
the PDSTB cohort was within an established range. These PD 
cases had been previously diagnosed, neuropathologically 
screened for confounding pathology and examined in a study of 
apoptosis and microglial activation at the Institute of 
Neuropathology, University of Munich, Germany (Kosel et al. 
1997b). 
4.3.2 Immunohi s tochemi s try 
Immunohistochemical reactions were performed as described 
in Section 2.2.1. All 34 cases were stained for SNCA (Becton-
Dickinson, clone 42) at a 1/300 dilution with a pre-treatment of 
5 min. in 100% FA and MHCII (Dako, clone CR3/43) at a 1/100 
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dilution with a Ht pre-treatment using EDTA. For the PDSTB 
group, additional immunohistochemistry was also carried out with 
anti-CD68 (Dako, clone PGMl) at a 1/200 dilution with no pre-
treatment. Control slides were included with omission of the 
primary Ab (Figures 4.2 and 4.6). 
4.3.3 Semi-quantitative evaluation of protein levels 
After immunohistochemical staining. Professor Graeber and 
I, both blind to case number, independently assigned semi-
quantitative severity ratings for SNCA, MHCII and CD68 
immunoreactivity. The SN was defined as the area extending 
laterally from the exit of the third nerve, superior to the 
cerebral peduncle and inferior to the medial lemniscus, ideally 
at the same level as the red nucleus, with the presence of 
melanised neurons or their remnants indicating the primary 
region of interest. The severity ratings were determined across 
the entire SN and based on the density of immunopositive 
structures, with 0 (none), 1 (mild), 2 (moderate) and 3 (high). 
For SNCA, both intra- and extracytoplasmic protein 
aggregates were considered provided they fell within the SN. 
This was particularly relevant in areas of severe neuronal loss, 
often observed more laterally, where significant SNCA pathology 
could still be observed. The morphological variation of SNCA 
variation was not assessed, simply the frequency of events. All 
clearly identifiable structures observable at a maximum of 40x 
magnification, including LBs, neurites, fibrils and smaller, 
punctate formations, were considered and none were given more 
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weight as a factor in the assignment of a severity rating, which 
took all of these structures into account. Therefore a case 
with many neurites and few LBs would be given an identical score 
to a case with many LBs and few neurites. 
For microglial response, severity was judged primarily by 
immunoreactivity. Morphology was taken into account in that 
blood vessel-associated perivascular immunoreactive cells were 
excluded from consideration. Because the thickening of 
microglial processes increases the apparent density of 
immunopositivity, cases which demonstrated a more active 
microglial response were clearly differentiated on the basis of 
immunoreactivity alone. There were no instances in which the 
severity rating would have changed on the basis of morphological 
features, i.e. cases with low MHCII immunoreactivity but most 
microglia adopting an amoeboid morphology or cases with high 
MHCII immunoreactivity but most microglia appearing more 
ramified. 
Regression analysis revealed the two sets of ratings were 
highly correlated (p < 0.0001). Ratings were then averaged to 
generate a severity rating score for each immunohistochemical 
stain. 
4.3.4 Statistical analysis 
Regression analysis. Student's T-test and General Linear 
Model test were carried out on SPSS version 13.0 for Windows. 
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4.4 Results 
4.4.1 Immunoreactivity for MHCII, CD68 and SNCA in the 
parkinsonian substantia nigra 
All of the cases examined showed the severe dopaminergic 
neuronal loss and extra-cellular (free-lying) neuromelanin 
typical of advanced PD. All were positive for SNCA and MHCII 
(Figure 4.2). In some cases, CD68-immunoreactive cells were 
very rare or absent from the brain, but some were always 
apparent in or around the vasculature. MHCII immunoreactivity 
was observed in microglial or macrophage-like cells and 
perivascular macrophages. CD68-immunopositive cells were 
primarily of a brain macrophage phenotype, i.e. cells with an 
enlarged immunoreactive cytoplasm containing lysosomal 
structures and/or neuromelanin degradation products and less 
ramified, stouter cell processes and less frequently of the 
appearance of the fully amoeboid macrophages associated with 
brain infarcts and MS lesions (Figure 4.6). SNCA-positive 
protein aggregates were observed in neurons, neuropil, white 
matter and occasionally glial cells. The cases assessed varied 
widely with respect to the extent of microglial MHCII and CD68 
expression and SNCA deposition observed. Cases' severity 
ratings and clinical data are listed in Table 4.1. 
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Table 4.1 Clinical data and average semi-quantitative severity 
ratings for the PDSTB cohort 
AAO, age at disease onset; AAD, age at death; AD PATH, severity 
of AD-type pathology (see www.ICDNS.org); A-R, akinetic-rigid; 
DD, disease duration; ER, entorhinal; IC, isocortical; F, 




TYPE AD PATH AAO AAD DD MHCII SNCA CD68 
PD08 M H-T - 63 72 9 2 1 1.5 
PDIO F H-T - 67 81 14 2 1 1 
PD15 M A-R ER3/IC3 57 71 14 2.75 3 2.25 
PD16 F H-T ER3/IC3 67 85 18 2.5 2.25 0.5 
PD17 M H-T ER2/IC1 57 75 18 2 1.5 2 
PD18 M A-R - 78 83 5 1.75 1 2.75 
PD19 F H-T - 55 73 18 1.75 2 2.25 
PD21 M H-T ER2 49 76 28 2.5 2.5 0.5 
PD22 F H-T - 65 75 10 2 2 2.75 
PD23 M A-R ER2/IC1 75 82 7 1 1.75 2 
PD24 M H-T ERl 72 81 9 2 2 1.25 
PD26 M A-R - 69 75 6 2 2.5 1.75 
PD28 M A-R ER2/IC1 65 82 18 2.5 1.5 1.5 
PD29 M H-T ERl 70 76 7 2 1 1.5 
PD32 M A-R - 86 89 3 2.75 2.5 2 
PD34 F H-T ER3/IC4 72 83 11 2 1.5 1.25 
PD36 M H-T - 66 76 10 2.5 2.5 3 
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4.4.2 Analysis of microglial immunostaining with respect to 
SNCA aggregation 
Despite the range of density of immunopositive structures 
observed across the group, regression and correlation analysis 
revealed a statistically significant relationship between SNCA 
deposition and MHCII immunoreactivity within individual cases (p 
< 0.01) (Figure 4.3). A General Linear Model test revealed no 
difference between PDSTB and University of Munich cases (p=0.01) 
and the relationship remained statistically significant when the 
two groups were considered independently (p = 0.02 and p = 0.01, 
respectively). No statistical relationship was observed between 
CD68 immunoreactivity and either MHCII or SNCA using regression 
analysis. 
Student's T-tests supported the findings of the regression 
analyses. MHCII was significantly higher in cases with a SNCA 
severity rating ^ 2 (n = 19) than in those cases with a SNCA 
severity rating < 2 (n = 15) (p < 0.01), and SNCA was 
significantly higher in cases with a MHCII severity rating ^ 2 
(n = 27) compared to those with a MHCII severity rating < 2 (n = 
7) (p < 0.005). Again, neither MHCII nor SNCA showed any 
relationship with CD68. 
Student's T-tests were carried out to assess whether the 
presence or absence of AD-type pathology (tau or A(3) in the 
hippocampus or SFG of cases from the PDSTB cohort affected SNCA, 
MHCII or CD68 severity ratings in the SN using the ratings of 
AD-type pathology assigned in the neuropathological diagnostic 
report generated for each case. No relationship was observed 
between MHCII, SNCA and the presence of AD-type pathology 
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elsewhere in the brain. CD68 was inversely related to AD 
pathology, but this may be attributable to both variables' 
relationship with DD (described in Section 4.3.3). 
4.4.3 Analysis of immunostaining with respect to clinical 
factors 
In the cohort of PDSTB cases (n = 17) for which clinical 
information was available, the relationship between 
immunoreactivity for SNCA, MHCII and CD68 and clinical history 
was explored. Cases were assessed based on clinical subtype (H-
T or A-R), sex, disease duration (DD), and ages of onset (AAO) 
and death (AAD) (Table 4.1) . Cases were evaluated both as 
individual data points (by Spearman's correlation and regression 
analyses) and in groups (by Student's T-test). No correlations 
were found between SNCA or MHCII and any of the clinical 
criteria examined, and no clinical classification seemed to 
reflect the relationship observed between SNCA and MHCII. 
A significant difference between CD68 immunoreactivity in 
PD cases with a DD of 10 years or less (n = 9, mean 7.3 ± 2.4 
years) compared to those with a DD greater than 10 years (n = 8, 
mean 17 ± 5.0 years) was detected using Student's T-test, with 
CD68 immunoreactivity significantly higher in cases with a 
shorter DD (p < 0.05) . DD was highly inversely correlated with 
AAO (p < 0.0005), which was thus also significantly higher in 
the two DD groups defined (p < 0.005) . AAD remained consistent 
across cases in both the shorter (n = 9, mean 78.9 ± 5.3 years) 
and longer DD groups (n = 8, mean 78.5 ± 5.2 years) . Hence DD, 
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and subsequently CD68 immunoreactivity, appeared to be a factor 
of disease onset rather than life expectancy. The presence of 
co-occurring AD-type pathology in the hippocampus or hippocampus 
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Figure 4.2 SNCA and MHCII in the Substantia Nigra 
(Preceding page) Immunohistochemistry demonstrated SNCA LB and 
LN and MHCII-expressing microglia in all cases of PD examined. 
Some cases demonstrated extensive SNCA pathology, as in A, case 
MIO, 40X. Microglia with a more rounded, ^activated' morphology 
tended to be more strongly immunoreactive than those that 
retained long, thin processes, as illustrated in B, case PD24, 
40X. Tissue sections from PD cortex demonstrated no 
immunoreactivity when primary SNCA (C, lOX) or MHCII (D, lOX) Ab 
was omitted, although the hematoxylin counterstain remains 
visible as on all other sections. 
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Figure 4.3 MHCII and SNCA in the SN are related 
Semi-quantitative severity ratings for all cases, sorted by 
MHCII. Severity ratings were averaged (AVE) across two 
independent observers. Linear regression and non-parametric 
correlation analyses found a statistical association between 
MHCII and SNCA severity ratings (p < 0.01). Both PDSTB and 
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Figure 4.4 CD68 is inversely associated with disease duration 
Using Students' T-test, CD68 severity ratings were significantly 
lower in cases with a disease duration (DD) greater than 10 
years (n = 8) compared to those with a DD less than or equal to 
10 years (n = 9 ) (p < 0.05). 
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4.5 Discussion 
4.5.1 SNCA immunoreactivity in the parkinsonian substantia 
nigra 
The observations on SNCA immunoreactivity in this study 
are in keeping with the many previous reports of SNCA in the SN 
in PD (Spillantini et al. 1997; Mezey et al. 1998; Irizarry at 
al. 1998; Spillantini et al. 1998). SNCA-immunopositive protein 
aggregates were observed throughout the SN in numerous 
conformations as have been described in Chapter 3 and elsewhere 
(Saito et al. 2003) . The 17 cases in this study from the 
University of Munich had all been diagnosed prior to the advent 
of diagnostic SNCA immunohistochemistry, and therefore these 
cases were carefully monitored to ensure that they fell within 
current diagnostic criteria as well. They represented a range 
of SNCA pathology nearly identical to that observed in the PDSTB 
cohort, which provides reassurance that both groups of cases are 
well within the normal range of idiopathic PD. 
The amount of SNCA observed in a particular case may be 
affected by endogenous differences between individuals or 
reflect an as-yet unknown pathological process. In the present 
cohort, the amount of SNCA-containing protein aggregates is not 
proportional to clinical factors including symptom onset or 
disease course. Cases in the PDSTB cohort with the highest 
levels of SNCA were mixed in predominant motor symptoms 
(tremulous or akinetic-rigid) and the presence of absence of 
confounding AD-type pathology, ranged from 49 to 86 years at 
AAO, and from 3 to 28 years in DD. 
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In a proposed staging model of SNCA aggregation in PD, a 
decrease of SNCA-containing protein aggregates in the SN is 
associated with the progression of PD (Braak et al. 2003). 
Based on this staging system, it would be likely that those 
cases with a lower SNCA burden had progressed to a more advanced 
stage of PD, with increased involvement of limbic and cortical 
brain areas. The cases in the PDSTB cohort were all reported to 
be in both clinically and neuropathologically advanced stages of 
PD at the time of death and would have fallen into the later, 
more severe of the proposed tiers. The finding that SNCA is not 
related to disease severity in the present cohort does not 
support the proposed model. The results reported here could be 
combined with a systematic evaluation of other brain areas to 
address this hypothesis more thoroughly. 
4.5.2 MHCII immunoreactivity in the parkinsonian substantia 
nigra 
Our finding of an overall correlation between SNCA 
deposition and MHCII-expressing microglia in the SN is in line 
with reports that both phenotypic changes are associated with 
neurodegeneration in PD and with studies of MSA, PSP and CBD in 
which an increased number of MHCII-expressing microglia were 
associated with areas of SNCA or tau aggregation respectively 
(Ishizawa and Dickson 2001; Ishizawa et al. 2004). Whether 
there is any pathogenic link between the two phenomena remains 
unclear. This finding lends support to the possibility that 
SNCA aggregation can somehow provoke or sustain microglial MHCII 
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expression through a mechanism mediated either directly by SNCA 
or through the incorporation of molecules with pro-inflammatory 
properties into SNCA-immunopositive protein aggregates. 
It is also noteworthy, however, that none of the clinical 
parameters evaluated showed any statistical relationship to 
either MHCII or SNCA. Previous studies have also failed to 
associate MHCII with clinical features of PD (Banati et al. 
1998; Orr et al. 2005) . A failure to find any correlation 
between MHCII and DD, AAO, AAD, gender or presenting motor 
symptoms raises questions about the significance of microglial 
MHCII expression as a marker of microglial involvement in PD and 
other chronic CNS diseases, particularly those of the aged 
brain. Microglia designated ^active' by their MHCII expression 
may not necessarily be functionally active. The lack of a 
relationship between MHCII and CD68 supports this possibility. 
Microglial MHCII expression under the conditions of slowly 
degenerative, late-onset neurological conditions may reflect a 
sort of ^microglial scarring' with a different, or no, 
functional relevance. MHCII expression has been hypothesised to 
reflect dystrophism, rather than activation, in aged human brain 
(Streit et al. 2004a), and a study of monkeys chronically 
treated with MPTP found that MHCII expression was persistent in 
the SN and absent from the still actively degenerating striatum 
long after MPTP exposure (Hurley et al. 2003). 
The presence of activated microglia in the post-mortem SN 
may be a reflection of agonal state prior to death rather than 
indicative of a chronic disease state, and the lack of any 
relationship between MHCII and clinical parameters could 
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therefore be attributable to factors such as hypoxia or 
infection prior to death altering microglial protein expression 
(Mattiace et al. 1990). However, this explanation cannot 
account for the correlation between MHCII and SNCA aggregates, 
which are presumably formed well before death and not as 
sensitive to confounding illnesses. Indeed, the very strong 
statistical relationship between MHCII and SNCA suggests that 
MHCII expression is fairly robust to agonal state. 
The inflammatory response in PD may peak early in the 
course of the disease, at which time a pathogenic link between 
MHCII and clinical progression could be detected, but by the 
time of post-mortem evaluation most relevant microglial activity 
may have stopped, particularly in cases with more prolonged 
disease durations. PET imaging studies of microglial activation 
in PD seem to support this hypothesis. In a study of early PD 
using recently diagnosed, drug-naive subjects, microglial 
activation as measured by binding of the ^^C-PK11195 ligand was 
upregulated in PD basal ganglia compared to control and also 
significantly correlated inversely with a marker for the 
dopamine transporter and positively with clinical motor severity 
(Ouchi et al. 2005b). However, a longitudinal study of ^^ C-
PK11195 binding in PD patients with a longer disease duration 
revealed that microglial activation remained greater in PD 
compared to controls, but that ^^C-PK11195 binding did not 
correlate to either clinical severity or ^®F-dopa uptake (Gerhard 
et al. 2005) . 
Microglial activation in PD is widespread and not limited 
to areas of marked cell death (Imamura et al. 2003b) . In the 
120 
present study, MHCII-expressing microglia were not limited to 
the area of the SN, although that was the only region formally 
assessed. In all cases, MHCII-immunopositive cells were also 
found throughout the cerebral peduncle and brainstem where no 
SNCA aggregates or obvious signs of neurodegeneration were 
detectable (Figure 4.5). MHCII levels outside the SN were 
generally less than, but reflective of, levels within the SN; 
cases with high MHCII in the SN demonstrated less MHCII 
elsewhere in the section, but more so than cases with low MHCII 
in the SN. 
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Figure 4.5 MHCII-immunoreactive microglia in the cerebral 
peduncle 
MHCII-expressing microglia appeared throughout the tissue 
sections in similar relative amounts to those observed in the 
substantia nigra and are demonstrated here in the cerebral 
peduncle. Case PD28 was assigned a severity score of 3 in the 
SN and contains more densely immunoreactive microglia in the 
cerebral peduncle (A) than case PD24 (B) , which was assigned a 
severity score of 2 in the SN and contains slightly fewer, more 
ramified immunoreactive cells. Both photos taken at lOX primary 
magnification. 
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4.5.3 CD68 immunoreactivity in the parkinsonian substantia 
nigra 
In spite of indications that microglial MHCII expression may 
not be indicative of current microglial involvement in the 
degeneration of the SN at time of death, high levels of CD68 in 
some cases indicate that microglial phagocytosis can still occur 
at that point. Microglial phagocytosis of neural debris is not 
a rapid process (Reichert and Rotshenker 1996; Kosel et al. 
1997a), and this peculiarity of the brain's intrinsic phagocytes 
may explain the persistence of some CD68-positive cells in the 
SN even after a long disease course. 
Of particular interest is the finding that phagocytes were 
found to be more prevalent in PD cases with a shorter DD, 
suggesting that phagocytosis peaks and then abates. The 
presence of surviving DA neurons in all cases examined somewhat 
undermines the hypothesis that activated microglia create a 
self-perpetuating inflammatory environment. Case PD21 had the 
longest DD in the cohort (28 years) , but an otherwise typical 
disease course, and the SN of this case demonstrated fairly high 
levels of MHCII and SNCA and almost no CD68-immunoreactive cells 
(Table 4.1). After nearly three decades of clinical PD, which 
is not thought to present until nearly 50% of all DA neurons of 
the SNpc and 70% of those in the ventrolateral tier of the SNpc 
are already dead (Fearnley and Lees 1991) , the small number of 
effectively normal-appearing DA neurons remaining in the SN 
suggest that neurons are specifically targeted by microglia when 
their survival is compromised rather than arbitrarily harmed. 
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Conversely, cases with many CD68-immunoreactive phagocytes 
in some areas displayed neighbouring areas in which CD68 was 
completely absent (Figure 4.6). Again, the apparent specificity 
of phagocytes to specific neurons and groups of neurons is not 
comparable to the widespread MHCII expression observed in 
adjacent sections from the same case. 
The significantly higher level of CD68 in cases with 
shorter disease duration suggests that it is these cases in 
which the active removal of neuronal debris is still ongoing. 
DD is independent of disease progression. Cases with a shorter 
DD had higher levels of CD68 and were less likely to contain AD-
type pathology than those cases with a longer DD, but they were 
in no way ^less advanced' pathologically. All demonstrated the 
same range of SNCA and MHCII immunoreactivity in the SN, as well 
as significant SNCA deposition in limbic and/or cortical 
regions. 
Cases with a shorter DD may have progressed more rapidly, 
or they may have remained pre-symptomatic for a longer period. 
The finding of the present study supports the former; the 
presence of phagocytes indicates that active cell death occurred 
more recently or to a greater extent. The brain may be 
increasingly sensitive to the initial stages of PD pathogenesis 
with age, or there may be a difference between early- and late-
onset cases of PD with respect to their formal pathogenesis, 
with parkinsonian-type, age-related neurodegeneration diagnosed 
as idiopathic PD subject to causative or pathogenic differences 
that lead to a faster disease progression. 
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4.5.4 Possible relevance of AD-type pathology 
All of the cases in this study were free from tau or A(3 
deposits in the SN, but the presence of additional 
neurodegenerative processes within the CNS may have a global 
effect on protein aggregation and/or microglial activation. 
The presence of AD-type pathology in the hippocampal 
formation and/or cortex was associated with a longer duration of 
PD symptoms prior to death but not statistically related to age 
at disease onset or death. CD68 expression was found to be 
statistically associated with the absence of AD-type pathology. 
It is likely that both these factors are affected by DD rather 
than each other. 
MHCII expression was not associated with the presence of 
AD-type pathology elsewhere in the brain, but in light of its 
association with SNCA in the SN and with A(3 in AD, an 
examination of brain areas in which SNCA and AD-type pathology 
are coexistent could be informative in understanding the 
differential effects of protein aggregates on microglia. 
In light of our observation that the presence of AD-type 
pathology was related to DD, the lack of association between 
SNCA immunoreactivity and clinical data was perhaps surprising. 
It may be the case that disease duration can influence the 
development of secondary pathological lesions without having an 
affect on those primary lesions most clearly associated with a 
particular disease. A comparison of the present finding with 
the presence of LB-type pathology in a cohort of AD cases, or of 
A(3 and tau in a cohort of DLB and/or MSA cases of varying DD, 
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Figure 4.6 Selectivity of CD68-iiimiunoreactive phagocytes for 
specific neuron clusters in a single case 
(Preceding page) Two adjacent images of PD36 contrast an area 
with numerous phagocytes (such as those indicated by an arrow) 
in close proximity to DA neurons (*) (A, 20X and B, 40X) to one 
in which DA neurons do not have any associated phagocytes (C, 
lOX) . Cortical tissue section used as a negative control with 
omission of primary antibody demonstrates no immunoreactivity 
(D, lOX) 
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4. 6 Conclusions 
This study demonstrates that throughout the SN, PD cases 
with higher levels of SNCA deposition contain more MHCII-
expressing microglia. However, neither marker is indicative of 
disease timeline or clinical subtype. Both MHCII and SNCA are 
likely to hold some as yet undetermined functional significance 
in the progression of PD, but attempts to link SNCA or MHCII to 
the clinical course of PD should be made with caution. The 
finding that CD68-immunoreactive phagocytes are associated with 
a shorter DD indicates that microglial activity does indeed 
relate to clinical disease course. Rather than lead to a 
cascade of cytotoxicity, our results suggests that microglial 
phagocytosis is selective and attenuated prior to the complete 
destruction of the SN. 
By demonstrating that MHCII expression is not comparable 
to phagocytosis, this study also highlights the importance of 
the choice of activation marker used in the conclusions that can 
be drawn from a study of microglia. 
Follow-up studies addressing the relationship between 
MHCII, CD68 and SNCA in other brain areas, particularly in which 
confounding AD-type pathology is also present or SNCA is 
completely absent, will help to elucidate the functional 
significance of MHCII expression in PD tissue and elaborate upon 
the relationship between MHCII expression and pathological 
protein aggregates. 
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Chapter 5: Microglial activation in 
Parkinson's disease-affected cortex 
5.1 Introduction 
The microglial response to neurodegeneration in animal 
models of PD has been reported as fairly confined to the 
nigrostriatal system, but these models are designed specifically 
to test that system. Idiopathic PD is far more complex both 
clinically and pathologically, with clinical deficits including 
prominent autonomic and cognitive impairment, and post-mortem 
tissue illustrating the extent of SNCA deposition and neuronal 
loss throughout subcortical and cortical brain regions 
(Jellinger 1991). While the presence of aggregated protein is 
generally regarded as a reflection of neuronal death in a 
region, neuronal loss has also been measured in the pre-
supplemental motor cortex in post-mortem PD tissue, an area 
devoid of SNCA-, A(3- or tau-containing protein aggregates 
(Macdonald and Halliday 2002) . The increase in number and 
anatomical distribution of MHCII-expressing microglia observed 
in post-mortem PD in comparison to animal models may be 
indicative of a more widespread degenerative process. 
Alternatively, MHCII expression in PD may represent a 
phenotypic ^scar' with no functional relevance to microglial 
protein expression. Observations in the SN of PD cases 
discussed in Chapter 4 indicate that microglial MHCII-expression 
persists in the SN long after most active neuronal death has be 
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presumed to have ceased. Age-related alterations in the 
microglial expression of activation-associated molecules 
including MHCII could confound the effects of PD on the 
microglial population, resulting in a constitutive upregulation 
of MHCII (Gehrmann at al. 1993; Streit et al. 2004a). 
5.1.1 Protein aggregation and microglial activation 
Previous studies of the relationship between activated 
microglia and neurodegeneration in post-mortem brains have 
assessed microglia in areas selected on the basis of co-
occurring pathological protein aggregates. This methodology 
presupposes that microglial activation is either pathologically 
linked to protein aggregation or attributable to a ^background 
noise' of confounding factors including age, cause of death, 
diet and drug intake. Studies of cortical microglia and SNCA 
aggregates in PD and DLB have not been conclusive (Shepherd et 
al. 2000; Mackenzie 2000; Rozemuller et al. 2000; Imamura et al. 
2003a). These studies are generally in accordance that 
microglial activation is greater in disease than control tissue, 
but otherwise discrepant, which has been attributed to 
methodology. While differences in tissue sampling, 
immunohistochemistry and particularly in quantifying 
immunoreactivity undoubtedly cloud the issue, it is also 
possible that the assumptions underlying the experimental design 
of these studies do not permit a full understanding of the 
microglial response in PD. 
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Microglial MHCII-expression has been linked with A|3 in AD 
tissue, with activated microglia observed in close proximity to 
amyloid plaques. A|3 has also been shown to stimulate microglia 
in vitro (Meda et al. 1995), supporting the hypothesis that 
aggregation of this protein can have a direct effect on the 
activation status of microglia in vivo. While it has been 
proposed that LBs can directly stimulate microglia (Togo et al. 
2001), a similar link has not been established between microglia 
and SNCA. In DLB, MHCII has been suggested to be more directly 
attributable to the presence of confounding AD-type tau 
pathology (Shepherd et al. 2000), and that may also apply to PD, 
where tau and AP are often found in addition to SNCA in areas 
including SFG and hippocampus. 
If MHCII is indeed dependent upon AD-type pathological 
protein aggregation, the co-occurrence of Ap and tau with SNCA 
could perhaps be considered more than just ^confounding', and 
rather be indicative of underlying pathological processes in PD 
that may potentially be treatable with drugs originally intended 
for AD. However this hypothesis cannot account for the high 
MHCII expression in the SN in PD, where AD pathology is absent. 
It is also possible that both MHCII and SNCA are indicative of a 
shared, underlying process and that the relationships detected 
between MHCII and A(3 or tau elsewhere in the brain are not 
relevant to PD. 
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5.1.2 Confounding influences on microglial activation 
If age is the major factor in increased MHCII expression, PD 
and age-matched control cases could be expected to demonstrate 
similar amounts of the protein. Disease-related alterations in 
the humoral immune system could lead to changes in microglia 
that are not reflected by protein deposition or PD progression. 
The assessment of a brain area in which no protein aggregates 
are present may highlight disease-specific, SNCA-, tau- and A(3-
independent alterations in microglial phenotype. Alternatively, 
the effect of drugs, particularly those used to treat PD, on 
microglial activation can perhaps be isolated with a large group 
of cases with varying drug histories. Of particular interest to 
PD research is the effect, if any, of NSAIDS, ibuprofen in 
particular, which could be an effective, inexpensive and 
accessible way to prevent or delay PD. 
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5.2 Aims 
The hypothesis of the present study is that microglial 
activation as represented by MHCII and CD68 expression is the 
result of a microglial phenotype associated with the 
pathogenesis of PD but independent of protein deposition. In 
addition to comparing PD cases with pathological protein 
aggregates in the SFG and cingulate cortex (CING) to PD-affected 
and control cases with no protein aggregated in those regions, 
the microglial response is compared within individual cases 
between SFG and CING, cortical regions associated with 
pathological protein aggregation, and the primary visual cortex 
(VI), which has not been reported to demonstrate any significant 
protein aggregation or neuronal death in PD. 
By comparing areas known to be affected by pathological 
protein aggregations to those that are not in cases with and 
without protein aggregates, while controlling as much as 
possible for clinical and pharmacological history and cause of 
death, it may be possible to tease out the major factors 
affecting in MHCII and CD68 expression in PD. 
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5 .3 Materials and Methods 
5.3.1 Hiiman tissue 
Human tissue was provided by the PDSTB and the University 
of Liege, Belgium. Formalin-fixed, paraffin-embedded tissue, 
microtome-cut in Sum sections, was used. Cohorts of control (n 
= 5) , PD (n = 26) and MSA (n = 3) cases were age- and sex-
matched (Table 5.1). The cases' individual clinical information 
is outlined in Table 5.2. 
5.3.2 Immunohistochemical stains 
Immunohistochemistry was carried out as described in 
2.2.1. The antibodies used, their manufacturer, dilution and, 
if any, antigen unmasking required are outlined in Table 5.3. 
Negative control slides, in which application of primary Ab was 
omitted from the protocol, were included to ensure specificity 
of imunostaining (Figure 5.7). 
Table 5.1 Clinical data compared across cohorts 
No statistically significant differences were observed in age at 
death (AAD) or sex of cases between control, PD and MSA cohorts. 
cohort AAD Male:Female (% 
Female) 
CONTROL 81. 4 ± 4.7 4:1 (20%) 
PD 78. 5 ± 5.5 18:8 (31%) 
MSA 63 .7 ± 18 2:1 (33%) 
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Table 5.2 Cases' clinical information 
Clinical information derived from retrospective analyses of 
clinical histories (described Section 2.2.1). PDD, Parkinson's 
disease with dementia; A-R, akinetic-rigid; H-T, hemi-tremulous; 
AAD, age at death; AAO, age at onset; DD, disease duration; 
NSAID, non-steroidal anti-inflammatory drug (1 = ibuprofen, 2 = 
aspirin, 3 = Vioxx); DAA, dopamine agonist; MAOBI, monoamine 
oxidase B inhibitor; choll, cholinesterase inhibitor. 
SEX DIAG 
PD 




C0N2 M - - 77 - - - -
C0N3 M - - 81 - - - -
C0N4 F - - 77 - - - — 
CONPDC02 M - - 88 - - - -
•CONPDC03 M - - 84 - - - -
MSA12 M MSA - 42 32 10 1 N/N/N 
MSA25 F MSA - 63 57 6 0 Y/Y/N 
MSA43 M MSA - 86 78 8 2 Y/Y/N 
PD04 M PDD/AD A-R 68 65 3 0 N/N/Y 
PD08 M PD H-T 72 63 9 0 Y/Y/N 
PDIO F PDD H-T 81 67 14 2 Y/Y/Y 
PD15 M PD A—R 70 57 14 2 Y/N/N 
PD16 F PD H-T 85 67 18 0 Y/Y/N 
PD17 M PD H-T 75 57 18 0 Y/Y/Y 
PD18 M PD A-R 82 78 5 0 N/N/Y 
PD19 F PD H-T 72 55 18 0 Y/Y/Y 
PD20 M PDD H-T 75 42 34 0 Y/Y/Y 
PD21 M PD H-T 76 49 28 0 Y/Y/N 
PD22 F PD H-T 76 65 10 2 Y/Y/N 
PD23 M PD A-R 82 75 7 2 Y/N/N 
PD24 M PDD H-T 81 72 9 1 Y/Y/N 
PD2 6 M PD/AD A—R 74 69 6 0 Y/Y/N 
PD28 M PD A-R 82 65 18 0 Y/N/N 
PD2 9 M PD H-T 76 70 7 2 Y/Y/N 
PD32 M PD A-R 89 86 3 3 N/Y/N 
PD34 F PD/AD H-T 84 72 11 0 N/N/N 
PD36 M PD H-T 76 6 6 10 0 N/N/N 
PD39 F PDD H-T 82 69 13 2 N/Y/N 
PD45 M PD A-R 80 60 19 0 Y/Y/N 
PD55 F PD H-T 76 58 18 3 Y/N/Y 
PD67 M PD H-T 83 73 9 2 Y/Y/N 
PD74 M PD H-T 85 76 9 2 Y/N/N 
PD81 M PD H-T 73 65 8 1 N/N/N 
PD86 F PD H-T 87 77 9 1 Y/N/Y 
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Table 5.3 Sources and usage or antibodies 
Ht, high-temperature; FA, formic acid. A(3 Ab clone 1E8 is a 
gift of Dr. S.M. Gentleman and not commercially available. 
Anti- Manufacturer Clone Dilution Pre-Treatment 
CD68 Dako PGMl 1/200 — 
MHCII Dako CR3/43 1/100 20 min. Ht EDTA 
SNCA Becton-Dickinson 42 1/300 5 min. 100% FA 
A(3 - 1E8 1/1000 8 min. 80% FA 
Tau AutogenBioclear AT 8 1/800 -
5.3.3 Quantitation 
Immunostaining was rated semi-quantitatively from 0-3 in 
both grey and white matter, as described below. In the case of 
MHCII and CD68, immunoreactivity in perivascular cells was 
considered an internal positive control for a successful 
reaction, but was otherwise not considered. Perivascular 
immunoreactivity ranged from faint to intense and generally 
correlated with the number of immunoreactive parenchymal cells 
in a given case (Figure 5.1 A, B) . For SNCA immunostains, the 
same condition applied to non-specific binding of anti-SNCA mAb 
to corpora amylacea, although in some cases corpora amylacea 
were present but not immunolabelled (Figure 5.1 C, D) . In the 
case of A(3 and tau, a positive control section from the 
hippocampus of an AD brain was provided by Dr. Stephen 
Gentleman. 
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For all immunostains, a score of 0 was assigned if no 
immunoreactivity (excluding perivascular cells and corpora 
amylacea) was observed. For MHCII in GM, CD68, SNCA, A(3 and 
tau, a score of 1 indicates readily identifiable immunopositive 
structures, but in general not more than one per field of view 
at lOx magnification. A score of 2 indicates immunopositive 
structures appearing with greatly increased frequency, one event 
per 40X field of view, in some areas of the section. Cases 
scored with a 3 demonstrated at least one immunopositive 
structure per field of view at 20X magnification throughout the 
section, with some areas demonstrating at least one 
immunopositive structure per field of view at 40X magnification. 
Severity ratings for MHCII in GM are illustrated in Figure 5.2. 
In SNCA-stained sections, a score of 0.5 was assigned when 
isolated LBs were not found but punctate immunopositivity was 
very frequent. For MHCII, a score of 0.5 was assigned to cases 
with only sparse, isolated events over the whole section. 
MHCII immunoreactivity was often so dense in the WM that 
it was necessary to increase the stringency of the criteria used 
in GM (Figure 5.2). MHCII in WM was scored at 2 when more than 
one immunopositive microglia was visible per 40X field, and 3 
when more than five immunopositive microglia was visible per 40X 
field. For the assessment of tau, which was quite infrequent in 
the cohort, cases were assigned a score of 1 when the number of 
tangles over the entire section numbered 10 or less. In the 
case of A(3, a distinction was in some instances made based on 
morphology. The mAb used to recognise A(3 plaques was very 
sensitive, which led to the identification of many more diffuse 
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plaques than would have been detected using a commercial mAb. 
Cases with very faint diffuse plaques were not assigned a 
severity rating higher than 1.5, regardless of the number of 
those plaques detected. This distinction was only relevant to a 
very small number of sections with exclusively, and with high 
numbers of, faint diffuse plaques. Otherwise, diffuse and cored 
plaques were considered together and weighted equally in 
determining a severity rating. 
To verify the semi-quantitative ratings, scoring was 
repeated on >10% of slides after a period of weeks. Another 
observer. Dr. Pascal Durrenberger, also scored >10% of slides. 
These ratings were statistically assessed and did not differ 
significantly from the original values. 
5.3.4 Statistical analysis 
Statistical analysis was carried out on SPSS version 13.0. 
Student's T-test, multivariate correlational analyses and 
General Linear Model multivariate analysis of variance and 
regression were carried out. Because not all datasets were 
normally distributed, T-tests did not assume normal distribution 
and the nonparametric Spearman's correlation was used instead of 
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Figure 5.1 Variability of immunoreactivity of MHCII and SNCA 
with perivascular cells and corpora amylacea ^  respectively 
In some cases, perivascular cells stained intensely (A, C0N3 
SFG, lOX) while in other cases iitununolabelling was very faint 
but still visible (B, PD08 SFG, lOX) . Similarly, non-specific 
binding of anti-SNCA mAb to corpora amylacea is observed in some 
cases (C, PD19 VI, 20X) and absent in others (D, C0N4 CING, 
20X). 
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Figure 5.2 MHCII severity ratings in white and grey matter 
The figure illustrates the difference in severity ratings 
assigned for MHCII in WM (A, C, E) and GM (B, D, F) due to the 
increased density of MHCII-immunoreactive microglia in WM. 
MSA25 was assigned a rating of 1 in both WM (A) and GM (B) in 
SFG. PD26 was assigned a rating of 2 in both WM (C) and GM (D) 
in CING. PD86 was assigned a rating of 3 in both WM (E) and GM 
(F) in VI. All images are taken at lOX primary magnification. 
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5.4 Results 
Semi-quantitative severity ratings for immunostaining of 
each case are presented in Table 5.4 (control and MSA cases), 
Table 5.5 (PD cases) and Table 5.6 (all cases, A(3 and tau 
severity ratings). 
5 .4 .1 Microglial activation across brain areas and disease 
states 
MHCII-expressing microglia were observed in all PD cases 
examined in SFG, CING and, notably, VI (Figure 5.3). Expression 
was higher in WM than GM. Within the GM, expression was 
generally highest at the border with WM. Cells appeared to be 
migrating from WM to GM or from GM to WM in deep cortical 
layers. In the rest of the GM, cells were fairly evenly 
distributed. Within individual cases, microglial MHCII was 
highly correlated across brain regions (p < 0.01). The 
relationship remained consistent even when comparing WM to GM 
and was independent of neuropathological diagnosis and the 
presence of protein aggregates (Figure 5.4). Student's T-test 
confirmed that there were no differences in microglial protein 
expression of either MHCII or CD68 across regions. 
Very high CD68 expression was observed in two of five 
control brains, resulting in higher average levels of CD68 in 
control compared to PD or MSA. Within the control cohort, this 
high CD68 showed no relationship to MHCII, SNCA or tau, and an 
inverse relationship with A|3. However, the small size (n = 5) 
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of the control cohort does not lend itself to intra-group 
comparisons. 
Among PD cases, levels of CD68 in the GM were correlated 
with MHCII in the GM in adjacent sections from the same block 
when all brain areas were analysed together (p < 0.05). The 
relationship was not present in the WM. 
A comparison of MHCII severity ratings between PD and 
control in each brain region using Student's T-test did not 
detect any significant differences between the two cohorts, 
although a trend toward increased MHCII in the PD cohort was 
observed. 
Cortical region was not found to have any effect on the 
amount of MHCII or CD68 observed, therefore brain regions were 
then analysed together in order to increase sample size. In 
these analyses, each case represents three data points rather 
than one. Combining data from different brain areas permitted 
more robust comparisons between PD and control. Comparing the 
combined cortical severity ratings between PD and control, MHCII 
is significantly increased in the WM of PD cases (p < 0.05) . 
MHCII in GM remained non-signifleantly higher in PD compared to 
control (p < 0.1). 
No significant difference in MHCII or CD68 was observed 
between PD and MSA or MSA and control. 
5.4.2 Comparison of SNCA across disease states 
Cortical SNCA in both PD and MSA is illustrated in Figure 
5.5. SNCA was significantly higher in PD SFG and CING than 
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control SFG and CING (p < 0.05 in both instances) as well as in 
the combined cortical dataset (p < 0.0001) (Figure 5.6). 
General Linear Model (GLM) multivariate analysis of variance and 
regression analysis confirmed that SNCA in GM and MHCII in WM 
are strongly associated with a diagnosis of PD (p < 0.0001 and p 
< 0.01, respectively). 
A comparison of MSA with control demonstrated a significant 
difference in SNCA in both the GM (p < 0.05) and the WM (p < 
0.01) . The only difference observed between MSA and PD was the 
frequency of SNCA aggregates in the white matter (p = 0.01) 
(Figure 5.6). 
5.4.3 MHCII, CD68 and protein aggregation 
Most PD cases and all MSA cases contained aggregated SNCA in 
at least one cortical region. A(3 and tau-containing protein 
deposits were also observed in many tissue sections, though not 
generally in large amounts (Figure 5.7 and Table 5.6). SNCA was 
observed very rarely in VI in PD cases, while A(3 and tau were 
observed there as frequently as in CING or SFG. A(3 and tau were 
consistently highly correlated both in GM and WM (p < 0.01) 
across cases. SNCA in GM was associated more strongly with a 
co-occurrence of tau (p < 0.001) than Ap (p < 0.05). A(3, tau 
and SNCA showed no statistical relationships among controls, in 
which they were observed very infrequently. 
In order to assess the effect of SNCA, AfJ or tau on 
microglial activation, severity ratings for MHCII and CD68 were 
compared in sections from within the PD cohort with and without 
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SNCA, tau, A(3, and any combination of the three using Student's 
T-test. A Spearman's nonparametric correlation analysis was 
also carried out on these data. Using combined cortical data, 
MHCII was not associated with protein deposition in either 
statistical analysis. CD68 was significantly more frequent in 
those sections with tau in the GM (p < 0.01) . When different 
brain regions were analysed individually, no associations 
between microglial and deposited proteins were observed in VI. 
In CING, GM MHCII correlated with GM A(3 and SNCA (p < 0.05) . In 
SFG, GM MHCII was correlated only with SNCA (p < 0.05) . However 
in VI, in which MHCII was comparable to MHCII in SFG and CING, 
MHCII did not correlate with any deposited proteins. CD68 
remained significantly correlated with tau in both SFG and CING 
(Figure 5.7). 
Controls were then compared to only those PD cases in which 
the sum of semi-quantitative ratings for SNCA, tau and A(3 did 
not exceed 1 in SFG, CING and VI (n = 8). These cases contained 
a level of protein aggregation comparable to that observed in 
non-neurologically affected aged brain. MHCII remained 
significantly higher (p < 0.05) in WM in PD compared to 
controls. 
5.4.4 Clinico-pathological assessment 
Cases were further analysed on the basis of clinical 
information. AAO, AAD and DD, as well as treatment with NSAIDS 
were assessed. 
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MHCII in GM and WM was significantly correlated with AAO and 
AAD in PD cases (p < 0.01) . AAO and AAD are highly correlated 
with each other (p < 0.001). A linear regression analysis found 
that AAD is the best predictor of MHCII expression in both GM 
and WM in the PD cohort of all the criteria, clinical and 
neuropathological, assessed in this study. Among controls, 
MHCII also correlated with AAD (p < 0.01) . A linear regression 
analysis of all cases in the study found that while AAD was the 
single best predictor of MHCII in GM, a diagnosis of PD was an 
equally good predictor of MHCII in WM (p < 0.001) . 
In contrast to MHCII, high SNCA deposition in PD patients 
was significantly correlated with an earlier AAO and AAD in the 
combined cortical dataset. Tau was also inversely correlated 
with AAD (p < 0.01). Analysing individual regions separately, 
these trends were still apparent but did not reach statistical 
significance. Student's T-test demonstrated that these trends 
were consistent across age ranges (AAO ^ 60, 65, 70, 75, 80; AAD 
^ 70, 75, 80, 85), although statistical significance was 
eventually lost due to shrinking group size. 
Treatment with NSAIDS in general had no effect on the 
criteria examined among PD cases. With combined cortical data 
from all brain regions, cases treated with aspirin (n = 8) did 
not differ from cases not treated with NSAIDS. However, cases 
treated with ibuprofen (n = 3) had significantly less SNCA, A|3 
and tau in GM than those cases not taking an NSAID (p < 0.05) 
(Figure 1.8), with a non-significant trend (p = 0.08) toward 
decreased MHCII in the WM. Compared to those treated with 
aspirin (n = 8) , cases treated with ibuprofen had significantly 
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lower AP and tau in GM (p < 0.05) and demonstrated the same 
trend toward decreased MHCII in WM (p = 0.06). While the number 
of cases used in this comparison is quite low, it is noteworthy 
that one of the three cases treated with ibuprofen was demented 
and the average age of the group was 80.3, higher than the 
overall average of the PD cohort, so the reduced protein 
aggregation observed is not skewed by a younger or less 
clinically impaired cohort. 
PM delay was not related to MHCII or CD68 within the PD 
cohort. Cause of death was not known in many cases. 
Bronchopneumonia was by far the most frequent clinical cause of 
death included in cases' clinical histories (Table 2.1). 
Treatment with direct DA agonists, monoamine oxidase B 
(MAOB) inhibitors and cholinesterase inhibitors, drugs all 
commonly used to treat the symptoms of PD, was also recorded 
with the intention of comparing cases treated with just one of 
the aforementioned drugs to all those cases not treated with 
that drug (Table 5.2). No effects of treatment with DA 
agonists, monoamine oxidase B (MAOB) inhibitors or 
cholinesterase inhibitors were observed, but because most cases 
had been treated with a variety of drugs in addition to L-DOPA, 
group sizes were not sufficient for our intended comparisons. 
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Table 5.4 Severity ratings assigned to control and MSA cases 
-J 
C a s e F r o n t a l c o r t e x C i n g u l a t e c o r t e x P r i m a r y v i s u a l c o r t e x 
MHCII CD6B SNCA MHCII CD68 SNCA MHCII CD6& SNCA 
WM GM KfM GM MM GM WM GM WM GM WM GM WM GM KTM GM WM GM 
C0N2 0 . 5 0 . 5 0 . 5 0 0 0 n / a n / a n / a n / a n / a n / a 0 0 0 . 5 0 0 0 
C0N3 0 . 5 0 2 0 . 5 0 0 1 0 . 5 3 1 0 0 0 . 5 0 . 5 3 1 0 0 
CON 4 0 0 2 . 5 2 1 0 . 5 1 0 . 5 2 . 5 1 0 0 1 0 . 5 3 2 0 0 
C0NPDCD2 2 1 0 0 0 0 1 . 5 0 . 5 0 . 5 0 0 0 2 . 5 2 2 2 0 0 
CONPDC03 2 . 5 1 . 5 0 . 5 0 . 5 0 0 2 2 0 . 5 0 . 5 0 0 1 . 5 2 . 5 1 0 . 5 0 0 
MSA12 1 0 . 5 0 . 5 0 1 . 5 1 . 5 0 . 5 0 . 5 0 . 5 0 1 . 5 0 0 . 5 0 . 5 0 0 0 0 
MSA25 1 1 0 0 2 . 5 0 . 5 0 . 5 0 . 5 0 0 2 . 5 1 . 5 1 0 . 5 0 0 0 0 
MSA43 3 3 0 . 5 0 . 5 1 . 5 1 . 5 3 3 2 2 . 5 0 . 5 0 . 5 2 . 5 2 1 1 . 5 0 . 5 0 
Table 5.5 Severity ratings for PD cases 
00 
C a s e F r o n t a l c o r t e x C i n g u l a t e c o ^ ^ x P r i m a r y v i s u a l c o r t e x 
MHCII CD68 SNCA MHCII CD68 SNCA MHCII CD68 SNCA 
WM GM WM GM WM GM WM GM WM GM WM GM WM GM WM GM WM GM 
PD04 0 , 5 1 0 1 0 . 5 3 1 . 5 1 . 5 0 . 5 1 1 2 . 5 1 . 5 1 . 5 2 3 0 2 
PDD8 0 . 5 0 0 0 0 0 . 5 1 . 5 0 . 5 0 0 0 1 2 0 . 5 0 . 5 0 . 5 0 0 
PDIO 2 . 5 1 . 5 0 0 0 2 1 . 5 1 0 0 0 . 5 1 . 5 1 0 . 5 0 . 5 0 . 5 0- 0 . 5 
PD15 1 . 5 1 0 0 0 1 . 5 1 . 5 1 0 0 . 5 0 . 5 2 0 0 1 1 0 0 
PD16 2 . 5 1 . 5 0 0 0 . 5 1 . 5 2 1 2 2 0 0 2 1 . 5 0 . 5 0 . 5 0 0 
PD17 1 . 5 1 . 5 0 0 0 . 5 2 N / A 2 0 . 5 0 . 5 0 1 . 5 1 . 5 1 1 0 . 5 0 0 . 5 
PD18 2 1 0 0 0 0 . 5 0 . 5 0 . 5 0 0 0 . 5 1 3 2 0 . 5 0 0 0 . 5 
PD19 1 . 5 0 . 5 0 . 5 0 0 0 . 5 1 . 5 0 . 5 1 0 0 1 1 1 1 . 5 1 0 0 
PD20 0 . 5 0 . 5 0 . 5 0 . 5 0 . 5 1 2 . 5 1 . 5 1 . 5 0 0 1 2 . 5 1 2 2 0 0 
P D 2 1 2 . 5 2 0 0 0 0 . 5 2 . 5 1 . 5 0 0 0 1 . 5 2 . 5 1 . 5 0 0 0 0 
PD22 1 0 . 5 0 . 5 0 0 . 5 0 . 5 2 1 0 . 5 0 0 1 1 1 1 . 5 0 0 0 
PD23 2 1 . 5 0 . 5 0 0 0 0 . 5 0 . 5 0 0 0 0 . 5 2 1 0 . 5 0 0 0 
PD2 4 1 0 . 5 0 0 0 0 1 . 5 0 . 5 0 0 0 0 . 5 0 . 5 0 . 5 0 . 5 0 0 . 5 0 
PD2 6 3 2 . 5 0 . 5 0 . 5 0 3 2 2 0 . 5 0 0 2 . 5 3 2 0 . 5 0 0 0 
PD2 8 1 . 5 1 0 0 0 1 0 . 5 0 . 5 0 . 5 0 0 . 5 1 1 . 5 1 0 . 5 0 . 5 0 0 
PD29 2 2 3 1 0 1 1 0 . 5 1 . 5 0 0 0 3 3 2 . 5 2 0 0 . 5 
PD32 2 1 . 5 0 . 5 0 . 5 0 0 3 1 . 5 2 1 0 0 . 5 2 . 5 2 1 2 0 0 
PD34 2 1 . 5 2 2 0 . 5 2 1 . 5 1 1 . 5 1 . 5 0 . 5 1 . 5 2 2 2 2 0 0 
PD36 1 . 5 1 . 5 0 . 5 0 0 . 5 1 1 . 5 0 . 5 1 0 0 1 1 0 . 5 0 0 0 0 
PD39 0 . 5 0 . 5 0 . 5 0 0 0 . 5 1 . 5 1 1 0 0 1 3 3 3 2 . 5 0 0 
PD45 3 2 0 . 5 1 . 5 G 1 2 . 5 2 . 5 0 . 5 1 . 5 1 2 . 5 2 1 1 . 5 1 0 . 5 0 . 5 
PD55 1 . 5 1 0 0 0 1 . 5 1 1 0 . 5 0 . 5 0 1 . 5 1 . 5 1 1 0 . 5 0 1 
PD67 3 2 . 5 0 . 5 0 . 5 0 1 . 5 3 1 . 5 0 0 0 . 5 1 3 2 0 0 0 0 . 5 
PD7 4 3 3 1 . 5 0 0 1 3 3 0 . 5 0 0 1 3 3 0 . 5 0 . 5 0 0 
PD81 1 0 . 5 1 . 5 1 0 1 1 1 1 0 0 1 . 5 1 0 . 5 1 1 0 . 5 0 . 5 
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Figure 5.3 MHCII in the PD and MSA visual cortex 
MHCII in the grey matter was comparable in PD (A; PD74, 20x) and 
MSA (B; MSA43, 20x) across all areas including visual cortex. 
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Figure 5.4 Semi-quantitative ratings across brain regions 
(Preceding page) Within individual cases, semi-quantitative 
ratings for MHCII are highly consistent across brain areas in 
both GM and WM (A, B) . CD68 in GM is also related to MHCII in 
GM (C) . Immunoreactivity for SNCA, tau and A(3 is not at all 
related to MHCII (D, E, F). SNCA is notably absent from VI (D), 
although MHCII and CD68, as well as Ap (E) and tau (F) , are 
observed there as frequently as in other areas. Cases are 
ordered consistently across graphs, from lowest to highest MHCII 
rating in SFG WM. 
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Figure 5.5 Cortical SNCA in PD and MSA 
Cortical SNCA aggregates associated with neurons in PD (A, PD26 
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Figure 5.6 Comparison of semi-quantitative MHCII and SNCA 
ratings from PD, MSA and control cohorts 
A Student's T-test comparing ratings for SNCA and MHCII between 
PD and control cases detected a significant difference only in 
MHCII in WM and SNCA in GM. A trend toward increased MHCII in 
GM was observed but not statistically significant. SNCA in WM 
was minimal in both groups. MHCII in the MSA cohort resembled 
PD, although the difference between MSA and control was not 
significant. The MSA cohort contained significantly more SNCA 
than controls in GM and than controls and PD cases in WM. *, p < 
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Figure 5.7 AD-type pathological protein aggregation in the PD 
cortex 
(Preceding page) Ap and tau were assessed in order to control 
for any confounding effects AD-type pathology my have on 
microglia in the PD cortex. Immunohistochemistry for A|3 
highlighted numerous diffuse and cored plaques in some cases (A; 
PD55 visual cortex, lOX) , while tau-immunoreactive threads 
(arrow) and tangles (*) were apparent in others (B; PD08 frontal 
cortex, 20X). Omission of primary Ap (C, lOX) or tau (D, lOX) 
antibody resulted in no immunoreactivity. 
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Table 5.6 AD-type pathological changes 
(Following page) Severity ratings for A(3 and tau are listed for 
each case, as well as the severity of AD-type pathological 
changes assigned on cases' neuropathological diagnostic reports 
using ICONS criteria. ICONS diagnosis of isocortical (IC) AD-
type pathological changes was based on aggregated tau and Ap in 
the SFG; entorhinal (ER) involvement was assessed in 
hippocampus, subiculum and entorhinal cortex. Semi-quantitative 
severity ratings for Ap were assigned in this study using a 
highly sensitive non-commercial mAb and did not take into 
account whether plaques were diffuse or cored, which accounts 
for any discrepancies between severity rating and ICONS 
diagnosis. 
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CASE ICDNS SFG CING VI 
Aijeta tau Abeta tau Abeta tau 
GH ¥H GH UH GH ¥H GH WH GH WH GH 
C0N2 
-
0 1.5 0 0 
- -
0 0 0 0 
C0N3 
-
0 1 0 1 0 0 0 1 0 0 0 0 
C0N4 
-
0 0 0 0 0 0 0 1 0 0 0 0 
CONPDC02 
-
0 2 0 1 0 2 0 0 0 1 0 0 
CONPDC03 
-
0 0 0 1 1 2.5 1 2.5 0 3 0 1 
HSA12 
-
0 0 0 0 0 0 0 1.5 0 0 0 0 
H3A25 ER2/IC1 0.5 2.5 0 0 0 1 0 0 1 2 0 0 
HSA43 
-
0 0 0 1 0 0 0 0 0 1.5 0 0 
PD04 ER4/IC4 0 1 0 2.5 0 1.5 1 2.5 2 3 0 2 
PD08 ERl 0 2.5 0 2.5 0 1.5 0 1 0 1.5 0 0 
PDIO 
-
0 1.5 0 0 0 1.5 0 0 0 2.5 0 0 
PD15 ER3/IC3 0 0 0 2 0 2 0 2 0.5 3 0 1 
PD16 ER3/IC3 0 0 0 0 0 2.5 0 1 1 2 0 0 
PD17 ER2/IC1 0 2.5 0 0 2 2.5 0 1 0 0 0 0 
PD18 
-
0.5 1 0 0 0 0.5 0 0 0 1.5 0 0 
PD19 
-
0 1.5 0 0 0 0 0 0 0 0 0 0 
PD20 ER2/IC1 0 1.5 0 0 0 2 0 0 0 0.5 0 1 
PD21 ER2 0 0 0 0 0 0.5 0 0 0 1 0 0 
PD22 
-
0 0 0 0 0 0 0 0 0 0 0 0 
PD23 ER2/IC1 0 1 0 0 0 0 0 0 0.5 2 0 0 
PD24 ERl 0 1.5 0 0 0 0 0 0 0 1.5 0 0 
PD2 6 ER3/IC4 1.5 3 1 3 1 2.5 1 3 0 3 0 1.5 
PD28 ER2/IC1 0 0 0 0 0 0 0 0 0 0.5 0 0 
PD29 ERl 0 1 0 1 0 0 0 0 0 1 0 0 
PD32 
-
0 0 0 0 0 0 0 0 0 0 0 0 
PD34 ER3/IC4 0 2 0 2 1 3 0 2 0 3 0 1 
PD3 6 
-
0 0 0 0 0 0 0 0 0 0 0 0 
PD39 ER3/IC1 0 2.5 0 1 0.5 3 0 1 0 0 0 0 
PD45 ER3/IC1 1 2 0 1 0 3 0 1 1 2 0 0 
PDS5 ER3/IC3 0 3 0 1 0 2 0 1 0 3 0 1 
PD67 
-
0 0 0 0 0 0 0 0 0 0 0 0 
PD74 ER2/IC2 0.5 1.5 0 0 0 1.5 0 0 0 0.5 0 0 
PD81 
-
0 0 0 0 0 0.5 0 0 0 0 0 0 
PD86 ERl 0 0 0 0 0 0 0 0 0 0 0 0 
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Figure 5.8 CD68 is associated with tau aggregates 
CD68-inimunoreactive phagocytes in PD cases are associated with 
the presence of tau-immunoreactive protein aggregates in a 
serial section from the same case across all brain regions and 
in SFG and CING cortex (Cx) (p < 0.05 in all instances) . The 
distribution of CD68 severity ratings is shown in pie charts in 
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Figure 5.9 The effect of NSAIDS on pathological protein 
aggregates 
PD cases treated chronically with ibuprofen showed significantly 
lower (p < 0.05) SNCA than those not taking an NSAID (*) and 
lower tau and A(3 that those not taking an NSAID or taking 
aspirin (**) . The ^none' category consisted of 14 cases, the 
^ibuprofen' category of 3 cases and the ^aspirin' category of 8 
cases. Using combined cortical data, the groups contained 42, 9 
and 24 data points, respectively. 
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5.5 Discussion 
Numerous previous studies have demonstrated a difference in 
the number and expression profile of microglia in PD and control 
tissue, suggesting that the microglial activation observed in PD 
is not entirely attributable to aging and agonal state prior to 
death and is instead related to the disease process (Imamura et 
al. 2003a; Orr et al. 2005; Gerhard et al. 2005) (McGeer et al. 
1988b; Aisen 2002; Imamura et al. 2005) . In this study an 
attempt is made to clarify both the disease- and pathological 
specificity of the microglial response as illustrated by common 
markers of activation. Additionally, the study was designed to 
test the hypothesis that microglial activation and protein 
deposition are related to one another by virtue of being 
associated with the same disease. 
5.5.1 Microglial activation and protein aggregation in PD 
cortex 
In regions that also contain protein aggregates, MHCII has 
been associated with the amount of deposited protein. In this 
study, both A(3 and SNCA correlate with MHCII in CING while only 
SNCA correlates with MHCII in SFG. One study of DLB has 
suggested that tau-containing neuritic plaques, and not cortical 
LBs, lead to increased MHCII-expressing microglia (Shepherd et 
al. 2000), while another study of DLB found a positive 
association between MHCII-expressing microglia and LBs 
(Mackenzie 2000). 
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Unlike those earlier reports, however, this study also 
quantified microglia in VI, a region almost entirely devoid of 
LB-type pathology. SNCA was highly significantly more frequent 
in the frontal and cingulate cortex, and effectively nonexistent 
in VI. In contrast, MHCII expression did not change over the 
three brain regions examined. When brain areas were analysed 
together, MHCII showed no relationship to SNCA, tau or A(3. Had 
this study been limited to brain areas known to foster SNCA 
aggregates in PD, our conclusions would have been more in line 
with previous studies. 
The number of MHCII-expressing microglia observed in a 
particular case was found to be highly conserved across brain 
areas independent of the presence of protein aggregates. The 
relationship between MHCII and protein aggregation may reflect a 
shared underlying mechanism reflecting neuronal death in which 
MHCII expression occurs first, and, in the case of VI, before 
protein aggregation can be detected. Alternatively, the two 
phenomena may be independent. 
5.5.1.1 Previous work on this subject 
The results of this study are not fully in agreement with 
earlier reports of cortical microglia in PD, however those 
studies are not in agreement with each other either. The method 
used to quantify and compare immunoreactivity varies widely 
across studies, and can have very meaningful effects on results. 
In perhaps the most comprehensive study of MHCII-positive 
microglia in PD brain, Imamura et al. found that MHCII was 
161 
significantly higher in cingulate and temporal cortex, among 
other regions, in PD compared to control brains (Imamura et al. 
2003b). The authors do not indicate whether their samples were 
taken from WM, GM or both. Their data clearly show a difference 
between groups, but their use of the Wilcoxon test, which 
assumes symmetrical distributions across groups, may have masked 
regional variability within the PD cohort. This study also 
reports that the presence of MHCII-positive microglia is not 
dependent upon the presence of LBs, as demonstrated by double 
immunohistochemistry for MHCII and SNCA. 
In contrast to the stark differences observed by Imamura 
et al., Rozemuller et al. report no observed differences in 
microglial MHCII expression in the cingulate gyrus of PD 
patients compared to controls provided that they did not have 
confounding AD-pathology (Rozemuller et al. 2000). The results 
are qualitative and therefore difficult to compare with other 
studies. Rozemuller et al. also report that microglia do not 
associate with LBs. 
Shepherd et al. compared cases of DLB with no cortical tau 
to cases of AD with no cortical SNCA and found that MHCII-
expressing microglia were significantly more frequent in AD 
cases than in either DLB cases or control brains, which did not 
significantly differ. The authors counted microglia in fields 
of view representative of the highest microglial density on the 
section. As the two previous studies, among others, have 
reported, microglia are known to cluster around plaques, and do 
not demonstrate this behaviour in the presence of LBs (Dickson 
et al. 1988; Arends et al. 2000; Rozemuller et al. 2000; Imamura 
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et al. 2003b; Xiang et al. 2006). By sampling a small number of 
areas with only the highest MHCII density, variations in the 
microglial response to different pathological changes was not 
taken into account. 
Mackenzie reports that, in transentorhinal cortex, cases 
of AD and mixed AD and DLB pathology have comparable numbers of 
MHCII-positive microglia, while so-called "pure" DLB cases with 
only SNCA aggregates had less MHCII than the aforementioned 
cases but significantly more MHCII than controls. In the 
MacKenzie study, microglia were manually counted from pial 
surface to the border with WM. Although only a small number of 
cases were examined, a positive correlation was detected between 
the number of LBs and the number of MHCII-expressing microglia 
in the "pure" DLB cohort. 
The only other report of MHCII immunohistochemistry being 
carried out in the PD visual cortex compared MHCII-expression 
there with SN. The authors use the lack of MHCII up-regulation 
in visual cortex in PD compared to controls to claim that the 
up-regulation of MHCII in the SN is "specific." It is unclear 
how MHCII in visual cortex was quantified (Orr et al. 2005). 
5. 5.1.2 Possible confounding effects of AD-related pathological 
protein aggregates on microglia in PD 
To further investigate the relationship between microglia 
and protein, PD cortical sections were grouped and compared 
based on the presence or absence of SNCA, tau and A(3. MHCII did 
not vary across these cohorts, while CD68-immunoreactive 
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phagocytes were more frequent events in regions that also 
contained tau immunopositive plaques and tangles. 
The relationship observed between CD68 and tau suggests 
that intracellular protein aggregates may not all trigger the 
same microglial response. Tau has been suggested to more 
accurately reflect clinical measures of cognitive deterioration 
in AD than A(3 (Berg et al. 1998) . Our finding further suggests 
that tau is a more accurate indicator of phagocytosis in 
surrounding tissue than A(3 in PD cases with co-occurring AD-type 
pathology. However neither CD68 nor tau was detected to be of 
significance to disease progression in PD. 
The extracellular nature of Ap aggregation may elicit a 
different response that intracellular tau or SNCA. A recent 
study suggests that the microglial response to an Ap aggregate 
resembles that to a bacterium and is quite different from that 
elicited by an ailing neuron. In the same study, it was reported 
that activation of microglia by A(3 renders them cytotoxic while 
also impairing their ability to express MHCII (Butovsky et al. 
2005) . A(3 may therefore be an additional factor confounding the 
use of MHCII as a marker to assess microglia, particularly in 
aging brain where plaques are common. The findings presented 
here suggest that if A(3 does indeed have a negative impact on 
MHCII in human brain, the effect is masked by a PD-related 
induction of MHCII. 
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5.5.2 Evidence for a disease-specific, SNCA-independent 
microglial response in PD 
More MHCII-expressing microglia are observed in WM in PD 
cortex than in control. This finding is independent of the 
presence of protein aggregates in PD cases. The comparison of 
PD cases without any pathological protein deposition with 
control cases (also, by definition, without significant 
pathological protein deposition) revealed that MHCII expression 
remains increased in WM as a factor of disease diagnosis rather 
than the presence of SNCA, tau or A(3. 
This finding suggests that while there is indeed a change in 
microglial phenotype associated with PD, the microglial 
phenotype is systemic in the PD brain, occurring either 
independently of or preliminary to the formation of either PD or 
AD-type protein aggregates in a particular brain region. 
5.5.3 The possible significance of white matter in PD 
pathogenesis 
A WM-specific increase in MHCII has not been previously 
described in post-mortem PD tissue. In combination with our 
finding that MHCII expression is consistent across cortical 
regions, this finding emphasises the importance of axonal 
degeneration in influencing the spread of PD. 
WM degeneration is a common feature of aged brain in post-
mortem human tissue, aged primates, and as measured by diffusion 
tensor imaging of elderly subjects (Dickson et al. 1990; Peters 
et al. 2000; Peters and Sethares 2002; Sandell and Peters 2003; 
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Salat et al. 2005). It is possible that an acceleration of WM 
degeneration plays a role in the progression of PD. This could 
account in part for the wide range of cognitive deficits 
encountered in late-stage PD. 
Additionally, myelin degeneration has been hypothesised to 
play a role in the pathogenesis of AD, and the same reasoning 
can be applied to PD (Bartzokis 2004; Braak and Del 2004). 
Microglia have been reported as more numerous in normal WM 
than GM (Gehrmann et al. 1993), and a global upregulation in 
MHCII may simply be more apparent in WM. If this is the case, 
then while the specific upregulation of MHCII in WM may be 
questionable, the upregulation of MHCII throughout the cortex is 
still clear. 
5.5.4 Microglia and aging 
The results presented here emphasise the importance of 
clinical data in any analysis of neuropathological change. Age 
and drug treatment, in particular, could be important factors 
affecting microglial phenotype. Microglial MHCII-expression has 
been reported to increase with increasing age (Streit et al. 
2004a) , and the data presented here support that finding, with 
MHCII in GM and WM in all three regions sampled correlated with 
AAD in both PD and controls. Although AAD is the single best 
predictor of MHCII expression in GM, MHCII in WM retains a 
disease-specific component. 
The age-related increase in MHCII expression within the PD 
cohort contrasts with the age-related decrease in SNCA and tau 
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detected among the same cases. The inverse relationship 
suggests that microglia may have a positive role in the 
elimination of protein aggregates. A decrease in aggregated 
SNCA in the SN as PD progresses has also been reported (Braak et 
32. 2003) . 
It is unclear how the microglial expression profile 
changes over time after activation. While CD68 may indicate 
phagocytosing microglia and disappear when that function is 
downregulated, MHCII expression may remain stable, regardless of 
the functional role occupied by the cell. Another marker of 
early microglial activation, PER, has been reported to respond 
similarly. PK11195 PET imaging studies of PER expression by 
microglia suggest that in early PD, PER is upregulated in the 
basal ganglia compared to control and corresponds to DA loss, 
while in later PD, after most DA has already been lost, the 
upregulation remains stable (Gerhard et al. 2005; Ouchi et al. 
2005b). 
5.5.5 Drug effects 
The effect of drug treatment on microglia has not been 
studied extensively in post-mortem tissue. We found that 
treatment with ibuprofen appeared to result in less aggregated 
SNCA, A(3 and tau among PD cases. 
NSAIDS have also been hypothesised to play a role in CNS 
inflammatory processes. Epidemiological evidence suggests that 
chronic administration of NSAIDS, and specifically ibuprofen, 
can reduce the risk of PD and AD (Aisen 2002; Chen et al. 2003; 
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Zonderman 2005; Chen et al. 2005; Bower et al. 2006). Molecular 
studies have also suggested that ibuprofen may reduce Ap 
production and deposition and suppress the inflammatory response 
of microglia in animal and in vitro models of AD (Lim et al. 
2000; Blasko et al. 2001; Yan et al. 2003). 
Aspirin was not found to affect microglial MHCII or CD68 
expression or the presence of SNCA, tau or A(3. However, a 
dosage effect may mask any effects that aspirin could have on 
PD. Ibuprofen is commonly prescribed in a dosage that is an 
order of magnitude higher than that of aspirin taken as a 
protective agent against heart disease. 
The wide-scale prophylactic administration of ibuprofen to 
the elderly has been suggested as a possible means to decrease 
the incidence of neurodegenerative disease (Aisen 2002). The 
data presented here support further studies examining the 
question, although the very small group sizes in this study 
limit the strength of the finding. 
168 
5.6 Conclusions 
This study describes a MHCII expression pattern in PD that 
appears to be globally unrelated to protein aggregation. MHCII-
expressing microglia were observed in increased numbers in the 
WM of PD cases compared to controls. This relationship was 
maintained when comparing PD cases with no cortical protein 
deposition to controls, suggesting that microglia may play an 
independent role in PD pathogenesis. New molecular markers of 
microglia in the PD brain could further elucidate the mechanisms 
underlying this phenomenon. MHCII upregulation was observed 
primarily in WM. This finding emphasises the importance of 
axonal degeneration in addition to, and separate from, protein 
aggregation in the pathogenesis of PD. 
Additionally, analysis of drug history within the cohort 
examined suggests that ante-mortem treatment with ibuprofen 
could play a meaningful role in ameliorating the microglial 
response to PD. 
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Chapter 6: Fc-gamma Receptor 2 expression 
in Parkinson's disease 
6.1 Introduction 
The work carried out in the previous two chapters indicates 
that microglial MHCII expression is increased throughout the PD 
brain compared to control, but that this expression is only 
tangentially linked to protein aggregation and clinical disease 
course. These data suggest that a widespread change in 
microglial function may play a role in the underpinning of PD as 
it progresses, but they also highlight the weakness of MHCII as 
a marker of microglial activation in PD within the context of 
assessing a post-mortem, aged human cohort. 
The Department of Neuropathology at Imperial College London 
has conducted a microarray study comparing brain tissue from 
post-mortem PD cases to age-matched control tissue (Moran et al. 
2006) . Several genes that may play a role in the immune 
functioning of the CNS were identified as upregulated on a 
transcriptional level in PD; one of these was the low affinity 
receptor for the Fc fragment of immunoglobulin G (IgG), type IIc 
(FCGR2C) . 
6.1.1 Fc Receptors 
Fc receptors (FcR) are glycoproteins that link the 
adaptive and innate branches of the immune system through the 
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binding of immunoglobulins (Ig), which can trigger or suppress 
immune cell responses including proliferation, phagocytosis and 
cytokine production. Fc-gamma receptors (FcgR) specifically 
bind IgG, the most common Ig in serum responsible for the 
recognition and elimination of pathogens by effector cells of 
the immune system. FcgR can also induce the internalisation of 
immune complexes bound to Ig leading to stimulation of the MHCI 
or MHCII antigen presentation pathway (discussed in Section 
1.1.2.4) (Amigorena and Bonnerot 1999). 
6.1.1.1 Structure of the FcgR2 molecules 
Three genes encoding FcgR2 have been isolated, FCGR2A, 
FCGR2B and the gene of interest in the present study, FCGR2C 
(Brooks et al. 1989; Qiu et al. 1990). All three genes encode 
an approximately 40 kDa glycoprotein containing an extracellular 
domain (ECD), a transmembrane region and an intracytoplasmic 
domain (ICD) . The ECD is highly conserved across the three 
genes, with 96% overall homology, while the ICD is markedly 
different between FCGR2A and FCGR2B. (Brooks et al. 1989). 
FCGR2C is likely to result from a crossover of FCGR2A and 
FCGR2B, as the ECD is nearly identical to FCGR2B (5 nucleotides 
differ) and the ICD is nearly identical to FCGR2A (19 
nucleotides differ) (Warmerdam et al. 1992) (Figure 6.1). 
The transcriptional redundancy of the three FCGR2 genes 
could result in an important functional heterogeneity. The ICD 
transcribed by FCGR2A and FCGR2C has been found to contain an 
immunoreceptor tyrosine-based activating motif (ITAM)-like 
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region which can be phosphorylated upon binding of Ig to the 
FcgR, leading to an activating signalling cascade resulting in 
cytokine production and phagocytosis in macrophages and B-cell 
activation (Figure 6.2). Transfection with FcgR2a induces 
phagocytosis in T cells (Hunter et al. 1994). Conversely, 
fcgr2b's ICD encodes an immunoreceptor tyrosine-based inhibiting 
motif (ITIM) (van den Herik-Oudijk IE et al. 1995). Binding of 
IgG to FcgR2b can inhibit macrophage and B-cell activation. 
Thus binding of IgG onto identical ECDs can suppress or activate 
immune function depending on whether that BCD is conjugated to 






Figure 6.1 Structural differences between the FCGR2 receptors 
encoded by genes FCGR2A, B and C. 
The receptor portion of the glycoprotein localised to the 
extracellular domain (ECD) is nearly identical in FCGR2B and C, 
and highly homologous to FCGR2A. The trans-membrane region 
(TMR) is also very highly conserved. FCGR2A and C contain an 
immunoreceptor tyrosine-based activation motif (ITAM)-like 
region, while FCGR2B contains an immunoreceptor tyrosine-based 
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Figure 6.2 ITAM-mediated signalling after FCGR2 binds IgG 
SRC-family protein kinase (SRCFK) phosphorylates tyrosine 
residues on the ITAM, which can then associate with Spleen 
tyrosine kinase (SYK). This activation of SYK leads to 
reorganisation of the actin cytoskeleton, a calcium burst, and 
the stimulation of molecules including mitogen-activated protein 
kinase (MAPK) which stimulate cytokine production. 
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6.1.1.2 Expression and detection of FCGR2s 
The three classes of FcgR, FcgRl, FcgR2 and FcgR3, also 
referred to CD64, CD32 and CD16 respectively, are expressed on 
monocytes, macrophages and granulocytes. FcgR2 is additionally 
expressed on platelets, megakaryotes, B lymphocytes (Rosenfeld 
et al. 1985; Unkeless 1989; Comber et al. 1989; Anderson et al. 
1990; King et al. 1990; Sarmay et al. 1990; Gewirtz et al. 
1992), peripheral blood lymphocytes (including T-cells) 
(Sandilands et al. 1995), the monocytic cell lines K562 and U937 
(Alevy et al. 1992), and endothelial cells of placenta and 
pancreas (Capel et al. 1994). The three genes encoding FCGR2 
are differentially expressed in various cell types. Among 
hematopoietic cells, FcgR2c mRNA is found in myelomonocytic 
cells and B lymphocytes but not megakaryocytic cells (Cassel et 
al. 1993). FcgR2C is the only FcgR2 expressed by natural killer 
cells (Metes et al. 1998). 
In the CNS, FcgR2 has been detected in cultured murine 
astrocytes and astrocytoma cell lines (Nitta et al. 1992). 
FcgR2/3 was detected on microglia in the degenerating mouse 
optic nerve (Reichert and Rotshenker 1996) . A study of post-
mortem formalin-fixed human brain affected by PD reported that, 
while FcgRl was expressed on phagocytosing microglia and FcgR3 
was observed on cells resembling lymphocytes in the SN, FcgR2 
was not detectable (Orr et al. 2005). 
IgG does not readily pass into the CNS from the blood due 
to its size and the impermissibility of the BBB (Pardridge et 
al. 1991), but circulating plasma cells can pass into the CNS 
and secrete IgG once there (Vrethem et al. 1992). When IgGs are 
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injected into the CNS, FCGR mediate their rapid egress from 
brain to blood, although their cellular localisation is not 
known (Zhang and Pardridge 2001). Additionally, motor neurons 
with axons projections outside the blood-brain barrier have been 
demonstrated to bring IgG into the CNS through retrograde axonal 
transport (Fabian and Petroff 1987). 
FcgR2 proteins are differentially identified by anti-FcgR2 
mAbs on specific cell types (Looney et al. 1986, Pulford et al. 
1986, Vaughan et al. 1985). Assessments of transfectants and 
epitope mapping have identified mAbs with higher affinities for 
FcgR2 derived from a particular gene or cell type (lerino et al. 
1993; van den Herik-Oudi j k IE et al. 1994), but no Ab specific 
to FcgR2c (or 2a or 2b), has been generated to date. 
6.1.2 IgG and FcgR in PD 
IgG appears to be altered in individuals with PD compared 
to controls, and this may affect disease pathogenesis. 
Injection of IgG isolated from individuals with PD into the 
rodent SN results in selective death of dopaminergic neurons and 
an increase in activated microglia (Chen et al. 1998; He et al. 
2002) . This response is not detected in FcgR -/- mice. An in 
vitro co-culture model of microglia and DA neurons suggests that 
neuronal death is attributable to microglial activation and 
supports the assertion that the mechanism of cell death is FcgR 
dependent. Additionally, IgG from patients with AD, ALS, 
peripheral neuropathy and stroke failed to elicit a microglial 
response, highlighting the disease-specificity of the phenomenon 
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(Le et al. 2001). Another study suggests that only a subset of 
PD patients' IgG can induce neuronal death and that the 
mechanism is dependent upon a synergistic effect of complement 
fragment C5a, which has also been shown to induce microglial 
activation in culture (Lacy et al. 1995; Moller et al. 1997; 
Wang et al. 2006). 
Dopaminergic drugs have been shown to have immunological 
effects which may also be relevant to PD patients. Treatment of 
guinea pigs with the DA agonists bromocriptine and pergolide, 
both used to treat PD, increases FcgR expression by splenic 
macrophages and the clearance of IgG-sensitised red blood cells, 
while treatment with DA antagonists decreases FcgR expression 
(Gomez et al. 1999). Bromocriptine, which inhibits prolactin, 
has also been shown to reduce the severity of autoimmune 
diseases (Reber 1993; Brennan et al. 1996). 
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6.2 Aims 
The aim of the present study is to assess the expression pattern 
on FcgR2 in PD brain. By using a panel of mAb recognising 
different epitopes of FcgR2, emphasis is placed on understanding 
how FcgR2C may be unique in human brain tissue. The possible 
role of FcgR2 in a generalised alteration in the interface 
between brain and immune system in PD is explored through the 
examination of multiple brain regions and an assessment of 
cases' clinical course and drug treatment histories. 
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6. 3 Materials and Methods 
6.3.1 Microarray analysis of PD tissue 
Messenger RNA (mRNA) from 15 PD cases (average AAD 80 ± 
5.7 years, 6 female) and 8 controls (average AAD 70.6 ± 12.5, 2 
female) were compared using Affymetrix microarrays (HG_U133 set) 
as described in Moran et al. 2006. Tissue from both medial and 
lateral SN was analysed. Intensity values for each probe were 
generated using the GeneChip Robust Multi Array algorithm (GC-
RMA) (Wu and Irizarry 2004). The Affymetrix probe 211395_x_at, 
corresponding to FcgR2C, was statistically significantly 
upregulated in PD cases compared to controls in the SN (p = 
0.007) . GC-RMA values for each case and brain area are listed 
in Table 6.1. 
Table 6.1 GC-RMA expression values of FCGR2 in a microarray 
comparison of PD and control SN 
(Following page) GC-RMA values were significantly higher in the 
lateral SN and in combined medial and lateral analyses in PD 
compared to control tissue (p < 0.05). Underlined cases are not 
included in the subsequent immunohistochemical analysis due to a 
lack of tissue availability. 
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Case medial SN lateral SN SFG 
C0N2 4.05620305 3. 57510749 3 .7014724 
CONS 3.83768191 - 3. 83678357 
C0N4 3.78517486 3. 56947987 3. 55616054 
CONS 4.74034599 3. 75533725 -
CON 9 3.70945704 3 .7046959 -
CON 10 3.7107468 3. 73765529 -
CONMS155 3.78210546 4 . 04849011 -
CONPDCOl 3.70480655 3. 73107557 -
PDOl 3.76592817 3 .7961834 3. 78865538 
PD02 5.07686821 4 . 63207744 -
PD04 3.77718922 3. 75796295 3. 64086477 
PD07 4.89738693 4 . 02680111 -
PD09 5.95073823 4 . 79770427 -
PDIO 3.79902611 3 .7814866 -
PD16 3.84674503 3. 62753775 -
PD20 3.79204421 - -
PD21 3.811174 - - . 
PD22 3.69495914 - -
PD28 4.9151158 4. 07961811 -
PD2 9 4.5113174 4 68572276 3. 89246976 
PD32 3.79642224 - -
PD34 4.18999165 - 3. 85770338 
PD36 4.60159076 - 4. 13547028 
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6.3.2 Human tissue 
Human colon was provided by the Department of 
Histopathology, Imperial College London. Snap-frozen sections 
12 pm in thickness were cut in the Department of Neuropathology 
from blocks provided by the PDSTB from SN, SFG and VI of PD 
cases and controls. Not all brain areas were available for each 
case. The cases used and tissue stained in each instance is 
outlined in Table 6.2. In all, 20 PD cases, one case of MSA, 
one case of atypical parkinsonism (ATYP) with no 
neuropathological features of PD, five control cases and one 
case of MS included in the control cohort were included in the 
study. In the PD cohort, average AAD was 80.6 ± 5.7 years and 8 
of 20 cases (40%) were female. In the control cohort, average 
AAD was 77.7 ± 11.1 years and 1 of 5 cases (20%) was female. 
Table 6.2 Clinical data and tissue areas assessed 
(Following page) DA agon denotes treatment with bromocriptine, 
pergolide, cabergoline, ropinirole or any combination of the 
aforementioned. NSAID, non-steroidal anti-inflammatory drug (0 
= not treated with NSAID, 1 = ibuprofen, 2 = aspirin, 3 = 
Vioxx) . AAO, age at disease onset; AAD, age at death; DD, 
disease duration; SFG, superior frontal gyrus; VI, primary 
visual cortex; SN, substantia nigra. 
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Case Sex AAO AM) DD NSAID DA agon Tissue 
CONMS155 F - 81 - - - SFG, SN 
C0NMSC32 M — 88 - - - SFG, SN 
CONMSC30 M - 75 - - - SN 
CONMSC34 M - 88 - - — SFG 
CONPDCOl M - 76 - - - SFG 
CONPDC05 M - 58 - - - SFG 
ATYPPD4 6 F 62 68 6 0 no SFG 
MSA4 3 M 78 86 8 2 yes SFG 
PDOl F 76 87 12 2 no SFG, VI 
PD02 M 75 84 9 0 yes SFG, VI, SN 
PD04 M 65 68 3 0 no SFG, VI, SN 
PD07 M 69 78 10 0 no SFG, VI, SN 
PD09 F 72 86 15 0 yes SFG, VI, SN 
PDIO F 67 81 14 2 yes SFG, VI, SN 
PD16 F 67 85 18 0 yes SFG, VI, SN 
PD20 M 42 75 34 0 yes SFG, VI, SN 
PD21 M 49 76 28 0 yes SFG, VI, SN 
PD22 F 65 76 10 2 yes SFG 
PD28 M 65 82 18 0 yes SFG, VI, SN 
PD2 9 M 70 76 7 2 yes SFG, SN 
PD32 M 86 89 3 3 no SFG, SN 
PD34 F 72 84 11 0 no SN 
PD36 M 66 76 10 0 no SFG 
PD55 F 58 76 18 3 yes SFG 
PD67 M 73 83 9 2 yes SFG 
PD74 M 76 85 9 2 yes SFG 
PD81 M 65 73 8 1 no SFG 
PD8 6 F 77 87 9 1 no SFG 
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6.3.3 Immunohi s to chemi s try 
IHC was carried out on formalin-fixed, paraffin-embedded 
tissue from parietal cortex as described in 2.2.4 and on snap-
frozen tissue from SFG, VI and SN as described in 2.2.5. Snap-
frozen sections from human colon were used as a positive control 
in Ab optimisation. Three mAbs directed against FcgR2 were 
used; their details and usage parameters are outlined in Table 
6.3. The specific epitope recognised by each mAb is not known. 
All three mAbs were tested on both formalin-fixed and snap-
frozen tissue. CIKmS was used subsequently for severity 
ratings. Omission of primary antibody resulted in no 
immunoreactivity (Figure 6.6). 
6.3.4 Antibody selection 
The mAbs used in this study, CIKmS, 7.30 and ATIO were 
selected on the basis of their differential reactivity with 
FcgR2 derived from different genes or cell types. In a previous 
epitope mapping study, 7.30 was localised quite near to the Fc 
binding region of the receptor, while CIKmS was identified as 
having a binding site more distant from the Fc binding site. 
Additionally, CIKmS but not 7.30 demonstrated 
immunoprecipitation of K562 cells (lerino et al. 1993). 
Another study of the binding patterns of FcgR2 mAbs indicates 
that CIKmS has a preferential affinity for FcgR2A-expressing 
cells while ATlO is able to bind both FcgR2A- and FcgR2B-
expressing cells. ATIO is the only mAB in this panel which has 
also been used on post-mortem human brain; ATIO was reported not 
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to label cells in formalin-fixed, paraffin-embedded tissue (Orr 
et al. 2005). 
Table 6.3 Suppliers and dilutions for mAbs used 
Anti- Supplier Clone Dilution 
FcgR2 Chemicon CIKmS 1/50 
FcgR2 LabVision 7.30 1/25 
FcgR2 Serotec ATIO 1/1000 
6.3.5 Severity scores and comparison of cases 
The full cohort of cases (PD, control, MSA and ATYP) was 
immunostained with CIKmS, and immunolabelling was compared semi-
quantitatively. Cases were rated for the presence and quantity 
of immunoreactive astrocytes and microglia with a score of 0, 
absent, 1, infrequent, and 2, frequent. A score of 0.5 was 
assigned if a very small number of cells was immunoreactive, and 
they were not entirely distinguishable from perivascular cells. 




6.4.1 Immunolabelling of three anti-FcgR2 mAbs 
CIKmS and ATIO robustly labelled macrophages in fresh-frozen 
colon, while 7.30 was only faintly immunoreactive with vessels 
(Figure 6.3). The optimal dilutions for CIKmS and ATIO were 
determined to be 1/SO and 1/1000, respectively. 
All three mAbs labelled fresh-frozen brain tissue. Visual 
cortex from a case which demonstrated very high MHCII 
immunoreactivity {PD04) was used to assess immunoreactivity. 
CIKmS showed the strongest immunoreactivity, labelling 
microglia, perivascular cells and astrocytes. ATIO labelled 
perivascular cells and microglia. 7.30 was observed to perform 
at the highest signal-to-background ratio at a 1/25 dilution and 
labelled astrocytes and some perivascular cells (Figure 6.4). 
Immunoreactive microglia were localised predominantly in WM with 
both CIKmS and ATIO (Figure 6.4). Immunoreactive astrocytes 
were infrequently observed, primarily in GM, often in clusters 
in the parenchyma or surrounding capillary walls with CIKmS and 
7.30 (Figure 6.S) . The pial surface of layer I was also 
strongly immunostained by CIKmS and 7.30, with astrocytic 
processes clearly labelled (Figure 6.6). 
Labelling of formalin-fixed, paraffin-embedded tissue was 
not as robust as that observed in snap-frozen samples. Only 
CIKmS showed any immunoreactivity, which was localised to 
microglia (Figure 6.7). Immunostaining of astrocytes and the 
pial surface was absent. ATIO and 7.30 did not label any 
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Figure 6.3 Immunoreactivity of a panel of FcgR2 mAbs on colon 
ATIO (A, 4x, and B, 20x) and CIKmS (C, 4x, and D, 20x) label 
macrophages in a section of fresh-frozen colon. 7.30 (E, 4x, 
and F, 20x) did not label these or other cells under the 
conditions and dilutions tested. 
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Figure 6.4 Immunoreactivity of a panel of FcgR2 mAb in PD white 
matter 
(Preceding page) White matter in visual cortex of PD brain 
(PD04) immunostained with ATIO and CIKmS (A and B, 40x) shows 




Figure 6.5 Microglia and astrocytes immunolabelled with anti-
FcgR2 mAb 
(Preceding page) A subset of microglia (A, PD09 SN, 40X) and 
astrocytes (B, PD04 VI, 40X) were immunoreactive for FcgR2 mAb 
CIKmS. Frozen section cutting artifact is also visible in both 
images. Microglia were also immunoreactive with mAb ATIO, and 
astrocytes were also immunoreactive with mAb 7.30. Additional 
hematoxylin-stained nuclei are also apparent in both images. 
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191 
Figure 6.6 Immunoreactivity below and at the pial surface 
(Preceding page) CIKmS (A) labels astrocytic processes in 
cortical layer I (PD04 visual cortex). 7.30 demonstrates a 
weaker staining of the same structures (B), while ATIO only very 
faintly labels them (C) (all photos taken at 40X primary 
magnification). Omission of primary antibody results in no 
immunoreactivity; the pial surface (indicated by arrows) as well 
as the rest of the section demonstrate only hematoxylin stained 
nuclei (D, lOX). 
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Figure 6.7 FcgR2 immunolabelling of formalin-fixed tissue 
Only mAb CIKmS showed any immunoreactivity for formalin-fixed 
tissue, but it was much weaker than the pattern observed on 
snap-frozen tissue. Immunoreactive perivascular cells and 
microglia were less frequent and not as clearly delineated. 
This image is taken from the contralateral hemisphere of the 
same region and case illustrated previously (PD04, VI, 4OX) . 
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6.4.2 Comparison of immunoreactivity across cases and brain 
regions 
All cases demonstrated immunolabelling of astrocytic 
processes at the pial surface, with varying degrees of 
intensity, which was used as an internal positive control. The 
frequency of immunoreactive cells varied considerably across 
cases. Semi-quantitative severity ratings are listed in Table 
6.4. 
Tissue sections from each region were compared on the 
basis of their originating from a PD or control case with 
Student's T-test. FcgR2-expressing microglia were far more 
prevalent in the SN of PD cases as compared to controls (p < 
0.005). No trend toward increased FcgR2-expressing microglia 
was observed in SFG. No control tissue was available for VI. 
FcgR2-expressing astrocytes were not significantly more common 
in PD SN or SFG than in control tissue. However, more FcgR2-
expressing astrocytes were observed in the SN of PD cases which 
also contained FcgR2-expressing microglia compared to those that 
did not (p = 0.01). 
One case of MSA and one case of atypical PD, with no 
neuropathological features of PD or any other neurodegenerative 
disease, were immunostained for FcgR2 and did not display any 
qualitative differences from a PD case. 
Regression and correlation analyses were carried out on 
severity ratings from different brain areas from the same case. 
Severity ratings from SFG and SN were highly significantly 
related (p < 0.01). No relationship was observed between either 
of those brain regions with VI. 
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6.4.3 Clinico-pathological assessment 
Cases from the PD cohort were compared on the basis of 
their sex, disease course and drug treatment history. No 
significant effects were observed on immunohistochemical 
detection of FcgR2. Drug treatment was assessed on the basis of 
treatment with an NSAID (ibuprofen, aspirin or Vioxx) and 
treatment with a DA agonist. Cases treated with bromocriptine 
or pergolide were analysed separately in addition to being 
included in a comparison between cases treated with any DA 
agonist and those that were not. 
PD cases with (n = 8) and without (n = 4) any demonstrable 
microglial FcgR2 expression in the SN (those with a severity 
score for microglia in the SN ^ 1) were also compared using 
Student's T-test. Non-significant trends suggest that treatment 
with a direct DA agonist is associated with the expression of 
FcgR2 by microglia in the SN. Cases demonstrating this pattern 
of immunoreactivity were more likely to have been treated with 
any DA agonist (p = 0.08) or bromocriptine or pergolide 
specifically (p = 0.07). 
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Table 6.4 Severity ratings for ircimunoreactive microglia and 
astrocytes 
Microglia (micros) and astrocytes (astrocytes) were assessed in 
SN, SFG and VI. A indicates that tissue was not available 
for a particular case and area. Severity scores were assigned 








CONMS155 0 1 0 0 - -
CONMSC32 0 0 0.5 0.5 - -
CONMSC30 0 2 - - - -
CONMSC34 - - 2 0 - -
CONPDCOl - - 1 1 - -
CONPDC05 - - 0 0.5 - -
ATYPPD4 6 - - 1 1 - -
MSA43 - - 2 1 - -
PDOl - - 2 0 0 0 
PD02 2 2 2 2 2 2 
PD04 2 2 1 1 2 2 
PD07 0 0 1 1 1 2 
PD09 2 1 2 2 1 1 
PDIO 0 1 1 2 0 0 
PD16 1 1 1 0 2 2 
PD20 2 2 2 1 1 0 
PD21 1 1 1 2 1 0 
PD2 8 1 1 1 0 2 0 
PD2 9 1 1 2 1 - -
PD32 0 0 1 1 - -
PD34 0 0 - - - -
PD36 - - 1 0 - -
PD55 - - 1 0 - -
PD67 - - 2 1 - -
PD74 - - 1 0 - -
PD81 - - 1 0 - -
PD8 6 - 1 2 - -
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6.5 Discussion 
6.5.1 Antibodies recognising different forms of FcgR2 are 
localised to different cell types in the CNS. 
Although they were known to have different cellular 
affinities, the marked difference in the staining patterns of 
the three mAbs evaluated was unexpected. A possible explanation 
for the differential immunostaining patterns of the three Abs 
assessed is that they do not bind FcgR2 protein derived from 
different FCGR2 genes {FCGR2A, FCGR2B, FCGR2C) with the same 
affinity, and that these genes are differentially expressed by 
different cell types. 
The respective binding sites of the mAbs used may further 
elucidate their affinity for different cell types. The epitope 
recognised by 7.30 is located in or near the IgG binding site 
(lerino at al. 1993). This binding site is not accessible to 
7.30 on microglia. It may be the case that microglia and 
astrocytes produce different isoform of FcgR2. Alternatively, 
the binding site of 7.30 may be structurally inaccessible in 
microglia. The latter could be due to a masking effect on the 
antigen, or microglia may contain only FcgR2 bound to IgG or 
another molecule. 
Unlike CIKmS, 7.30 did not immunoprecipitate K562 cells 
(lerino et al. 1993). Microglia may share more properties with 
these cells as they are also hematopoietically derived, which 
could explain their increased affinity for CIKmS. 
Only CIKmS labelled formalin-fixed tissue, and it did so 
only weakly. Differential binding of mAbs to formalin-fixed 
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tissue may be dependent on the specific epitope recognised by 
each mAb. CIKmS, ATIO and 7.30 have distinct binding sites on 
the FcgR2 protein (Brooks at al. 1989; Micklem et al. 1990; 
Greenman et al. 1991; lerino et al. 1993). Their relative 
ability to label formalin-fixed tissue may be indicative of the 
structure of their respective recognised epitopes. It has been 
suggested that epitopes with a linear structure are more easily 
bound by Ab after formalin-fixation (Sompuram et al. 2006). The 
absence of tyrosine in or near the recognised epitope also 
decreases sensitivity to formalin fixation (Sompuram et al. 
2004). Alternatively, ATIO and 7.30 may recognise epitopes on a 
region of the FcgR2 molecule more sensitive to degradation than 
that bound by CIKmS. 
6.5.2 Microglial FcgR2 is increased in PD SN 
The only significant difference observed in comparisons of 
PD with control tissue and of PD cases with different clinical 
courses was an increase in FcgR2-expressing microglia in the SN 
of PD cases (p < 0.005) . The subsequent comparison of PD cases 
with and without microglial FcgR2 expression in the SN indicates 
that FcgR2 expression in astrocytes is increased in cases that 
also express the protein in microglia. 
Of primary importance in understanding the relevance of 
the upregulation of FcgR2 protein is identifying the gene 
responsible for this upregulation. Due to the high homology of 
FCGR2 genes, FcgR2 encoded by different genes is not always 
distinguishable by Abs, particularly in the case of FCGR2C, 
which shares half its sequence with FCGR2a and half with FCGR2B. 
However, FCGR2A and FCGR2C encode a macrophage-activating IT AM 
motif while FCGR2B encodes a negative regulator of B-cell 
activation with an inhibitory ITIM motif (van den Herik-Oudijk 
IE et al. 1995). Thus, different cells expressing FcgR2 could 
be involved in opposing regulatory mechanisms. 
Only FCGR2C was significantly upregulated in PD SN in a 
microarray-based comparison of mRNA from PD and control tissue 
(Moran et al. 2006). In the present study, only FcgR2 
expression by microglia differs between PD and control, while 
FcgR2 expression by astrocytes and perivascular cells remains 
fairly consistent. These data suggest that microglia may be the 
cells driving the observation of a transcriptional upregulation 
of FCGR2C, although further investigation is required to address 
this hypothesis. 
6.5.3 FcgR2 and microglia 
Previous reports of FcgR2 immunoreactivity in post-mortem 
human brain have been discrepant. Weakly FcgR2-immunoreactive 
microglia have been described in AD brain. While FcgRl was 
expressed constitutively on resting and activated microglia, 
FcgR2 was limited to expression on microglia with an activated 
phenotype (McGeer et al. 1989; Akiyama and McGeer 1990). A 
study of gliomas found FcgR2-immunoreactive cells only in the 
immediate area of the tumour and none in the brain parenchyma 
(Morimura et al. 1990). In normal human brain, expression of 
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FcgR2 had been described primarily in the choroids plexus, 
leptomeninges and perivascular cells (Peress et al. 1989). 
One previous study of FcgR2 expression in post-mortem PD 
brain reported that the protein was not present anywhere in the 
tissue. This study used the ATIO Ab and formalin-fixed, 
paraffin-embedded tissue (Orr et al. 2005). The present study 
confirms those results, but the use of snap-frozen tissue 
indicates that FcgR2 is widely present in the brain and 
detectable with IHC prior to formalin fixation and embedding. 
6.5.4 FcgR2 and astrocytes 
The expression of FcgR2 in astrocytes was more consistent 
across cases than that observed in microglia, particularly on 
the border of the pial surface. This expression may not have 
pathological repercussions. 
FcgR2 localisation in astrocytes does not seem to have 
been previously reported in human tissue. Astrocytic cell lines 
have been documented to express FcgR2 in culture (Nitta et al. 
1992) . The role of astrocytes in delimiting the brain from 
vasculature and connective tissue at the pial surface has long 
been established (Peters et al. 1991). However, the extent to 
which they regulate immune signalling between the CNS and 
periphery is not well understood. 
The differential detection of FcgR2 in astrocytes by 
different mAbs suggests that the astrocytes may contain a 
different form of the protein, possibly derived from a different 
gene, as discussed in Section 6.5.1. The localisation of mRNA, 
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with the ability to discriminate between transcripts of 
different genes, could be very useful provided that the FcgR2 
found in astrocytes and microglia is transcribed there rather as 
opposed to being taken up from the surroundings. 
6.5.5 FcgR2 and PD 
Orr et al. also report that in post-mortem PD SN, FcgRl 
was observed on phagocytic microglia and FcgR3 was observed on 
lymphocyte-like cells. IgG was observed on neurons, 
significantly more so in cases of early-stage PD as opposed to 
late-stage (Orr et al. 2005) . The presence of three different 
FcgRs on three different cell types suggests that IgG-related 
signalling may be a very sophisticated mechanism of cellular 
communication in the CNS. 
The importance of FcRs has been highlighted by the 
development of a model of nigral cell degeneration in which 
injection of IgG derived from PD cases triggers microglial 
activation and neuronal death through a FcR-dependent pathway 
(Chen et al. 1998; Le et al. 2001; He et al. 2002) . However, 
the FcgR -/- mice used in these studies are deficient in FcgRl 
and FcgR3, not FcgR2. A direct link between FcgR2 and neuronal 
death and/or microglial activation has not been described. 
6.5.6 Drug effects on FcgR2 expression in PD 
Previous studies have presented evidence that increases in 
DA can increase FcgR expression. Treatment with DA-agonists 
leads to an upregulation of FcgR in spleen-derived macrophages 
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in guinea pigs (Gomez at al. 1999). FcgR binding of IgG is also 
increased in vivo in human blood monocytes treated directly with 
DA (Sandor et al. 1983). 
A trend toward a relationship between treatment with 
direct DA agonists and increased FcgR2 in the SN in PD is 
reported here. Further study with increased case numbers and a 
more uniform cohort of PD cases is warranted to further 
investigate this phenomenon. The effect of DA agonists or DA 
replacement with L-DOPA could perhaps complicate the glial 
response to PD and account for some of the discrepancies 
observed, for example, in PET imaging studies of PER expression 
by microglia, which have reported a correlation between clinical 
severity and PER in drug-naive patients and no such correlation 
after 8 year follow-up (Gerhard et al. 2005; Ouchi et al. 
2005a). Perhaps the widespread MHCII expression observed in 
cortical regions unaffected by pathological protein deposition, 
as described in Chapter 5, could also be attributed to the 
phenomenon of increased immune signalling caused by dopaminergic 
drugs. An assessment of drug-naive patients compared to those 
recently starting treatment could be very informative, although 
such cases rarely occur in post-mortem studies. 
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6. 6 Conclusions 
The present study demonstrates that, contrary to an 
earlier report (Orr et al. 2005), FcgR2 expression does occur in 
human brain and is upregulated in PD, suggesting that IgG 
signalling may indeed be involved in the development of 
progression of PD. The possible significance of this finding 
and its relationship to a compromise of the immune system in PD 
is not yet clear. The results indicate that treatment with DA 
agonists may play a role. In addition, the importance of 
astrocytes in mediating immune response in the brain is 
underscored by their expression of FcgR2. A key question 
remains as to whether the FcgR2 protein observed in microglia 
and astrocytes is derived from the same or different genes and 
which one(s), since both activating and inhibitory signalling 
pathways can be initiated by binding to nearly identical 
proteins. Because microglia and astrocytes are differentially 
identified by the anti-FcgR2 mAbs, it is tempting to think that 
they may contain FcgR2 derived from different gene transcripts. 
Because FcgR2C is specifically upregulated in a microarray 
dataset comparing PD mRNA expression to control in the SN, and 
FcgR2 protein is specifically upregulated in microglia in the 
SN, while astrocytes do not differ across cohorts, it is also 
tempting to attribute the increase in microglial FcgR2 protein 
to an increase in FcgR2C transcription. However, extensive 
further analysis is required to make that assertion. An attempt 
to localise FcgR2C mRNA using in situ hybridisation with 
radiolabelled oligonucleotide probes was unsuccessful; the 
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abundance of the protein was not sufficient to stand out clearly 
from background (data not shown) . The use of laser-capture 
microdissection followed by real-time polymerase chain reaction 
could be informative. 
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Chapter 7: CD163 expression in the PD 
brain 
7.1 Introduction 
Another gene found to be upregulated in PD in a microarray 
comparison of PD and control SN is CD163. CD163 is also known 
as RM3/1, haemoglobin scavenger receptor (HbSR), M130, pl55 or 
ED2 (Law et al. 1993; Hogger et al. 1998a; Sulahian et al. 2000; 
Kristiansen et al. 2001). CD163 is expressed by many subsets of 
cells of monocytic lineage and is a member of the scavenger 
receptor cysteine-rich (SRCR) family of receptors. CD163 
expression has not been previously described in PD. 
7.1.1 Structure and cellular localisation 
CD163 is a 130-kDa glycoprotein with a short cytoplasmic 
region, a transmembrane region and an extracellular region 
composed of 9 SRCR domains (Figure 7.1) (Law et al. 1993; Hogger 
et al. 1998a). Four splice variants of CD163 have been 
described which differ in the cytoplasmic region (Hogger et al. 
1998a; Hogger et al. 1998b). The cytoplasmic "tail" of CD163 is 
thought to function in signalling endocytosis of the receptor 
upon its binding a ligand and also contains phosphorylation 
sites that may be involved in calcium-mobilisation (Kristiansen 
et al. 2001; Ritter et al. 2001). The SRCR domain is a highly 
conserved domain 100-110 residues in length (Sarrias et al. 
2004). SRCR domains contain a common structural fold which 
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consists of a 6-stranded p-sheet surrounding one a-helix (Figure 
7.1) (Hohenester et al. 1999). 
CD163 is one of only two SRCR group B scavenger receptors 
expressed on monocytes; most other group members localise to 
lymphocytes. "Group B" denotes the presence of 8 cysteine 
residues and 4 disulfide bridges in each SRCR, rather than 6 
residues and 3 bridges per SRCR as found in group A family 
members (Aruffo et al. 1997). CDl63-immunopositive macrophages 
have been described brain, liver, lung and skin as well as in 
lymphoid tissue from spleen, lymph node, thymus and tonsil (Van 
den Heuvel et al. 1999). Soluble CD163 (sCD163) is also found 
in plasma under normal conditions (Kristiansen et al. 2001; 
Moller et al. 2002). sCDl63 is thought to be derived from the 
proteolytic shedding of CD163 by monocytes and macrophages. The 
shedding of CD163 can be induced in vitro by stimulation of 
FcgRs and can be blocked by inhibition of protein kinase C and 
metalloproteinases (Droste et al. 1999; Matsushita et al. 2002; 
Sulahian et al. 2004). 
The initial report of CD163 in brain specified that 
perivascular and meningeal macrophages were immunopositive while 
microglia were not (Graeber et al. 1989; Van den Heuvel et al. 
1999; Kim et al. 2006). CDl63~expressing cells have also been 
characterised in late-stage phagocytosis of facial motor neurons 
after axotomy, suggesting a migration of perivascular cells to 
the site of injury (Angelov et al. 1996). 
Studies of post-mortem brains affected by MS, HIV 
encephalitis (HIVE) and AD have also identified CD163-
immunoreactive microglia. In MS, some ramified microglia were 
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weakly immunoreactive in active and chronic active lesions, and 
CD163 was increased in perivascular cells (Fabriek et al. 2005). 
In contrast, HIVE brain tissue demonstrated numerous CD163-
immunoreactive ramified microglia both near lesions and remote 
from any pathological changes (Roberts et al. 2004). In the 
same study, tissue from 1 of 4 AD brains contained clusters of 
CD163-expressing microglia, and cases of CJD and a case of 
systemic sepsis with CNS micro-abscesses demonstrated only 
limited perivascular expression of CD163. 
207 





(B and C from Hohenester, Sasaki, and Timpl 1999) 
Figure 7.1 Schematic of CD163 and SCRC structure 
CD163 is represented in A, illustrating the cytoplasmic, trans-
membrane (TM) and extra-cellular regions. Each circle 
represents a SRCR domain. SRCRs 6 and 7 are separated by an 
inter-domain spacer (Hogger et al. 1998a). B and C are adapted 
from a publication of the crystal structure of the SRCR domain 
of Mac-2 binding protein, a member of the SRCR family class A. 
They are orthogonal views of the 6-stranded (3-sheet and single 
a-helix which compose the SRCR domain (Hohenester et al. 1999). 
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7.1.2 Function and regulation of CD163 
The primary known function of CD163 is as a regulated 
haemoglobin scavenger receptor which binds haptoglobin (HP) -
bound haemoglobin, leading to the production of heme-oxygenase 1 
(HMOXl) (Figure 7.2) (Kristiansen et al. 2001). Heme molecules 
released into plasma after the rupture of red blood cells have 
the potential to increase oxidative stress on its surroundings. 
Heme in the plasma is bound with very high affinity by 
haptoglobin (Wejman et al. 1984) . Subsequent to its 
internalisation after binding with CD163, the metabolism of 
haemoglobin appears to lead to the down-regulation of the 
inflammatory response (Otterbein et al. 2003). CD163 may be 
involved in modulating inflammatory processes in 
atherosclerosis. CD163-immunoreactive cells have been observed 
in both early and advanced atherosclerotic lesions, in which 
ferritin and haemoglobin accumulate, in contrast to CD68-
immunoreactive phagocytes which are only observed in advanced 
lesions (Li et al. 2004) . 
In addition to, or in conjunction with, its role in 
haemoglobin scavenging, CD163 expression is regulated by pro-
and anti-inflammatory signalling in the microenvironment in a 
manner that supports its role in the resolution of inflammation. 
IFNG and TNF-induced macrophage activation leads to a down-
regulation of CD163 in vitro (Zwadlo et al. 1987; Buechler et 
al. 2000b). CD163 expression is induced by glucocorticoid both 
in vitro and in vivo (Zwadlo-Klarwasser et al. 1990; Wenzel et 
al. 1996). IL-6 and IL-10, also considered to have anti-
inflammatory effects, increase CD163 expression in human 
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monocytes and macrophages in vitro (Sulahian et al. 2000; 
Buechler et al. 2000a). 
In experimental, antigen-induced arthritis in rats, CD153-
expressing macrophages were only observed in the later, healing 
phase (Verschure et al. 1989). In contrast, CD163 upregulation 
in perivascular cells in , the brain occurs very early in 
experimental autoimmune encephalitis, (Polfliet et al. 2002). 
In humans, infiltration of CDl63-expressing macrophages into the 
synovium has been associated with disease activity in the 
inflammatory condition spondyloarthropathy, although whether 
those macrophages indicate a worsening or an abatement of 
inflammation is unclear (Baeten et al. 2005). In post-operative 
cardiopulmonary bypass and coronary artery bypass graft surgical 
patients, circulating CD163 protein is increased in the 
resolution phase of systemic inflammation (Goldstein et al. 
2003; Philippidis et al. 2004). CD163 expression was again 
observed to be sensitive to treatment with glucocorticoids 
(Goldstein et al. 2003) . In an elegant demonstration of the 
CD163 signalling cascade in vivo, the binding of haemoglobin-
haptoglobin to CD163 led to secretion of IL-10 and a subsequent 
induction of HMOXl in bypass patients 24-48 hours after surgery 












Figure 7.2 Haemoglobin-haptoglobin uptake by CD163 
When CD163 binds haptoglobin-haemoglobin complex, 
internalisation and breakdown of heme leads to activation of 
heme-oxygenasel (HMOXl), with subsequent production of carbon 
monoxide (CO), iron (Fe2+) and biliverdin, a by-product of heme 
metabolism. This in turn down-regulated pro-inflammatory 
signalling. 
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7 .2 Aims 
The aim of the present study is to immunohistochemically 
assess the expression pattern of CD163 in PD brain. CD163 has 
been implicated in an anti-inflammatory signalling cascade, it 
is of particular interest what clinical implications may be 
associated with its pattern of expression. Additionally, the 
relationship between CD163 and FcgR2 can be explored at the 
protein level. 
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7 .3 Materials and Methods 
7.3.1 Microarray analysis of PD tissue 
Microarray data was provided as previously described 
(Section 6.3.1). Three Affymetrix probes corresponding to CD163 
were upregulated in PD SN and SFG compared to control tissue. 
The probes, 203645_s_at (CD163(1)), 215049_x_at (CD163(2)) and 
216233_at (CD163 (3)) were upregulated with p values of 0.0008, 
0.002 and 0.003, respectively (Figure 7.11). Microarray GC-RMA 
values for each case and brain area are presented in Table 7.1. 
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Table 7.1 GC-RMA. expression values (log2 transformed data) of GDI63 
(represented by 3 probes) in a microarray comparison of PD and control SN 
N) 
CASE 
2 0 3 6 4 5 _ s _ a t 
M e d i a l SN 
2 1 5 0 4 9 x _ a t 2 1 6 2 3 3 _ a t 2 0 3 6 4 S _ 3 _ a t 
L a t e r a l SN 
2 1 5 0 4 9 _ x a t 2 1 G 2 3 3 _ a t 2 0 3 6 4 5 s a t 
SFG 
2 1 5 0 4 9 X a t 2 1 6 2 3 3 _ a t 
C0N2 7 . 6 4 6 3 7 3 4 9 5 . 6 2 9 1 0 4 5 2 8 7 4 6 6 1 9 9 6 7 2 3 6 2 8 5 7 4 5 2 7 8 2 8 4 6 2 9 6 4 1 9 4 2 1 5 7 3 8 4 3 1 5 8 3 1 8 0 9 2 3 63 2 7 8 0 0 0 8 3 9 
C0N3 5 . 4 2 9 3 8 6 3 9 3 . 2 9 8 6 8 7 0 3 3 0 2 5 5 1 8 6 7 
- - -
4 2 4 2 2 3 7 7 5 1 . 9 5 5 6 9 6 4 4 2 9 9 9 9 7 0 1 2 
C0N4 6 . 4 6 5 1 7 4 6 1 4 . 4 4 0 4 2 8 5 2 2 9 2 9 6 6 8 6 9 6 0 0 7 2 5 9 8 7 3 2 7 6 3 9 6 2 7 2 9 9 8 6 5 3 0 4 
- - -
CONG 7 . 1 6 7 6 9 0 9 6 5 . 2 5 3 4 4 2 3 4 2 . 6 1 3 1 8 3 4 7 3 7 5 5 6 2 7 1 5 4 9 5 2 2 0 0 9 2 6 9 9 1 5 9 1 8 
- - -
C0N9 4 . 63 6 5 2 1 4 3 2 . 5 5 0 5 0 4 9 2 8 2 9 7 0 2 1 6 4 7 9 3 8 7 6 3 3 3 0 2 9 9 8 1 8 9 2 7 4 2 9 8 3 4 9 4 1 9 2 1 4 0 0 1 1 . 7 8 6 6 7 2 1 2 8 7 2 5 4 5 8 6 
CONIO 5 . 3 8 9 7 2 652 3 . 0 7 6 3 6 1 5 2 82 6 3 8 8 5 5 4 9 3 7 8 5 4 1 1 2 8 1 2 4 4 3 5 1 2 8 4 8 6 9 4 7 8 
- - -
CONPDCOl 4 1 4 9 4 3 9 3 1 2 . 8 9 7 4 7 9 3 5 2 8 2 3 5 7 8 9 2 4 1 6 8 9 5 5 9 5 2 5 3 9 8 9 3 9 7 2 . 8 4 3 1 9 4 7 
- - -
C0NHS155 7 . 7 0 3 2 4 1 1 6 5 . 4 4 3 1 0 4 1 2 9 1 4 8 6 7 5 7 8 . 5 9 4 0 6 1 8 6 3 4 8 2 5 3 5 5 2 8 5 6 7 4 3 4 8 
-
- -
PDOl 5 5 5 1 3 3 5 9 6 3 . 2 9 9 5 4 8 8 6 3 0 6 1 4 9 3 6 1 5 6 9 6 1 9 5 6 6 4 . 0 7 1 2 4 0 3 3 1 5 4 8 4 6 4 7 5 4 9 1 5 8 1 9 9 2 5 3 0 3 9 8 5 7 3 0 5 4 9 6 9 0 6 
PD02 9 . 8 0 2 7 1 7 6 2 7 . 4 2 4 2 1 0 2 2 3 1 2 4 1 8 9 9 7 9 2 4 1 9 0 4 5 4 7 2 4 1 2 8 9 1 3 3 2 6 9 2 3 7 5 2 
- - -
PD04 6 9 1 6 4 5 4 5 6 4 . 5 7 3 1 5 1 4 9 2 9 0 5 8 9 2 66 6 5 7 7 6 7 2 2 3 4 0 5 5 2 8 3 4 9 2 . 9 1 0 8 0 4 4 5 2 8 3 1 8 6 0 6 3 . 0 1 0 6 5 8 9 2 9 2 7 7 7 3 9 8 
PD07 3 . 8 1 3 0 0 1 2 7 7 . 8 7 7 7 0 3 3 6 3 3 8 2 3 9 1 4 6 8 4 4 0 9 0 0 4 3 6 1 7 4 5 1 3 8 9 3 0 3 6 2 5 4 4 2 
- - -
PD09 1 1 . 3 2 9 4 4 0 5 9 2 8 9 5 9 9 4 6 4 4 2 8 4 1 8 2 8 1 0 . 0 9 6 4 0 1 5 7 8 2 1 7 7 6 0 2 3 1 3 2 2 4 2 0 3 
- - -
PDIO S. 7 6 3 3 4 6 9 4 3 9 7 5 0 7 1 7 2 3 0 2 4 2 1 7 6 2 5 6 3 4 8 1 2 5 2 3 2 7 1 9 3 1 4 4 2 9 9 3 5 9 0 0 1 
-
- -
PD16 6 6 8 2 1 2 5 5 3 3 7 8 6 4 0 9 1 6 3 0 9 9 6 4 1 0 7 6 8 4 3 4 9 5 7 7 4 3 6 4 8 7 4 6 8 3 2 3 9 5 3 6 3 7 
- - -












PD28 8 . 3 2 5 8 0 6 8 6 . 1 3 3 6 3 9 1 2 8 2 7 7 8 5 2 2 6 7 5 0 0 5 8 8 4 4 7 4 1 1 5 5 3 8 2 9 2 1 9 9 1 1 4 
- -
-
PD29 1 0 . 1 1 5 6 8 3 6 7 . 9 3 9 8 6 9 2 1 3 7 6 0 0 3 0 2 6 9 8 6 6 3 4 1 8 6 7 . 8 1 6 1 1 5 3 2 9 8 9 8 1 7 3 7 9 6 6 3 0 9 6 2 5 7 . 9 3 9 5 8 1 2 8 3 3 3 5 9 2 7 1 1 




PD34 7 5 4 2 0 9 7 4 7 5 8 6 3 5 7 5 7 9 2 7 7 4 6 5 2 8 6 -
- -
6 8 2 0 1 0 4 1 3 3 9 5 9 4 1 8 8 1 3 1 7 0 3 4 0 9 4 
PD3 6 8 4 8 3 5 6 8 1 1 6 2 2 5 7 2 3 8 5 2 8 3 8 1 0 3 3 8 
-
- -
5 5 5 5 2 2 5 5 6 3 9 7 5 4 7 5 3 2 2 8 6 7 8 6 9 5 4 
7.3.2 Human tissue samples 
Post-mortem PD and control tissue was provided by the 
PDSTB. An outline of the cases used and their clinical history, 
if available, is provided in Table 7.2. Tissue sections from 
SN, SFG, caudate and putamen (C/P) (including internal capsule), 
nucleus basalis of Meynert (NBM) (including anterior commisure) , 
VI and spinal cord (SC) were assessed if available. 
MS spinal cord was provided by the MSTB. Spinal cord with 
and without demyelinating lesions from five cases of MS (MS81, 
MS89, MS90, MS126, MS133) was examined. For each case, one 
section from cervical, thoracic and lumbar cord was assessed. 
After semi-quantitative ratings were assigned blindly, serial 
sections immunostained for MHCII were compared with those 
labelled with CD163. 
A section from the SN of a case of MS observed to have 
florid SNCA pathology, high MHCII expression and numerous CD68-
immunoreactive macrophages (MS69) was also immunolabelled with 
CD163. This case, MS69 (also described in Chapter 3), had no 
clinical history of parkinsonism but did suffer from falls. The 
pathology observed in the SN post-mortem could indicate the 
early, pre-symptomatic phase of PD. 
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Table 7.2 Cases' clinical information 
PDD, Parkinson's disease with dementia; ILBD, incidental Lewy 
Body disease; AAO, age at onset; AAD, age at death; DD, disease 
duration. 
Case Diagnosis PD 
type 
Sex AAO AAD DD 
CONPDC02 - - M - 88 -
CONPDC03 - - M - 84 -
CONPDC04 - - M - 84 -
CONPDC05 - - M - 58 -
MS69 MS/ILBD - F 54 86 32 
MS81 MS - M 25 72 47 
MS89 MS - F 45 71 26 
MS90 MS - M 23 62 39 
MS126 MS - M n/a 75 n/a 
MS133 MS - M n/a 63 n/a 
PD04 PDD/AD A-R M 65 68 3 
PD16 PD H-T F 67 85 18 
PD18 PD A-R M 78 82 5 
PD21 PD H-T M 49 76 28 
PD2 6 PD A-R M 69 74 6 
PD28 PD A-R M 65 82 18 
PD2 9 PD H-T M 70 76 7 
PD32 PD A-R M 86 89 3 
PD34 PD/AD H-T F 72 84 11 
PD39 PDD H-T F 69 82 13 
PD86 PD H-T F 77 87 9 
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7.3.3 Antibody selection 
Several monoclonal anti-CDl63 mAbs are available 
commercially. A study of CD163 in post-mortem human tissue 
found that two clones, EDHu-1 and 10D6, robustly labelled 
paraffin-embedded formalin-fixed human tissue with a similar 
pattern of immunoreactivity (Kim et al. 2006) . Based on that 
report, 10D6 (NovoCastra) was chosen for use in the present 
study. The antibody was optimised for use on formalin-fixed 
paraffin-embedded human brain at a dilution of 1/200 with Ht 
antigen unmasking with EDTA (as described in Section 2.2.4.3). 
7.3.4 Immunohistochemistry 
Immunohistochemistry was carried out as described in 
2.2.4. Vector VIP (Vector) was used as a chromogen in lieu of 
DAB, resulting in purple immunoreactivity. Omission of primary 
antibody resulted in no immunoreactivity (Figure 7.4). 
7 .3 .5 Semi-quantitative severity ratings 
Semi-quantitative ratings were assigned for GM and WM in all 
areas examined. A score of 0.5 was assigned if only one or two 
immunoreactive cells were observed in the entire tissue section. 
A score of 1 was assigned if microglia were observed to express 
CD163 with a frequency less than 1 cell per lOX field of view. 
A score of 2 was assigned if CDl63-immunoreactive microglia were 
observed with more consistency, generally at a frequency greater 
than 1 cell per lOX field of view but less than 1 cell per 20X 
field of view. A score of 3 was assigned if CD163-
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immunoreactive microglia were observed with a frequency greater 
than 1 cell per 20X field of view in some areas. Often CD163-
immunoreactive microglia appeared in small clusters. Scores of 
1.5 and 2.5 were assigned to those cases in which a small area 
of the section warranted a higher rating than the majority of 
the section. Perivascular immunoreactivity was not considered. 
7.3.6 In silico pathway analysis 
The interactions of CD163 were examined using PathwayAssist 
software version 3.08 (AriadneGenomics). 
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7.4 Results 
All sections showed some immunoreactivity for CD163 in 
perivascular cells, but the intensity of this labelling varied 
considerably from case to case. In some, vessels appeared to be 
full of CD163-immunopositive cells while in others the labelling 
was very faint and did not suggest any abnormality in the vessel 
(Figure 7.3). The amount of perivascular immunoreactivity 
observed was often a reflection of the extent of microglial 
immunoreactivity. Labelling of microglia was less frequent and 
was not observed in all cases. Semi-quantitative severity 
ratings for immunolabelling of microglia is outlined in Table 
7.3. 
219 
Table 7.3 Semi-quantitative severity ratings for microglial 
CD163 immunoreactivity 
SC, spinal cord; SFG, superior frontal gyrus. C/P, caudate and 













CONPDC02 1 1 1 1 1 0 0 1 2 1 1 
CONPDC03 1 0 0 0 0 0.5 0.5 0.5 1 0.5 0.5 
CONPDC04 0 3 3 1.5 1.5 n/a n/a n/a n/a 2 2 
CONPDC05 1 1 0.5 0.5 0.5 1 1 0.5 0.5 0.5 0.5 
MS69 0 
MS81 - 0 0 - - - - - - - — 
MS89 - 0 0 - - - - - - - -
MS90 - 0 0 - - - - - - - -
MS126 - 0 1 - - - - - - - -
MS133 - 0 0 - - - - - - - -
PD04 2 0.5 0.5 n/a n/a 1 1 0 0 0.5 0.5 
PD16 1 n/a n/a 1 1 1 1 2 2 0 0.5 
PD18 1 0 0.5 1.5 1.5 2 1 1 0 1 0 
PD21 0 1.5 1 0 0 0 0 2 1 0.5 1 
PD2 6 1 0 1 0.5 0 0 1 1 1 0.5 0 
PD28 0.5 0 0 0.5 0.5 0.5 0.5 0 0.5 0 0 
PD29 1.5 3 3 3 3 3 3 3 3 2 2.5 
PD32 3 1.5 1.5 1 0.5 1 1 0.5 1 3 3 
PD34 1 1 1 2 2 1 1.5 1.5 1.5 0 0.5 
PD39 0 2 2.5 1 2 0.5 0.5 1 1 2 0.5 
PD86 2 n/a n/a 0.5 1 1 1 0 0 1 1 
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7.4.1 CD163 in control brain and spinal cord 
CD163 was observed in perivascular cells in all six brain 
regions of each of the four control cases examined. With the 
exception of PDC04, CD163 expression was generally limited to 
perivascular cells (Table 7.3, Figure 7.4). In sections from 
PDC04 cortex and spinal cord, but not SN, CDl63-immunoreactive 
microglia were observed in both GM and WM at levels comparable 
or higher than that observed in PD (Figure 7.7). PDC04 was 
noteworthy in that the cause of death for the case was listed as 
•"multiple organ failure with possible MRSA.' 
The average AAD of the control cohort was 78.5 ± 14 years. 
This high standard deviation is primarily due to the inclusion 
of one relatively young control case, PDC05, in the cohort, 
which had an AAD of 58 years. This case did not differ from the 
other controls in CD163 immunoreactivity profile. 
7.4.2 CD163 in MS spinal cord 
Although MHCII immunostained numerous microglia and 
macrophages in and around lesions, immunostaining for CD163 was 
nearly negative in all MS spinal cord sections assessed (Figure 
7.5 A-D) . If any cells were observed in spinal cord tissue, 
rather than associated with vessels, they were generally rare, 
isolated events. Areas of demyelination were not 
distinguishable on the basis of CD163. One exception to this 
was a cluster of ramified microglia that expressed CD163 and 
were localised to an area that also contained numerous MHCII-
immunopositive macrophages (Figure 7.5, E and F). 
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7.4.3 CD163 in ILBD/pre-PD 
CD163 immunostaining of MS69 was, aside from the labelling 
of some perivascular cells, negative. The SN of MS69 contained 
numerous LBs (Figure 3.2), and contained numerous MHCII-
immunoreactive microglia and CD68-immunoreactive phagocytes 
(Figure 7.6). 
7.4.4 CD163 in PD brain and spinal cord 
The PD cohort of 11 cases demonstrated a range of CD163 
immunoreactivity profiles. As in all other sections assessed, 
CD163 was observed in close association with vessels, both on 
perivascular cells and, within larger vessels, within 
peripheral, blood-borne cells. CD163 was only infrequently 
observed on cells in the brain parenchyma, often in clusters of 
microglia. In the cortex, these cells or clusters appeared to 
be distributed at random. In the SN, CD163 was consistently 
higher in the SN than in the rest of the tissue section. 
One case in the PD cohort, PD29, contained small micro-
abscesses throughout the brain which were detected upon 
neuropathological diagnosis. PD29 was a clinically and, aside 
from these micro-abscesses, neuropathologically typical PD case. 
MHCII expression in PD29 was high, but not unusual beyond the 
immediate area of the abscess, where a cluster of MHCII-
expressing cells could be observed. CD68 immunoreactivity was 
localised primarily to those areas of inflammation. CD163 
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immunoreactivity was exceptionally high throughout the brain of 
PD2 9 (Figure 7.7). 
7.4.4.1 Comparison with control cases 
The PD and control cohorts were compared with Student's T-
test. The groups were age-matched. Mean AAD in the PD cohort 
was 80.5 + 6 years; that of the control cohort was 78.5 ± 14 
years. No statistically significant differences were observed 
between the two groups. Severity ratings in SN, C/P, internal 
capsule and SFG GM and WM were consistently higher in PD than 
control, although not statistically significantly so. GM and WM 
in VI and SC, as well as anterior commisure, were similar in 
both groups. 
7.4.4.2 Anatomical comparisons 
A Spearman's nonparametric correlation analysis of all the 
brain areas assessed detected a relationship between CD163 in 
the SN and CD163 in the internal capsule (p < 0.05) . CD163 in 
the C/P was highly correlated with CD163 in the SFG GM (p < 
0.005) and WM (p < 0.05). 
7.4.4.3 Clinico-pathological analyses 
PD cases were compared to each other on the basis of sex, 
AAD, DD and treatment with DA agonists using Student's T-test. 
No differences were detected between males and females, cases 
treated with DA agonists and those to whom DA agonists had not 
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been prescribed, or cases with AAD ^ 80 and cases with AAD < 80. 
Cases with a DD < 10 years (n = 6) had a significantly higher 
CD163 severity score in the SN than those with DD ^ 10 years (n 
= 5 ) (p < 0.05) (Figure 7.8, Figure 7.8). PD cases with DD < 10 
years also had a significantly higher severity rating in the SN 
than controls (p < 0.05) (Figure 7.9). Spearman's nonparametric 
correlation analysis confirmed this finding (p < 0.01). 
7.4.5 In silico analysis of CD163 and meta-analysis of 
microarray results 
The proteins that regulate, bind to or are regulated by 
CD163 were retrieved from MedLine using the PathwayAssist 
software package (v3.08, AriadneGenomics). A number of proteins 
reported to interact with CD163 were also upregulated in the 
same microarray dataset in which CD163 was identified (Moran et 
al. 2006). IL-10, IFNG, insulin (INS) and transferrin (TF) are 
all significantly more highly expressed by PD cases than 
controls in the SN and have been reported to regulate CD163 
(Figure 7.10) . HMOXl and HP were not significantly higher in PD 
than control, although a trend toward higher expression in PD 
cases was observed. HMOXl was higher in PD with a p-value = 
0.1, and HP was upregulated in PD with p = 0.07. 
Based on the immunohistochemical finding that CD163 protein 
expression in the SN is primarily restricted to PD cases with 
shorter DD, the mRNA expression of HP and HMOXl was re-assessed 
in cases grouped by DD < 10 years (n = 7) and DD > 10 years (n = 
8) . In the short DD group, HP was significantly higher than 
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control (p = 0.05), and HMOXl expression approached significance 
at p = 0.07. In the longer DD group, expression of these two 
genes did not differ at all from control (p = 0.37 and p = .22, 
respectively) (Figure 7.11). 
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Figure 7.3 Perivascular CD163 in PD 
Immunoreactive perivascular cells are shown in two PD cases (lOX 
magnification). The intensity of perivascular staining often 
reflected microglial immunoreactivity. PD32 (A) had many GDI63-
immunoreactive microglia in surrounding tissue, while PD21 (B) 
had none. 
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Figure 7.4 GDI63 in control SN 
Aside from occasional immunopositive perivascular cells (such as 
those indicated with arrows) , the SN of control cases was not 
immunoreactive for CD163 (A, PDC05, lOX) . Many PD cases shared 
this immunoreactivity profile. Omission of primary antibody 
resulted in no immunoreactivity (B, lOX) in contrast to high 
immunoreactivity observed on tissue from PD29 used as a positive 




Figure 7.5 CDl63 in MS spinal cord 
MS spinal cord was devoid of CD163 (A) but rife with MHCII-
expressing macrophages (B) (MS90, 4X) . Only in one region of 
MS126, a cluster of CDl63-immunoreactive microglia were observed 
(in box, C, 4X, E, 40X) which appeared to correlate with a 
cluster of MHCII-expressing cells (in box, D, 4X, F, 40X). 
228 
,1? i •• 
^ J ' -
- - ; , 
T** ' ^ •* 1* 






J, . # •, 
. " 
- • - - - ? 
i •- - . 
. r V , 




• ^ ^ 





- # , V » 
. 
-













• V " . -
IT 




Figure 7.6 CD163 in incidental Lewy body disease 
MS69 contains numerous MHCII-immunoreactive microglia (A, 20X) 
and CD68-immunoreactive phagocytes (B, 20X) in the substantia 
nigra, but no parenchymal cells immunoreactive for CD163 (C, 
lOX) . Only faint immunoreactivity associated with blood vessels 
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Figure 7.7 CD163 expression after infection 
Two cases demonstrated abnormally high numbers of CD163-
immunoreactive microglia. PDC04 (A, SFG, 40X) was infected with 
MRSA prior to death and contained CDl63-expressing microglia but 
no other signs of neurological complications. The cortex of 
PD29 (B, VI, 40X) contained small microabscesses which contained 
many CD163-immunoreactive cells. CD163-immunoreactive microglia 






Figure 7.8 High levels of CD163 observed in a PD case with 
disease duration less than 10 years 
The SN of PD32 contains both perivascular (arrow) and 
parenchymal (arrowhead) GDI63-ixnmunoreactive cells (B, 20x) , as 
well as small clusters of phagocyte-like cells similar to those 
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Figure 7.9 CD163 is increased in PD cases with short disease 
duration (DD) 
No significant difference between CD163 immunoreactivity in the 
SN was observed between PD and control (A). PD cases with a DD 
< 10 years (n = 6) had significantly more CD163 immunoreactive 
microglia than PD cases with a DD ^ 10 years (n = 5) or controls 
(n = 4 ) (p < 0.05), as indicated by a ***' (B). This finding is 
in line with observations of increased CD68 in the SN of PD 




Figure 7.10 Upregulated CDl63-intacting genes 
Genes in red are significantly upregulated in PD compared to 
control. Those in yellow are specifically higher in PD cases 
with a short DD. ILIO, interleukin-10; IFNG, interferon-gamma; 
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Figure 7.11 Meta-analysis of microarray results 
The initial microarray results (comparing PD to control SN) are 
depicted in A, with three CD163 probes (CD163(1), 203645_s_at; 
CD163(2), 215049_x_at; CD163(3), 216233_at) upregulated and a 
non-significant trend toward upregulation of haptoglobin (HP) 
and hemeoxygenase-1 (HMOXl) . When the PD cohort was separated 
into two groups based on disease duration, the group with CD ^ 
10 years was found to drive the upregulation (B). HP was 
significantly upregulated in that group while HMOXl was 
upregulated with p = 0.06. Only one of three CD163 probes 




CD163 immunoreactivity appears to show an association to 
PD both in terms anatomical localisation and disease course. 
The SN stood apart from other brain areas evaluated in the 
higher number of immunoreactive cells, all demonstrating a 
microglial or macrophage-like morphology, observed in the region 
specifically in those cases with a short disease duration. 
7.5.1 CD163 and the timeline of neuronal death 
DD but not age at death was associated with CD163 
immunoreactivity in the SN, indicating that disease progression 
may be a factor in the expression of this receptor in cells of 
monocytic lineage. This finding is in line with the earlier 
finding that CD68, an indicator of phagocytosis, is inversely 
associated with DD in the SN in PD (Section 4.4.3). Unlike CD68 
however, which is indicative of the process of phagocytosis, 
CD163 has been linked specifically to the anti-inflammatory end 
phase of inflammation. CD163 is expressed on anti-inflammatory 
type-2 macrophages which express IL-10, but not on pro-
inflammatory type-1 macrophages that express TNF-A and IL-lB 
when both macrophage types are exposed to IFNG (Verreck et al. 
2006) . The absence of CD68 in PD cases with a longer DD 
suggests that phagocytosis, and perhaps neuronal death, do not 
persist indefinitely in the SN. CD163 may be one of the 
molecules that modulates the shift from pro- to anti-
inflammatory response by microglia. 
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The inclusion of MS69, potentially an example of pre-
symptomatic PD, in this study is informative in this respect. 
While the SN of this case was rife with LBs and CD68-
immunoreactive phagocytes, no CD163 was observed. CD163 is not, 
therefore, functionally correlated with the presence of CD68 or 
the act of phagocytosis, and the molecule does not appear in the 
SN sufficiently early to prevent substantial neuronal death. 
PDC04 and PD29, cases with numerous GDI63-immunoreactive 
microglia, may further illustrate the functional role of CD163 
in the brain. PDC04 had probable MRSA, methicillin-resistant 
Streptococcus aureus, which has been identified as a causative 
factor in some brain abscesses (Roche et al. 2003), and may have 
been in an atypical inflammatory state prior to death. PD29 
also had micro-abscesses. CD163 IHC did not highlight specific 
lesions in these cases; CDl63-immunoreactive microglia were 
distributed throughout the brain parenchyma. The expression 
pattern observed was similar to, although less pronounced than, 
that described in HIVE (Roberts et al. 2004) . CD163 seems 
therefore to be a particularly sensitive marker of infection and 
may indicate brain tissue affected by viral or bacterial 
processes that would otherwise appear normal. 
7.5.2 The origins of CDl63-expressing microglia 
A study of CD163 in HIVE and simian immunodeficiency 
virus has demonstrated that CD163-immunopositive 
perivascular cells in normal Rhesus monkeys are able to 
enter the brain and differentiate into microglia within 24 
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hours (Kim et al. 2006), supporting earlier findings of 
perivascular cell turnover in the CNS (Bechmann et al. 
2001a). In the same study, a subset of blood macrophages 
with a similar phenotypic profile to GDI63-immunoposotive 
perivascular cells was identified and hypothesised to 
represent the peripheral precursors to perivascular, and 
ultimately perhaps microglial, cells in the brain. 
It is beyond the scope of any study of post-mortem 
tissue to distinguish between parenchymal microglia on the 
basis of their origins and timeline of differentiation. 
However, the present study has also demonstrated that 
infectious and neurodegenerative diseases present very 
different profiles of GD163 expression. The suggestion 
that GDI63-immunoreactive peripheral cells could easily 
migrate into the brain and retain their anti-inflammatory 
status could have great implications for the treatment of 
neurodegeneration, but the study of GD163 in animal models 
of PD is imperative in order to better understand its role 
in neurodegeneration. 
7.5.3 CD163 and MHCII 
In all of the PD cases examined, MHCII expression was 
consistently fairly high throughout the SN and cortex (Tables 
4.1 and 5.4). MHCII-expressing cells are more numerous than 
those expressing CD68 or CD163 in every case examined, and MHCII 
expression is not affected by DD. Also unlike CD163 and CD68, 
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which are localised to the immediate area occupied by DA neurons 
in the SN, MHCII is widely distributed throughout the tissue 
section (Section 4.5.2 and Figure 4.5). MHCII expression may 
not be an indication of the expression of molecules that promote 
active tissue destruction or the occurrence of antigen 
presentation and T-cell recruitment (Schmitt et al. 2000). In 
the facial nucleus axotomy model, the upregulation of MHCII by 
parenchymal microglia contralateral to the site of injury did 
not affect neuronal survival (Streit and Graeber 1993). 
The observation of few, if any CDl63-expressing cells in 
the spinal cords of MS cases is in line with a previous study of 
CD163 in post-mortem MS tissue reporting that CD163 was observed 
only in a subset of actively demyelinating plaques (Fabriek et 
al. 2005) . This finding is in striking contrast to the 
intensity of MHCII immunoreactivity in serial sections and 
highlights the different role CD163 must play in the microglial 
inflammatory response. 
7.5.4 CD163 and age 
Unlike MHCII, CD163 did not appear to be dependent on AAD. 
One relatively young control case, PDC05 {AAD = 58 years) was 
included in the study and did not differ from the other control 
cases examined, suggesting that age was less relevant to CD163 
expression than disease. Within the PD cohort, AAD was not 
correlated with CD163 in any of the brain areas examined. This 
finding could be of use in other studies of microglia in aged 
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brain, as it indicates that not all markers of microglial 
activation are equally affected by increasing age. 
7.5.5 Evidence for an anti-inflammatory signalling pathway 
upregulation in PD 
CD163 expression has been reported to be stimulated by IL-10 
and HP and inhibited by IFNG (Sulahian et al. 2000; Buechler et 
al. 2000b; Kristiansen et al. 2001). The role of IL-10 in 
promoting survival and reducing microglial production of pro-
inflammatory and potentially cytotoxic molecules has been 
described (Szczepanik et al. 2001; Kremlev and Palmer 2005; 
Arimoto et al. 2006); CD163 has been suggested to play a similar 
regulatory role (Philippidis et al. 2004). 
The upregulation of CD163, along with IL-10, IFGN and other 
co-regulatory molecules in the microarray comparison of PD and 
control SN suggests that microglia and macrophages may be 
working to reduce inflammation in the PD SN. The specific 
upregulation of CD163, as well as HP and HMOXl, in the SN of PD 
cases with a shorter DD suggests that the protein may play a 
role in attenuating the microglial inflammatory response. HP 
expression in the brain is sensitive to intraperitoneal LPS 
injection in mice, and HP mRNA and protein has been reported to 
be expressed by astrocytes after ischemia (Kalmovarin et al. 
1991; Lee et al. 2002). HMOXl expression by microglia has been 
demonstrated to reduce iNOS expression and nitric oxide release 
as well as to be inducible by astrocytes in vitro (Min et al. 
2006) . If there is in fact an anti-inflammatory mechanism in 
241 
place in microglia at some point in the timeline of PD, that 
mechanism could potentially be effected earlier and result in 
less or slower neuronal death. 
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7.6 Conclusions 
The present study indicates the specificity of CD163 
expression in parenchymal microglial cells for PD cases with a 
short DD. Preliminary results suggest that CD163 upregulation 
in other brain areas may also be related to degenerative 
processes, and follow-up studies comparing cases with distinct 
clinical profiles will further elucidate the mechanisms by which 
CD163-expressing cells are recruited to an area. 
Animal studies in which the time course of CD163 
expression after CNS injury will be very informative. MPTP 
lesions could provide specific examples of neuronal 
degeneration, while a facial nucleus axotomy model could allow 
for a thorough investigation of CD163 expression in regenerative 
and degenerative states. The effects of early CD163 induction 
or inhibition could provide mechanistic evidence of the anti- or 
pro-inflammatory effects of the molecule. 
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Chapter 8: General conclusions 
The work presented in this thesis demonstrates the 
complexity of the microglial response in PD, emphasising the use 
of immunohistochemistry for markers of microglial activation in 
understanding disease progression. In Chapter 3, 
immunohistochemistry for SNCA is standardised in order to 
establish the neuropathological criteria against which 
microglial activation can be compared. In Chapter 4, a 
stochastic relationship between microglial MHCII expression and 
SNCA deposition in the SN of PD cases is demonstrated. 
Furthermore, microglial MHCII expression and phagocytic 
behaviour are compared. Phagocytosis is found to relate to 
clinical course, with high CD68 in the SN associated with cases 
which had a shorter disease duration. In contrast, neither 
MHCII nor SNCA were found to correlate with the clinical 
criteria assessed. In Chapter 5, the relationship between 
pathological protein deposition, MHCII expression and 
phagocytosis is further investigated by assessing these factors 
in the superior frontal, cingulate and primary visual cortices. 
MHCII expression is far more widespread in PD than SNCA 
aggregation and was increased in the white matter of PD cortex 
compared to control. This finding was independent of the 
extent, if any, of protein deposition in associated grey matter. 
However in frontal and cingulate cortices, in which SNCA 
deposition occurred, MHCII expression in grey matter did 
correlate with the extent of SNCA. In combination, these 
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results suggest that microglial response and SNCA aggregation 
may occur in parallel but are not aetiologically linked. A 
relationship between the number of CD68-expressing phagocytes in 
PD cortex and tau, but not A|3 or SNCA, was also identified, 
highlighting the possible specificity of phagocytosis to 
specific protein aggregates. Additionally, a possible link 
between ante-mortem consumption of ibuprofen and reduced 
aggregation of SNCA, tau and A(3 in PD was identified. Ibuprofen 
has been suggested to have possible neuroprotective effects 
against the onset of PD; the work presented here provides the 
first neuropathological evidence for a pharmacological link 
between ibuprofen and PD. 
The results described in Chapters 4 and 5 indicate that 
microglial MHCII expression is not dependent upon SNCA 
aggregation, and that systemic changes in microglia may occur in 
PD. These findings highlight the need for new markers of the 
microglial response to neurodegeneration in order to better 
understand their role in PD. In Chapters 6 and 7, novel 
candidate proteins identified in a whole genome transcriptome-
wide comparison of PD and control post-mortem tissue are 
evaluated for their pathological and clinical relevance. 
The IgG receptor FcgR2 was found to be expressed in 
astrocytes, perivascular cells and microglia and was 
specifically upregulated in microglia. The raRNA upregulation of 
FCGR2C detected by microarrays is hypothesised to be 
attributable to microglial expression. This study marks the 
first report of FcgR2 involvement in PD. 
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The macrophage scavenger receptor GDI 63 was expressed in 
microglia and perivascular cells. This study marks the first 
assessment of CD163 in PD post-mortem tissue. Increased CD163-
expressing microglia were strongly associated with shorter 
disease duration in PD cases. This study exemplifies how 
protein back-mapping can result in further hypothesis-driven 
analysis of microarray data, as a regulatory network surrounding 
CD163 was also found to be upregulated in PD and/or dependent 
upon DD at the mRNA level. The results of this chapter provide 
evidence for an anti-inflammatory signalling mechanism in the 
PD-affected SN which is likely to occur within 10 years of 
symptom onset. 
Finally, evidence is presented that argues against the 
interpretation of the expression of glial inflammation-
associated molecules such as MHCII as indicative solely of a 
neurotoxic response on the part of microglia. Microglial 
involvement in PD is complex and may evolve over the course of 
the disease as more brain areas become affected by 
neurodegeneration. Furthermore, through transcriptome-wide 
screening, key molecules involved in the transformation of 
microglia from a resting to active state are identifiable and 
may be exploitable as potential therapeutic targets in order to 
reduce the extent and rate of neuronal death. 
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Appendix I: Immunohistochemistry with 
formalin-fixed, paraffin-embedded tissue 
Arrange sections (lO-ym thick mounted on Superfrost Plus 
slides) in a plastic slide rack. 
1. 10 min. xylene 
2. 10 min. xylene 
3. 5 min. 100% IMS 
4. 5 min. 100% IMS 
5. 5 min. 90% IMS 
6. 5 min. 70% IMS 
7. 5 min. distilled H2O 
8. 30 min. 0.3% H2O2 in methanol 
9. 3 min. distilled H2O 
ANTIGEN UNMASKING (IF REQUIRED) 
10. 3 x 5 min. PBS 
11. Remove each slide from PBS, dry with paper towel and 
encircle tissue section with delimiting wax pen. 
12. Place slide in level, humidified chamber. 
13. Apply primary antibody diluted in PBS with 0.3% Triton-
XlOO, 2% normal serum (from horse if using a monoclonal 
antibody, from goat if using polyclonal antibody, both from 
Vector). 
13. Incubate overnight at 4°C. 
14. 3 x 5 min. PBS 
15. Return slides to humidified chamber. 
16. Apply secondary antibody (hose-anti-mouse for a monoclonal 
primary antibody or goat-anti-rabbit for a polyclonal primary 
antibody, both from Vector) diluted 1/100 in PBS. 
17. Incubate 1 hour at room temperature. 
18. 3 x 5 min. PBS 
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19. Return slides to humidified chamber. 
20. Apply ABC complex (Vector), diluted 1/200 in PBS. 
21. Incubate 1 hour at room temperature. 
22. 2 x 5 min. PBS 
23. 10 min. PBS 
24. Transfer to DAB solution for 2 min. 
(alternatively, incubate with alternative visualising 
agents Vector NovaRed or Vector VIP, both from Vector) 
25. 3 min. distilled H2O 
26. Dip in Mayer's haematoxylin. 
27. Rinse in tap water until clear. 
28. 5 min. 70% IMS 
29. 5 min. 90% IMS 
30. 5 min. 100% IMS 
31. 5 min. 100% IMS 
32. 8 min. xylene 
33. Coverslip with DPX mountant 
PBS : 
lOx stock solution: Combine 27g sodium dihydrogen orthophosphate 
dihydrate (NaH^POj.ZH^D), 20g potassium chloride (KCl) , 800g 
sodium chloride (NaCl), 193.3g disodium hydrogen orthophosphate 
12-hydrate (Na2HP04.12H2O) . Top up to 10 L with distilled H2O, 
pH 7.4. 
Working solution: Dilute 10 x stock PBS 1:10 in distilled H2O 
for use. 
DAB: 
Stock solution: dissolve 5 g DAB powder (Sigma) in 200 mL 
distilled H2O. Store at -20°C in 4 mL aliquots. 
DAB solution in PBS: Add one thawed 4 mL aliquot of DAB to 400 
mL PBS. Add 0.5 mL 30% H2O2. 
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Appendix II: Immunohistochemistry with 
unfixed, snap-frozen tissue 
1. Remove sections from -80C freezer and allow to thaw for 5-10 
min. 
2. 5 min. 3.7% buffered formalin 
3. 2 min. 50% acetone/50% distilled H2O 
4. 3 min. 100% acetone 
5. 2 min. 50% acetone/50% distilled H2O 
6. 2 min. distilled H2O 
7. 30 min. 0.3% H2O2 in methanol 
8. 2 min. distilled H2O 
9. 2 min. TBS 
10. 2 x 5 min. TBS with 1% BSA 
11. Remove each slide from solution, dry with paper towel and 
encircle tissue section with delimiting wax pen. 
12. Place slide in level, humidified chamber. 
13. Apply primary antibody diluted in TBS with 2% normal serum 
(from horse is using monoclonal antibody, from goat is using 
polyclonal antibody). 
14. Incubate overnight at 4°C. 
15. 1 min. TBS 
16. 3 x 5 min. TBS with 1% BSA 
17. Return slides to humidified chamber. 
18. Apply secondary antibody diluted 1/100 in TBS, 
19. Incubate 1 hour at room temperature. 
20. 1 min. TBS 
21. 3 x 5 min. TBS with BSA 
22. Return slides to humidified chamber. 
23. Apply ABC complex, diluted 1/200 in PBS. 
28( 
24. Incubate 1 hour at room temperature. 
25. 1 min. TBS 
26. 2 x 5 min. TBS with 1% BSA 
27. 1 min. TBS 
28. Transfer to DAB solution for 2 min. 
29. 3 min. distilled H2O 
30. Dip in Mayer's haematoxylin. 
31. Rinse in tap water until clear. 
32. 5 min. 70% IMS 
33. 5 min. 90% IMS 
34. 5 min. 100% IMS 
35. 5 min. 100% IMS 
36. 8 min. xylene 
37. Coverslip with DPX mountant 
TBS 
Mix 1 part 0.5 M Tris with 9 parts PBS. Adjust pH to 7.4 
TBS with 1% BSA: 
Add 1 g BSA to 100 mL TBS. Stir until dissolved. 
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Appendix III: Histological staining protocols 
Haematoxylin & Eosin (H & E) staining of formalin-
fixed, paraffin-embedded sections 
1. 10 min. xylene 
2. 10 min. xylene 
3. 5 min. 100% IMS 
4. 5 min. 100% IMS 
5. 5 min. 90% IMS 
6. 5 min. 70% IMS 
7. 5 min. H2O 
8. 5 min. Mayer's haematoxylin (Raymond A. Lamb) 
9. Rinse in tap water until clear 
10. 15 sec. 1% acid alcohol 
11. 20 sec. rinse in tap water 
12. 5 min. 1% eosin Y 
13. Rinse in tap water until clear 
14. Brief dip in 70% IMS 
15. 2 x 1 min. 100% IMS 
16. 8 min. xylene 
17. coverslip with DPX mountant 
1% Acid alcohol recipe: 1 mL HCl, 99 mL 70% IMS 
Eosin Y recipe: 
5% stock solution: 5 g Eosin Y, 100 mL distilled H2O, 1 g 
thymol 
1% Eosin working solution: 20 mL 5% Eosin stock, 80 mL 0.625% 
CaCl2. Filter before use. 
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Luxol Fast Blue (LFB) 
1. 10 min. xylene 
2. 10 min. xylene 
3. 5 min. 100% IMS 
4. Incubate in LFB solution overnight at 60°C. 
5. Dip each section in 100% IMS 
6. Rinse in tap water. 
7. Dip each section very briefly in lithium carbonate (LiCOa) 
Grey and white matter should be easily distinguishable. 
8. 5 min. rinse in tap water 
9. 45 sec. Mayer's haematoxylin 
10. Rinse in tap water until clear. 
11. 15 sec. 70% IMS 
12. 2 x 1 min. 100% IMS 
13. 8 min. xylene 
14. coverslip with DPX mountant 
Luxol Fast Blue recipe: 1 g LFB powder, 1 L IMS, 5 mL 10% acetic 
acid. 
Saturated LiCOa recipe: add LiCOa to distilled water while 
stirring. When precipitate persistently falls out of solution, 
it is saturated. 
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Appendix IV: Publications arising from this 
work 
The following articles are based on work presented in this 
thesis and have been published in peer-reviewed journals prior 
to submission: 
Croisier, E., Moran, L.B., Dexter, D.T., Pearce, R.K.B., 
Graeber, M.B. Microglial inflammation in the substantia nigra: 
relationship to alpha-synuclein deposition. Journal of 
Neuroinflammation 2:14, 2005. 
Croisier, E., Elfant, D., Deprez, M., Goldring, K., Dexter, 
D.T., Pearce, R.K.B., Graeber, M.G., Roncaroli, F. Comparison 
of commercially available anti-a-synuclein antibodies. 
Neuropathology and Applied Neurobiology 32(3), 2006. 
Croisier, E. and Graeber, M.B. Glial degeneration and reactive 
gliosis in alpha-synucleinopathies: the emerging concept of 
primary gliodegeneration. Acta Neuropathol (Berl) 112(5), 2006. 
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